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Abstract 
 
Rheumatoid arthritis (RA) is a systemic autoimmune disease and the second most 
common form of arthritis. The efficacy of current treatments for RA is limited by an 
increased risk of off target effects and a high percentage of non-responders. To try and 
overcome this, human antibodies that bind specifically to damaged arthritic cartilage, but 
not healthy cartilage, were developed for means of delivering drugs to the joints. The 
antibodies are specific to collagen type II (CII), the major cartilage protein, that has been 
post-translationally modified by reactive oxidants (ROS, resulting in ROS-CII), which is 
abundantly found in inflamed joints. It has previously been shown that fusing anti-ROS-CII 
antibodies to either a mouse version of etanercept or viral-IL-10 significantly enhanced 
the therapeutic effect on the inflamed knee in a mouse model of arthritis. 
 
Herein, a new treatment modality was created to attempt to utilise the anti-ROS-CII 
antibodies to target biological scaffolds to the arthritic joint. As a biological scaffold, 
microvesicles (MV), a subset of extracellular vesicles released from the plasma membrane 
of nearly all cells, were utilised. Specifically, MV derived from neutrophils (PMN) were 
used. MV from PMN have been previously shown to penetrate cartilage and exert 
chondro-protective effects in the context of inflammatory arthritis.  
 
Antibodies specific to ROS-CII retained their binding capabilities after enrichment upon 
MV, and anti-ROS-CII enriched MV exhibited the ability to localise specifically in the 
arthritic joint in vivo. The targeted MV were then co-loaded with anti-inflammatory 
 iii 
therapeutics to deliver a pro-resolving ‘magic bullet’ to the arthritic knee in vivo. 
Importantly, targeting MV with anti-ROS-CII alongside combined treatments led to the 
complete amelioration of knee inflammation.  
 
Overall, this study demonstrates the attainability of targeting a pro-resolving biological 
scaffold to the arthritic joint. The potential of co-delivering MV alongside anti-
inflammatory therapeutics is beneficial to simultaneously protect cartilage and reduce 
inflammation.  
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Chapter 1: Introduction 
1.1 Arthritis 
Around 10 million people in the United Kingdom currently have a form of arthritis, with an 
estimated global incidence of around 350 million individuals. Arthritis is a group of diseases 
that cause pain and inflammation in the joints. It is a leading cause of disability and results in 
a reduced quality of life with significant morbidity. Not only does arthritis cause a severe, 
detrimental impact to the sufferer, but it also carries a heavy socio-economic burden 1.  
 
The two most common subtypes of arthritis are osteoarthritis (OA) and rheumatoid Arthritis 
(RA). The variance between these two subtypes is great, with RA classically referred to as 
‘inflammatory arthritis’, typically caused by a loss of tolerance and subsequent autoimmune 
disease in an individual. OA has often been recognized as ‘non-inflammatory arthritis’ due to 
the nature of its onset, often caused by injury or wearing of cartilage. Nonetheless, the 
involvement of an inflammatory component in OA has become more recognized over the 
past decade 2. 
 
1.1.1 Rheumatoid Arthritis 
RA is a chronic, systemic inflammatory disease affecting around one percent of the 
population. It is a complex, multifactorial disease and unlike many inflammatory diseases has 
little known regarding etiology. Autoantigens in RA have been identified, as have genetic and 
environmental risk factors, however the underlying mechanism of disease is still unclear.   
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Figure 1. Comparison of a healthy and rheumatic joint. Rheumatic joints are characterized by the infiltration of immune cells, 
synovial changes, cartilage destruction and the excessive production of cytokines and reactive oxidants. Image created with 
Biorender. 
 
1.1.1.1 Aetiology 
RA involves a complex interplay of genetic factors and environmental triggers. There has 
been a long-established, well documented association of the HLA-DRB1 locus, which codes 
for a human leukocyte antigen 1. The common amino acid motif ‘QKRAA” found in HLA-DRB1 
alleles indicates a susceptibility to developing RA, suggesting that predisposition in human 
leukocyte antigens, potentially including T-cell repertoire selection, antigen presentation, or 
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alteration in peptide affinity, have a role in the development and promotion of disease 3,4. 
Moreover, like many autoimmune diseases, there is an imbalance between sexes, with the 
ratio of females being diagnosed roughly 3:1 compared to males 5. Observational studies 
have also implied that females with RA overall do worse than men with disease 6. This has 
been attributed to X-linked genetic factors and hormonal differences, although a direct 
mechanism is unclear 5,7. 
 
Certain environmental triggers have been established in RA, in both HLA-DRB1 allele positive 
individuals and in those without susceptibility genotypes. Smoking was first paired with 
increased risk in 1987, when an association between smoking and hospitalisation due to RA 
was observed in a gynaecological study 8. Henceforth, there were numerous clinical studies 
supporting the association and it has become the most prominent environmental factor in 
RA pathogenesis 9.  Additional environmental triggers come from infectious agents such as 
Epstein-Barr virus, Escherichia coli, cytomegalovirus and their by-products 1,10. Such 
infectious agents have been long linked to RA and are thought to pose a threat due to 
molecular mimicry, resulting in a loss of tolerance- although unifying mechanisms remain 
elusive.  Many contributing genetic and environmental factors have been established in RA, 
however some of the fundamental underlying mechanisms of disease are still unknown. 
These gaps in the knowledge mean that a cure for RA is currently non-existent, and current 
treatment and therapies aim to relieve the symptoms of disease but often fall short.  
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1.1.1.2 Pathogenesis 
Several different cell types are thought to be responsible for the pathogenesis of RA, as 
demonstrated in Figure 1. The adaptive autoimmune response, mediated by T cells and B 
cells, is known to be a major contributing factor to the initializing of the inflammatory 
cascade. Both T cells and B cells, as well as members of the innate immune system such as 
macrophages and neutrophils, migrate into the synovial tissue, leading to the production of 
immune mediators and degradative molecules. This production results in degradation of the 
extracellular matrix within the joint, as well as degradation of healthy cartilage. Within the 
inflamed arthritic joint there are detrimental changes to the native cells that reside in the 
synovium and bone. Synoviocytes undergo hyperplasia, angiogenesis occurs and the 
differentiation of mature osteoclasts results in bone erosion 11. Synovial hyperplasia is 
incompletely understood, however cytokines are known to be crucial to the process 12.  
Synovial fibroblasts become activated because of the abnormal presence of pro-
inflammatory cytokines in the arthritic joint, of which tumour necrosis factor alpha (TNFα) 
and interleukin-1 Beta (IL-1) are paramount. Exposure to such cytokines results in the 
synovial fibroblasts in turn producing TNFα and IL-1, which induces the production of 
degradative enzymes by chondrocytes residing in cartilage, such as matrix metalloproteases 
(MMP), aggrecanases and cathepsins- enzymes which play the main role in the destruction of 
cartilage in arthritis 12,13.  
 
The presence of autoantibodies in RA is a prominent feature and has become an important 
part of diagnosis. There have been many reports on autoantibodies to several varying 
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proteins in RA, however rheumatoid factor (RF) and anti-citrullinated protein/peptide 
antibody (ACPA) are the most clinically relevant to date. RF was the first described human 
autoantibody and is found in around 70-80% of RA patients 14,15.  RF is specific to the Fc 
region of Immunoglobulin G (IgG) antibodies, and themselves usually exist as 
Immunoglobulin M (IgM) isotypes 15.  RF can be detected in up to 10% of healthy individuals, 
however the nature of RF found in healthy individuals to those found in RA differs, with 
healthy RF showing low affinity for IgG and polyreactivity 15.  
 
Within the rheumatoid synovium, high affinity RF are produced by B cells which contain 
multiple replacement mutations in their complementarity-determining region (CDR), which 
indicates the role of T-cell help. Furthermore, synovial fibroblasts have been found to 
support the accumulation and survival of B-cells in the rheumatoid synovium, hence 
encouraging the production of RF and autoantibodies 16.  RF also plays a major role in the 
formation of immune complexes in RA. Immune complexes, comprised of immunoglobulins 
bound to their cognate antigens, have long known to be found in patients with RA. In the 
rheumatoid synovium, most immune complexes are composed of antibodies with RF 
specificity 17. 
 
ACPA are highly specific for RA and have thus become an important aspect of diagnosis. As 
well as a useful diagnostic tool, there is sufficient evidence to suggest ACPA play a role in the 
pathophysiologic process of RA. For many years, these antibodies were referred to by 
numerous names including anti-perinuclear factor, anti-keratin antibodies and anti-filaggrin 
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antibodies, until the crucial finding was discovered that linked each of the antibodies. Each 
antibody targets epitopes in which arginine has been post-translationally converted to 
citrulline by the action of peptidyl arginine deiminase (PAD) enzymes 18,19. Although 
citrullination does not exist exclusively in RA, it has become a hallmark of disease.  The 
pooled sensitivity and specificity of ACPA analysis in RA is around 67% and 95% respectively 
20. Not all RA patients are ACPA positive, which explains the low sensitivity in the ACPA 
analysis. However, the high specificity of ACPA analysis out performs RF for diagnosing RA 20. 
 
The pathogenesis of RA has been further understood in the development of murine models 
of inflammatory arthritis. Multiple models exist, all of which replicate areas of human 
disease. Collagen induced arthritis (CIA) shares multiple similarities of human RA, including a 
breach of tolerance and the production of autoantibodies. CIA involves immunization of type 
II collagen in complete Freund’s adjuvant (CFA), creating an autoimmune response towards 
articular cartilage within the joint. The result is a polyarthritic disease, characterized by 
synovial inflammatory infiltration, cartilage and bone erosion and synovial hyperplasia similar 
to human RA 21,22. Furthermore, the transfer of serum from CIA mice to non-immunized 
recipient mice results in the development of arthritis 23. Such models using antibody cocktails 
against CII are referred to as collagen-antibody-induced arthritis and demonstrate a strong 
role of the innate immune system in the development of RA.  
 
Additional models using immunization with CFA exist, including the methylated bovine serum 
albumin (mBSA) model. This model involves priming the immune system using mBSA in CFA, 
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followed by locally administering mBSA alone within the knee joint. The result is pathology 
comprising immune complex mediated inflammation, followed by articular T cell mediated 
responses 24. The inflammation is localized to the site of mBSA injection, so the model is 
often used as a monoarticular model with one single knee joint inflamed. Although the mBSA 
model has fewer similarities to human RA, the characteristic of localized inflammation has 
proved useful in a murine model. Additional murine models of RA include transgenic murine 
models, such as the TNF-α transgenic model in which the overexpression of TNF-α results in 
spontaneous arthritis, and the K/BxN model, in which crossing the TCR transgenic KRN line 
with mice expressing the MHC class II molecule Ag7 results in spontaneous arthritis 25. 
 
1.1.1.3 Current Therapies 
The traditional therapies for RA are disease modifying anti-rheumatic drugs (DMARDs), non-
steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids 26. Over recent years the 
development of small molecules and biologics have been instrumental in managing disease 
in a proportion of RA patients 27–31, however there are still hurdles existing in treating the 
disease that need to be overcome. 
 
To manage the pain and stiffness associated with RA, NSAIDs and analgesics are 
administered. The use of NSAIDs is greatly supported, however their role of first line 
treatment has reduced due to concerns about limited effectiveness, inability to modify the 
disease and off target side effects, such as in both the gastrointestinal and cardiovascular 
systems 32.  NSAIDs are often needed to be administered alongside proton-pump inhibitors 
 27 
for gastro-protection 32. DMARDs are the main course of treatment for a patient with RA. 
They are a heterogeneous group of drugs, with varying mechanisms of action- some of which 
are still incompletely understood. Overall, DMARDs reduce joint swelling and pain, limit 
progressive joint damage and decrease acute-phase markers 32. Examples of DMARDs used 
for the management of RA include methotrexate, sulfasalazine and leflunomide. DMARDs are 
used individually or in combination to manage the symptoms and disease progression in RA 
with combinations varying across different countries 32. Adverse effects of DMARD’s can be 
minor, for example nausea, or serious, including hepatotoxicity. To monitor serious side 
effects patients are required to have regular blood tests and liver function tests whilst taking 
DMARDs long term.  
 
The first biological agents to be licensed for the treatment of RA were TNF inhibitors, 
including infliximab and etanercept. Anti-TNF treatment plays a key role in the current 
treatment of RA by either blocking the TNF receptor or by inhibitor binding to TNF, ultimately 
inhibiting the pro-inflammatory cascade. Other key examples of biologics include: (i) 
abatacept, a fusion protein composed of the Fc portion of an IgG1 with the extracellular 
domain of CTLA-4. Abatacept works by preventing T-cell activation by inhibiting CD80/CD86 
binding by antigen presenting cells 33; (ii) rituximab, or sometimes known as anti-CD20, is a 
chimeric mouse/human antibody. Rituximab induces B-cell  death by a mechanism that isn’t 
fully understood, however direct signalling, complement dependent cellular cytotoxicity and 
antibody dependent cellular cytotoxicity all appear to play a role 34; and tocilizumab, also 
 28 
referred to as anti-IL-6. Tocilizumab is a humanized monoclonal antibody that inhibits IL-6, a 
pro-inflammatory cytokine involved in the pathogenesis of RA 35. 
 
Biologics are conventionally combined with DMARDs to limit disease and associated 
symptoms; however over the years it has become apparent that what works in one patient 
may not be efficacious for another. For example, around 30-40% of patients do not respond 
to anti-TNF therapy and will likely be subsequently treated with alternative biologics, such as 
tocilizumab and abatacept 36. Studies have also suggested the overall rate of non-responders 
to biologics is around 30-40%, which is a major drawback of the therapy 37.  The high rate of 
non-response results in undesirable side effects with no therapeutic benefit to the patient. 
The reasoning of patient non-response to biologics has been an area of investigation for 
some time, and the ability to predict non-responders before initiating treatment would be 
beneficial for both the patient and healthcare provider.  There are many contributing factors 
that have been proposed to influence response to biologics, including prior treatments, 
genomics, smoking status and serum biomarker profile 38. An alternative proposed theory of 
non-response is due to the high systemic concentrations of the biological agent and 
inadequate local concentrations in the arthritic joints 39. The high systemic concentrations 
result in off target side effects, such as opportunistic infections 33,40,41. Furthermore, the 
heterogeneic nature of RA adds additional complexity when treating patients. One study 
found that heterogeneity in early pathological characterization of the synovial tissue from RA 
patients has a relationship with the likelihood of responding to biologics 42.  
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The introduction of biologics drastically changed the treatment of RA for the better. The 
standard of care for patients has improved greatly, with better clinical results and a greater 
knowledge of the pathogenesis of RA. However, many patients still have inadequate control 
of their arthritis activity due to non-response or becoming resistant to the beneficial effects 
of therapies. There is still a great need for additional and alternative treatment options, 
specifically to target the subset of patients of whom biologics are inefficient to control their 
disease.  
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1.1.2 Osteoarthritis 
Osteoarthritis (OA) is the most common subtype of arthritis, affecting around 8 million 
people in the UK alone 43. OA isn’t an epidemic that is exclusive to the UK, and is a major 
source of pain, disability and socio-economic burden worldwide. OA is a complex, 
multifactorial disease with many genetic, biological and biomechanical components at play. 
Although the focus of current research is early intervention and disease prevention, the most 
effective treatment for severe osteoarthritis remains to be joint replacement, which comes 
with a plethora of drawbacks. 
 
Figure 2. Schematic representing the changes in the joint due to severe osteoarthritis. Osteoarthritic joints are characterised 
by a loss of cartilage, the formation of osteophytes and an inflamed synovium. Image created with Biorender. 
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1.1.2.1 Aetiology 
OA is primarily considered a disease of age related wear-and-tear of cartilage in the joints 
and hands, however over recent years the aetiology of OA has found to have a genetic 
component.  OA is a widely heterogeneous disease, and the search for specific genes that 
give rise to OA has been formidable. Inheritance studies involving families and twin pairs 
have been able to demonstrate that genetic factors can be attributable to the development 
of OA in between 39-78% of cases 44–46.  
 
There are many known environmental factors that drastically increase both risk and 
progression of OA. The most prevalent is age, however obesity and previous knee injury are 
also important risk factors. One study identified the lifetime risk of a person developing 
symptomatic knee OA to be nearly 1 in 2, and more than 1 in 2 if a history of knee injury is 
present 47. For obese individuals the risk increased to nearly 2 in 3 47.  The study also found 
that a higher body mass index at later ages accounted for the greatest variability in lifetime 
risk estimates 47.  There is also a gender bias involved, with OA being more common in 
women than men. Around 18% of women over the age of 60 suffer from OA compared to 
around 10% of men 48,49. The role of oestrogen in the development of OA has been widely 
investigated, however a direct mechanism remains unclear 49.   
 
One of the biggest challenges in managing and treating OA is the variability of disease. As 
aforementioned, it is an incredibly heterogeneous disease, which has no single aetiology. 
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Many risk factors are known; however, it remains to be an unpreventable disease that’s 
difficult to treat successfully.  
 
1.1.2.2 Pathogenesis 
Until recently, OA has been typically viewed as a non-inflammatory disease due to the strong 
association with damaged cartilage and early observations noting fewer leukocytes within 
the synovium when compared to RA 50. Despite this classification, over the past few decades 
the role of inflammation within OA progression has become better understood, as 
demonstrated in Figure 2, and the disease is recognised as more than simply ‘wear and tear’.  
 
OA is often classified into primary and secondary subtypes. The difference between primary 
and secondary OA depends on a known cause- secondary OA has developed following an 
obvious injury or trauma to a joint whereas primary OA has no known cause. With increased 
understanding of the multifactorial nature of OA, the primary and secondary classification 
may oversimplify the disease. For example, the risk of post-traumatic OA following meniscal 
injury of the knee joint is strongly linked to family history of arthritis and the other risk 
factors previously aforementioned 51. However, for both primary and secondary OA, the 
immune system is now known to play a pivotal role in the progression of disease. The tissue 
that has long attracted great attention with regards to the pathogenesis of OA is articular 
cartilage. This is due to the striking changes that occur in the tissue throughout the 
progression of OA, often resulting in a complete loss of articular cartilage in affected joints. 
Cartilage is a unique tissue of the human body; it contains no nerves or blood vessels, unlike 
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the subchondral bone beneath it. The lack of vasculature means the tissue is naturally 
hypoxic. It has one primary cell type, namely chondrocytes, which make up only 5% of the 
total tissue. Most of the tissue is composed of a specially adapted extracellular matrix (ECM) 
maintained by the native chondrocytes, which is abundant in collagen and proteoglycans. 
The quality of the ECM is crucial for the maintenance of healthy cartilage and thus healthy 
joints. There are known changes that occur in cartilage during OA, both to the chondrocytes 
and the all-important matrix.  
 
It is known that upon activation, chondrocytes produce several pro-inflammatory cytokines 
including IL-1, IL-6 and TNFα. Activated chondrocytes also produce reactive oxygen species 
(ROS) and matrix degrading enzymes, including metalloproteases- some of which have 
apparent beneficial matrix remodelling roles in healthy cartilage and some of which are 
pathogenic 49.  The release of pathogenic matrix metalloproteases (MMP), including MMP1, 
MMP3 and MMP13, causes destruction of the ECM, which leads to a physiological alteration 
of articular cartilage and can result in the progressive degradation of cartilage 52. 
Furthermore, the production of ROS by chondrocytes and other cells within the inflamed 
joint results in an imbalance of oxygen within the cartilage. Chondrocytes, which are adapted 
to thrive in the hypoxic environment, undergo cell death when exposed to excessive ROS. 
ROS also plays a strong role in ECM degradation, and studies have shown matrix degradation 
and cartilage loss in animal models treated with ROS scavengers is slowed 53.  
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It is unknown what causes chondrocyte activation in OA, and as the disease is so 
heterogeneous it is likely the source of activation will vary between patients. Chondrocyte 
activation is hypothesised to occur as a result of inflammatory signalling from other origins 
within the joint, for example from the synovium or subchondral bone 49. Synovitis is a 
common feature of OA, even within the early stages of disease. Common features include 
the proliferation of synovial fibroblasts (also known as synoviocytes), tissue hypertrophy and 
increased vascularity 54. One function of synoviocytes is to synthesise natural lubricants for 
the joint, such as hyaluronic acid. In situations such as arthritis, this should benefit the 
damaged knee, however it has been found that OA patients show a deficiency in the 
production and have reduced lubricating capabilities 49,55. Similarly to chondrocytes, 
synoviocytes become activated and release pro-inflammatory cytokines, degradative 
enzymes and ROS. It is speculated that the activation is likely to be secondary to the pro-
inflammatory mediators released during an initial insult to the joint. Following an initial 
insult, synovial tissue drives the degeneration of the joint through a positive feedback cycle 
49,54. The presence and extent of synovitis is also predictive of the progression of OA and 
cartilage loss 56, although there is a less consistent relationship with structural changes of the 
joint 49. Although OA is an incredibly heterogeneous disease, the role of synovitis is crucial in 
the disease progression of most patients.  
 
1.1.2.3 Current Therapies 
The mainstay of current treatments for OA involve physical measures, drug therapy and 
surgery for late stage disease 57. There is a strong emphasis on physical measures and 
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lifestyle changes in the treatment of OA, as pharmacological interventions to modify the 
disease are lacking, especially in comparison to RA treatment. The pharmacological therapies 
that are available only have the potential to reduce symptoms, particularly pain. None of the 
existing treatments are capable of reversing cartilage damage or protecting cartilage from 
further degradation 57.  
 
A large proportion of OA treatment comes in the environmental changes that can be made 
to improve symptoms and slow the progression of disease. Weight loss is suggested, 
particularly in individuals with an overweight or obese body mass index. Weight loss can help 
to adjust the unbalanced mechanical stress on the joint, reduce pain and also reduce OA risks 
57,58.  Additionally, moderate exercise has been identified to strengthen the muscles 
surrounding the joint and potentially delay the progression of OA 59. 
 
Surgery will only be considered for severe cases of OA and joint replacement is the most 
extreme intervention. Additional surgical procedures, such as arthroscopic irrigation and 
debridement are able to temporarily relieve pain, but are not considered beneficial for long 
term recovery 57,60. Microfracture is a technique that aims to penetrate the underlying 
subchondral bone to induce bone marrow stromal cells to repair the damaged bone and 
cartilage. This technique is widely associated with the production of fibrocartilage, an inferior 
and less durable cartilage compared to the native form 57. As aforementioned, total joint 
replacement (or arthroplasty) is the most extreme intervention, but is also regarded as the 
best option for advanced OA, with the ability to eliminate pain and reinstate joint function in 
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a high proportion of patients. The artificial implant has a limited lifespan of around 10-15 
years, which is one of the reasons why arthroplasty isn’t recommended for young patients. 
Additionally, the outcome of arthroplasty also varies depending on which joint is being 
replaced, resulting in long term outcomes varying significantly 61.   
 
There are five subtypes of pharmacological intervention currently used for the treatment of 
OA: acetaminophen, NSAIDs, serotonin-norepinephrine reuptake inhibitors (SNRIs), opioid 
analgesics and intra-articular injections 57. Acetaminophen, more commonly known as 
paracetamol, is a common, ‘over-the-counter’ painkiller used to treat arthritis as well as a 
variety of other ailments. Acetaminophen is considered relatively safe and effective, and so it 
the first line oral-analgesic for mild to moderate OA. Patients with severe symptoms or those 
who do not respond to treatment will likely be introduced onto stronger analgesics. As 
previously discussed, NSAIDs are a group of drugs that provide both anti-inflammatory 
actions as well as analgesic effects. In randomized control studies, NSAIDs have continually 
outperformed acetaminophen for pain relief in OA patients. However, there are concerns 
with adverse events such as in individuals taking regular NSAIDs, with an estimated 
occurrence in 30% of patients 57,62. Opioids are being increasingly used for the treatment of 
moderate and severe OA to manage the associated pain. One meta-analysis study found that 
the numbers of OA patients in the United States being prescribed opioids has steadily 
increased, from 31% in 2003, to 39% in 2006 and 40% in 2009 63. Opioids are associated with 
a range of common adverse side effects however, including nausea, vomiting and dizziness, 
which in some patients can outweigh the beneficial pain relief effects of the drugs 57.  SNRI’s 
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primary use are in the treatment of depression, but SNRI are also now FDA approved for the 
management of chronic musculoskeletal pain, including OA 57. Drugs such as Duloxetine have 
shown promising results in blinded, placebo controlled studies 64. It holds potential as an 
alternative drug to alleviate OA pain for patients who do not respond well to the more 
commonly used drugs.  Intra-articular injections are selectively used to treat OA. 
Corticosteroids and hyaluronic acid are both used to alleviate pain and to visco-supplement 
the joint, respectively. Corticosteroid injections are used in patients with moderate to severe 
OA who do not respond well to the other treatment options mentioned, whereas hyaluronic 
acid injections are recommended for treatment of hip or knee OA. The efficacy of hyaluronic 
acid injections have come under scrutiny in previous years and hence the recommendation 
for injection has been downgraded from an inconclusive level to a non-affirming level 57.  
 
There are currently drugs in the pipeline that hope to overcome the unsatisfactory and 
unwanted side effects that occur with the current standard of pharmacological treatment. 
The ideal therapy for OA should alleviate pain whilst also reducing symptoms and restoring 
the normal function of the joint. Bone morphogenetic protein 7 (BMP7) is a biological agent 
that is FDA approved for the treatment of bone nonunions and spinal fusion. BMP7 has 
entered clinical trials for the treatment of symptomatic knee OA and passed phase one with 
no dose-limiting toxicity found 57.  
 
A drug consisting of fibroblast growth factor (FGF), namely sprifermin, underwent a proof of 
concept study to evaluate efficacy and safety whilst administered intra-articularly. Treatment 
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with sprifermin reduced the loss of cartilage thickness and volume 65. Sprifermin also 
reduced joint space narrowing in a dose dependent manner with no significant difference in 
adverse events between the control and experimental groups 65. The local administration of 
sprifermin by intra-articular injection likely attributes to the lack of adverse events and high 
therapeutic potential. Additional studies are needed to understand greater this novel OA 
biologic, however the initial findings are extremely promising.  
 
 
1.2 Cartilage  
Cartilage is one of the key components of synovial joints, and plays an important role in the 
mechanical load-bearing function of the joint. As discussed, the etiologies of RA and OA 
differ, however in both diseases the destruction of cartilage is part of the underlying 
pathophysiology.  
1.2.1 Healthy Articular Cartilage 
Healthy adult articular cartilage is an avascular tissue, composed of a complex extracellular 
matrix (ECM) comprised of collagen, proteoglycans and other non-collagen proteins 66. The 
native environment of cartilage is unlike any other tissue within the body. It is an avascular, 
hypoxic tissue composed abundantly of ECM. As shown in Figure 3, articular cartilage is 
subdivided into three distinctive zones; superficial, intermediate and deep zones 66. The 
cartilage morphology within each of these zones differs, and likely reflect the differences in 
ECM composition. There is only one cell type found in cartilage, the chondrocyte, which 
make up around only 1-5% of the total tissue mass 67.  Chondroblasts, which are 
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mesenchymal progenitor cells in situ, are found in the superficial layers of the cartilage. 
Chondroblasts will form into chondrocytes embedded within lacunae upon migration into 
deeper layers of cartilage. Chondroblasts are important for ECM production, particularly 
collagen II synthesis. Chondrocytes are found within the superficial, intermediate and deep 
zones. The tidemark represents the area where cartilage meets bone, and is often referred 
to as calcified cartilage due to the chondrocyte derived collagen II fibres becoming 
structurally cemented to collagen I deposited by osteoblasts 68. The composition and 
structure of important ECM proteins also changes when moving into deeper cartilage layers.  
 
 
Figure 3. Schematic showing the structure of healthy articular cartilage. Cartilage is sectioned into three different zones: 
superficial, intermediate and the deep zones. The tidemark represents the area where cartilage meets bone. Chondrocytes 
are the only cell type within articular cartilage and are responsible for the maintenance of the extracellular matrix through 
the production of collagen II and proteoglycans. Image created with Biorender. 
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1.2.1.1 Chondrocytes 
Chondrocytes are sparsely embedded within the ECM with no vasculature to provide 
nutrients, hence they rely on the diffusion of nutrients and metabolites from the articular 
surface 67. Chondroblasts and chondrocytes within the superficial zone have a small and 
flattened morphology, chondrocytes within the middle zone are rounded and within the 
deep zone group into clusters 66. The main function of chondrocytes within the superficial 
and middle zones is the maintenance of the ECM. Chondrocytes have an important role of 
maintaining the ECM by homeostatic low turnover replacement. Damage to articular 
cartilage leads to the degradation of ECM, and in many situations the rate of loss of ECM 
proteins is greater than the capacity for the native chondrocytes to replenish them.  
 
The well-defined structural composition of articular cartilage is maintained through the 
actions of the mechanically sensitive chondrocytes. Chondrocytes have been described as 
residing in a ‘resting’, yet metabolically active, state. Chondrocytes react to small changes in 
the ECM to appropriately assemble and degrade components accordingly. This interaction is 
paramount for cartilage homeostasis and the phenotypic changes of chondrocytes observed 
in arthritis play a key role in the degradation of cartilage.  
 
1.2.1.2 Collagens 
Collagen is the most abundant macromolecule found in cartilage ECM, making up around 
60% the tissue 67. Of this dense collagen presence within the ECM, 90-95% is collagen type II 
(CII), but collagens III, VI, IX, X, XI, XII and XIV all contribute to form the ECM 69. Within 
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articular cartilage, collagen is arranged into vast fibrils with a range of 20nm to 120nm in the 
superficial zone and deep zone, respectively.  
 
CII is formed of 3 α chains. There are around 34 genes associated with collagen formation. 
Collagen synthesis usually begins with the transcription of genes associated with the 
formation of an alpha peptide, thus alpha 1, 2 or 3. Translation of the mRNA then occurs to 
produce pre-propeptides. Three modifications of the pre-propeptide occur which lead to the 
formation of the alpha peptide: (i) the signal peptide on the N-terminal dissolves to form 
propeptide, (ii) lysines and prolines on the propeptide are hydroxylated by hydroxylase 
enzymes, which aids cross linking, and (iii) glycosylation occurs at the hydroxyl groups on the 
lysines. Following these three modifications, the hydroxylated and glycosylated propeptides 
form a triple helix, making procollagen as shown in Figure 4. Once outside the cell, collagen 
peptidases then act upon the procollagen to form tropocollagen. Collagen fibrils are then 
formed through the actions of lysyl oxidase on the tropocollagen, which acts on lysines and 
hydroxylysines resulting in the covalent bonding between tropocollagen molecules.  
 
As demonstrated in Figure 4, the 3 α chains of CII all contain the (Gly-X-Y)n, but vary in their 
amino acid sequence. Of the other collagen types, collagen IX and XII have been found to 
associate with CII fibres and contribute to their crosslinking. Collagen VI has been identified 
in the pericellular regions of cartilage and Collagen X is expressed by hypertrophic 
chondrocytes, so often found in the growth plate 69.  
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Figure 4. The triple helix structure of procollagen. Collagen is composed of three alpha chains formed through the formation 
of propeptide. Telopeptides are important for collagen crosslinking and are a site for cleavage by proteases.  Image created 
with Biorender. 
 
 
1.2.1.3 Proteoglycans 
The most predominant proteoglycan present in cartilage is the large chondroitin sulphate 
proteoglycan aggrecan. As suggested by its name, following secretion aggrecan self 
assembles in an aggregating fashion with hyaluronan into a supramolecular structure. The 
core protein of aggrecan has a high molecular weight (230 kDa) and consists of three 
globular domains, G1, G2 and G3 69. Aggrecan also has three interglobular domains, keratin 
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sulphate and chondroitin sulphate glycasminoglycan attachment domains and a short 
interglobular domain between G1 and G2. The ability of aggrecan to bind to hyaluronan in 
the ECM is important for providing a mechanism for the fixation of aggregation within the 
matrix. Aggrecan and hyaluronan have also been found to be important for pericellular 
matrix formation and maintenance of matrix homeostasis 69.  
 
Decorin, biglycan and fibromodulin are smaller, non-aggregating proteoglycans found in 
cartilage in similar molar quantities as aggrecan 70. Decorin and fibromodulin interact with 
type II collagen fibrils within the ECM and have a role in fibrillogenesis and interfibril 
interactions 70. Biglycan surrounds chondrocytes and is thought to have an interactive role 
with collagen VI 70. Figure 5 summarises these interactions of proteoglycans either with each 
other, or with CII.  
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Figure 5. Schematic of proteoglycan aggregation and interaction with collagen II. Aggrecan self assembles with hyaluronan 
into a supramolecular structure. Keratin sulphate and chondroitin sulphate bind to aggrecan through attachment domains. 
Decorin and fibromodulin interact with collagen II fibrils. Image created with Biorender. 
 
As previously mentioned, the turnover of CII is very low, with a half-life greater than 100 
years. Although collagen has a very low turnover, aggrecan and other proteoglycans continue 
to be regularly synthesized within the ECM.  
 
1.2.1.4 Water 
The most abundant component of cartilage, contributing up to 80% of its wet weight, is 
water. Water is found predominantly in the intrafibrillar space within the collagen, as well as 
in low levels the intercellular space. The remainder is located in the pore space of the ECM 
70,71.  
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Water in articular cartilage plays an incredibly important role for both nutrient transport and 
weight bearing. The relative water concentration decreases from 80% at the superficial zone 
to 65% in the deep zone. The flow of water through the cartilage zones is important to 
transport and distribute nutrients to the resident chondrocytes. The frictional resistance to 
water flow and combined pressurization of water within the matrix forms the two basic 
mechanisms by which cartilage is able to withstand significant loads 70. 
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1.2.2 Arthritic Cartilage 
Cartilage damage is a key feature of degenerative joint diseases, including RA and OA. The 
mechanisms underlying the degradation of cartilage in arthritis have been elucidated in 
recent years, with a complex combination of factors playing a pivotal role.  
 
1.2.2.1 Cell Activation 
Cell activation plays a central role in cartilage degradation, particularly in RA. Destruction of 
cartilage is primarily mediated through proteolytic enzymes, which are produced by 
activated cells within the joint in response to the release of local mediators. Such mediators 
can include cytokines, prostaglandins, matrix breakdown products, complement, reactive 
oxygen species and neuropeptides; all of which are involved in chronic inflammation 72.   
 
Chondrocyte phenotype and dedifferentiation has been recognised as a potential initiating 
event for cartilage loss 73. As shown in Figure 6, the dedifferentiation of chondrocytes results 
in a fibroblast-like cell, and reduced production of important anabolic products such as CII 
and aggrecan 74. Sox9 is a transcription factor that is essential for early chondrogenesis and 
the fate of chondrocytes. Sox9 inhibits the progression of chondrocytes from proliferation to 
prehypertrophy, and the acquisition of an osteoblast like phenotype 75. Sox9 is expressed 
highly in healthy articular cartilage, but this high expression can be lost during arthritis 75. 
Additionally, exposure of chondrocytes to excessive pro-inflammatory mediators can result in 
activation. For example, exposure of chondrocytes to IL-1 and TNF results in reduction of 
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the synthesis of ECM components, such as CII and aggrecan 76,77. In addition, MMP1, MMP3 
and MMP13 are overproduced, as well as a disintegrin and metalloproteinase with 
thrombospondin motifs 4 (ADAMTS4) 78. Furthermore, exposure to pro-inflammatory 
mediators results in ageing and apoptosis of chondrocytes 76. 
 
 
Figure 6. Schematic of the cellular and secretory changes in the arthritic joint. The exposure of chondrocytes and synoviocytes 
to inflammatory cytokines from invading immune cells results in phenotypic changes. Chondrocyte dedifferentiation occurs, 
resulting in reduced production of extracellular matrix proteins and increased reduction of matrix metalloproteases. 
Synoviocytes undertake an aggressive phenotype and become fibroblast-like synoviocytes (FLS). FLS produce excessive 
levels of inflammatory cytokines and pro-angiogenic factors. Image created with Biorender. 
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Fibroblast-like synoviocytes (FLS) are known to play an extremely important role in arthritic 
cartilage destruction. The activation of synoviocytes is well documented, and there is a 
phenotypic switch, which is often likened to that of a tumour cell. As highlighted in the 
schematic in Figure 6, the chronic exposure of synoviocytes to inflammatory cytokines such 
as TNF results in the continuous stimulation of synoviocytes towards an aggressive FLS 
phenotype 13. FLS upregulate adhesion molecules, which results in FLS cells interacting with 
ECM and subsequently the destruction of cartilage and bone. Synovial invasion is 
characterized by the attachment of the synovial pannus to cartilage, and is mediated through 
the upregulation of adhesion molecules on FLS, such as vascular cell adhesion protein 1 
(VCAM-1).  
 
Pro-inflammatory mediators secreted by FLS cause detrimental changes in bone remodeling, 
particularly in RA. As demonstrated in Figure 7, in healthy bones, signalling via the classical 
Wnt pathway is critical for bone deposition and remodeling. Bone remodeling begins with 
activation mediated through cells of the osteoblast lineage.  These cells undergo structural 
changes and express receptor activator of NF-ĸB ligand (RANKL) 79. RANKL interacts with a 
receptor present on the osteoclast precursors, called RANK. This interaction of RANKL with 
RANK causes activation and differentiation of hematopoietic cells into osteoclast lineage, and 
hence the process of resorption begins 79. RANKL is blocked by osteoprotegerin (OPG), which 
is secreted from osteoblasts and other bone marrow derived cells. OPG regulates bone 
resorption by inhibiting the final differentiation of osteoclasts, and instead activating their 
apoptosis 79.  
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Wnt signalling is mediated through multiple endogenous mechanisms, including Dickkopf 
proteins (Dkk). It has been identified that overexpression of Dkk-1 leads to excessive 
inhibition of Wnt signalling and is critical for bone erosion in RA 80 . Excessive levels of pro-
inflammatory cytokines, including TNF-α, by activated FLS and infiltrating immune cells 
causes overexpression of Dkk-1 and hence inhibition of Wnt signalling. As a result, RANKL is 
overexpressed and activation and differentiation of osteoclasts occurs. The chronic presence 
of pro-inflammatory cytokines means the balance of resorption and deposition is lost, and 
bone resorption occurs at a high rate, which over time can cause joint deformity and 
functional disability 80,81.  
 
 
Figure 7. Schematic showing the differences in resorption and deposition in healthy and rheumatoid bones. In healthy 
individuals, the balance of resorption and deposition is maintained through the actions of osteoclasts and osteoblasts. Pro-
inflammatory cytokines produced by the activated synovium results in Dkk-1 overexpression and an inhibition of Wnt 
signalling, and hence inhibition of osteoblast deposition. These signalling events inhibit osteoblast activity whilst enhancing 
osteoclast activity. Image created with Biorender. 
 
 50 
1.2.2.2 Catabolic Factors 
Cartilage breakdown is mediated through catabolic factors, particularly the overproduction 
of proteolytic enzymes. The production and expression of proteolytic enzymes are regulated 
through local mediators, such as cytokines, growth factors, reactive oxygen species and 
prostaglandins 72. The metalloproteinase (MMP) family are a group of over 20 proteins with 
important roles in cartilage homeostasis and breakdown. They are divided into five 
categories: collagenases, stromelysins, gelatinases, membrane type MMPs and aggrecanases. 
The first four categories make up the matrix MMPs, whereas aggrecanases belong to the 
ADAMTS family (a disintegrin and metalloproteinase with thrombospondin motifs).  
 
Due to the role MMPs have in degrading collagen II and aggrecan, they play a central role in 
cartilage destruction in arthritis. Collagen II degradation occurs early in the pathogenesis of 
arthritis, and is an irreversible event that usually takes place in the superficial layer. Fibrillar 
CII is broken down by the collagenase subunit of MMP; MMP1 and MMP3 82. After initial 
proteolysis and denaturation of CII by MMP1 and MMP13, the collagen triple helix breaks 
into fragments, which act as substrates for other MMP including gelatinases 83.  
 
As well as collagen degradation, the proteolysis of aggrecan is another major effect of MMPs. 
Aggrecan can be degraded by many enzymes and two cleavage sites have been identified: 
one between amino acids Asn341 and Phe342 and the other between amino acids Glu373 
and Ala374 72. MMP1, MMP3, MMP13 and cathepsin B have been found to all cleave the 
Asn341-Phe342 site 72,84. The Glu373-Ala374 site is characteristic of the proteolytic activity of 
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the ADAMTS family, particularly ADAMTS4 and ADAMTS5. ADAMTS5 has been shown to be 
most upregulated during arthritis and plays a dominant role in aggrecan degradation 85. 
Deletion of the active protein has shown to protect against both an osteoarthritic mouse 
model and an inflammatory arthritis mouse model 86.  
 
1.3 Loss of Tolerance in Autoimmune Disease as a result of Post-
Translational Modification of Protein  
It is estimated that between 50-90% of proteins in the human body are subject to post-
translational modification 87. Some of the most explored post-translational modifications in 
the literature include phosphorylation and glycosylation, which have important roles in 
enzyme activity and protein folding, respectively. Post-translational modifications can occur 
on the amino acid side chain or at the proteins C or N termini, and are usually a chemical or 
enzymatic process. Most post-translational modifications are essential for biological 
functions of the subjected protein; however, a proportion of such modifications are 
redundant and can bring detrimental side effects. 
 
Post-translational modification can play a role in the loss of tolerance through the creation of 
neo-antigens, to which the immune system has never been exposed or tolerized to.  Self-
tolerance is an ingrained mechanism of the immune system to discriminate self from non-
self. An intricate network of central and peripheral immune tolerance mechanisms to 
prevent an immune reaction against self-proteins. In most cases, this mechanism is 
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successful in avoiding a self-attack through the elimination of self-reactive T-cells in the 
thymus, deletion and receptor editing of autoreactive B-cells in the bone marrow, as well as 
numerous mechanisms in the periphery including anergy (functional unresponsiveness) and 
deletion (through induction of apoptosis) 88–90. However, in cases where these mechanisms 
do not function correctly and self-reactive cells are not eliminated, there is a loss of self-
tolerance which can culminate into autoimmune disorders. The loss of self-tolerance can 
result in a cascade of excessive, chronic inflammation targeted at host tissue. As discussed 
earlier, one way of detecting the role of post-translational modification in autoimmune 
diseases is to test for the presence of autoantibodies against post-translationally modified 
self-proteins. The presence of autoantibodies to post-translationally modified proteins in 
autoimmune diseases such as RA and type 1 diabetes supports the hypothesis that post-
translational modification of protein plays an important role in disease progression 91–94.  
 
Post-translational modification is categorized into two subtypes: (a) enzymatic and (b) 
chemical modifications. As will be detailed in the following chapters, my work has focused on 
chemical post-translational modification in the context of arthritis. In RA, enzymatic post-
translational modifications of protein have been highlighted extensively in recent years. As 
aforementioned, ACPA are highly specific for RA and have thus become an important aspect 
of diagnosis. As well as a useful diagnostic tool, there is sufficient evidence to suggest ACPA 
play a role in the pathophysiologic process of RA. ACPA targets epitopes in which arginine has 
been post-translationally converted to citrulline by the action of peptidyl arginine deiminase 
(PAD) enzymes 18,19. Although citrullination does not exist exclusively in RA, it has become a 
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hallmark of disease.  The pooled sensitivity and specificity of ACPA analysis in RA is around 
67% and 95% respectively 20. Not all RA patients are ACPA positive, which explains the low 
sensitivity in the ACPA analysis. 
 
 
1.3.1 Reactive Oxygen Species 
Post-translational modifications of proteins have been identified to occur in the presence of 
excessive ROS. ROS are highly reactive small molecules, which at normal physiological levels 
have an important role in cell signalling. ROS either readily accept another electron or 
transfer their unpaired electron to another molecule 95. They are a normal byproduct of 
cellular metabolism and an intricate oxidant/antioxidant system exists to regulate their levels 
and avoid oxidative stress 96. The different varieties of ROS can be formed by both enzymatic 
and non-enzymatic reactions.  
 
 
Figure 8. Schematic showing the reactions involved in the generation of reactive oxidant species.. Superoxide anion (O2−•) is 
the precursor of most ROS. Hydrogen Peroxide (H202) is derived from O2−• by dismutation. H202 can either be fully reduced 
to water, or partially reduced into another ROS, the hydroxyl radical OH•. 
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Although an antioxidant system exists, ROS are often produced in abnormally large quantities 
in the human body under many conditions, such as joint disease, asthma, ageing and cancer 
95. The reactivity of each ROS molecule varies widely, but the overproduction of ROS has 
shown to lead to the damage of DNA and proteins. 95. Superoxide anion (O2−•) is the 
precursor of most ROS. O2−• is a pro-inflammatory compound that damages cells and the 
extracellular matrix of tissue. O2−• also promotes the recruitment of neutrophils to locations 
of inflammation 95. As shown in Figure 8, Hydrogen Peroxide (H202) is derived from O2−• by 
dismutation, either spontaneously or by an enzyme called superoxide dismutase 97. H202 can 
either be fully reduced to water, or partially reduced into another ROS, the hydroxyl radical 
OH•. The formation of OH• is catalyzed by reduced transition metals, forming one of the 
strongest oxidants in nature. 
 
Neutrophils are key producers of ROS, especially in the context of inflammation. Neutrophils 
release an enzyme called Myeloperoxidase, which catalyzes a reaction between H202 and 
calcium ions, resulting in the production of the ROS compound hypochlorous acid.  
An additional known oxidative post-translational modification in RA is glycation. Non-
enzymatic glycation is a post-translational modification resulting in the spontaneous addition 
of a sugar molecule to a protein. Oxidative stress is associated with sugar oxidants that result 
from sequential oxidative reactions, and which generate advanced glycation end products 
(AGE). AGE have been found to play a physiological role in inflammatory autoimmune 
diseases, and this non-enzymatic glycation is evident in RA, despite the absence of 
 55 
hyperglycemia. The relationship between AGE and oxidative stress has been highlighted, with 
AGE presence stimulating the production of ROS in neutrophils 98. Figure 9 illustrates 
oxidative glycation that result in the formation of AGE. The carbonyl group of ribose sugar 
interacts with a free amine group on lysine, causing the formation of a Schiff base. The Schiff 
base rearranges into the more stable Amadori product, which is considered the first product 
of glycation 99.  Interaction of Amadori products with arginine causes the formation of 
pentosidine. Pentosidine is formed through metal-catalyzed oxidation of Amadori product in 
the presence of arginine 100. Furthermore, high levels of pentosidine and 
carboxymethyllysine in the serum, synovial fluid, and urine of RA patients have been 
detected, and reflect the high levels of AGE compounds present within the body 101,102. 
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Figure 9. Representation of the formation of Amadori product and advanced glycation end products by oxidative glycation. 
When the carbonyl group of Ribose interacts with a free amine group on lysine, they form Schiff base, which is reversible. 
The Amadori product is considered the first glycation product. This undergoes spontaneously induced breakdown and 
rearrangement to form stable advanced glycation end products. The example of pentosidine is shown, which occurs when 
the lysine Amadori product cross links with arginine in collagen. 
 
 
 
1.3.2 Post-Translational Modification of Protein by ROS  
Inflammation is generally categorized into two subtypes: acute and chronic inflammation. 
Acute inflammation is short lived, self-resolving and usually beneficial for the host. Chronic 
inflammation occurs when there is a malfunction in the resolution stage of the process, 
resulting in a prolonged and dangerous activation of the immune system. The production of 
ROS is central to the progression of many inflammatory diseases 99. The main producers of 
ROS within the family of immune cells are polymorphonuclear neutrophils (PMN). ROS 
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released by PMN can act as both a signalling molecule and a mediator of inflammation. 
During phagocytosis, neutrophils experience a ‘respiratory burst’ due to increased 
respiration, resulting in the generation of large quantities of ROS 100.  During RA, billions of 
PMN are found in the synovial fluid and therefore could be major contributors of 
extracellular ROS in the joint space 103,104.  
 
Traditionally, ROS have been regarded to function primarily as anti-microbial agents, but 
their role as secondary messengers has become prevalent in recent years. ROS hold 
characteristics that are prerequisites for signalling molecules: they are small, diffusible and 
can be rapidly produced and degraded. There is strong evidence to suggest their role in 
homeostasis, cell proliferation and differentiation, and inflammatory response 100,105. 
However, due to their toxicity there is only a narrow range in which they function as 
messengers effectively. The overproduction of ROS, as is often seen during chronic 
inflammation, can lead to direct injury to proteins, lipids and nucleic acids, resulting in cell 
death 106. The overproduction of ROS during chronic inflammation has also been found to 
cause post-translational modification of matrix proteins. Post-translational modification of 
cysteine, methionine and tyrosine by ROS are well characterized and shown in Figure 10. 
Studies have previously demonstrated the importance of ROS post-translational modification 
in the context of arthritis and type I diabetes 94,107,108. As will be discussed in the next 
chapter, collagen type II (CII) is the most abundant protein in cartilage, and therefore is an 
obvious target for modification by excessive levels of ROS within the inflamed, arthritic joint.  
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It was previously found that CII that has been post-translationally modified by reactive 
oxidants is a neoantigen in RA 108.  
 
During inflammation, phagocyte NADPH oxidase (NOX2), inducible nitric oxide synthase 
(iNOS), and myeloperoxidase (MPO) are all primary sources of reactive oxygen, nitrogen and 
halide species, which are capable of post-translationally modifying proteins. A variety of 
reactive oxygen, nitrogen and chlorine species are able to post-translationally modify 
protein, including the hydroxyl radical (•OH), the carbonate radical (CO3•-), hypochlorite 
(OCl-) and products formed from reactions involving peroxynitrite (ONOO-). These reactive 
species are able to modify a wide range of amino acids within the protein. Cysteine residues 
are readily oxidized due to the existence of a free thiol (-SH) group. The free thiol group can 
be oxidized to form a disulfide bond with another thiol group.  In the presence of oxidants 
such as •OH, cysteine can also be oxidised to cysteine sulfenic, sulfinic and sulfonic acid 
derivatives, as demonstrated in Figure 10(A). Methionine can also be oxidized in a similar 
manner to form methionine sulfone Figure 10(B). Other oxidative post-translational 
modifications include tyrosine oxidation to 3,4-dihydroxyphenylalenine, or inter- or intra-
molecular di-tyrosine cross-linking via the formation of tyrosyl radicals Figure 10(C). 
Chlorination of proteins, mediated by HOCl produced by MPO, is another important 
modification that can occur on proteins which causes altered protein function. Chlorination 
has been most reported to occur on tyrosine residues, forming chlorotyrosine as seen in 
Figure 10(C). Chloramines on lysine and histidine residues constitute important 
intermediates in stable end products of chlorination. 
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Figure 10. Structures of amino acids after post-translational modifications by reactive oxygen, nitrogen and chlorine species. 
Structures of some of the post-translationally modified forms of (a) cysteine residues, (b) methionine residues and (c) 
tyrosine residues. Adapted from Ryan et al 109.  
 60 
 
 
1.4 Antibodies to Post-Translationally Modified Collagen II 
1.4.1 Autoantibodies to Collagen II Post-Translationally Modified by Reactive 
Oxidants in Arthritis Patients 
CII was first proposed as an autoantigen in RA in 1964 110. Autoreactivity to CII has been 
highlighted in the pathogenesis of RA, with autoantibodies found in between 3-27% of 
patients 111,112. Most studies have shown the prevalence of autoantibodies to CII to be low, 
and the titers do not compare to the current gold standard biomarker of anti-CCP antibodies. 
The arthritogenic nature of CII is well established and is the basis for one of the most 
established models of murine RA. Collagen induced arthritis (CIA) involves immunizing rats 
and mice with CII in complete or incomplete Freund’s adjuvant (CFA/IFA). The immunization 
results in polyarthritis, whereas similar immunizations with other collagen types does not 
have the same effect 113. Furthermore, arthritis could be induced when using CII from a 
variety of sources (chicken, bovine and bovine vitreous), but not when CII was thermally 
denatured 113,114.  
 
Although studies have highlighted the presence of autoantibodies to CII in a subset of 
patients with RA and the arthritogenic nature of CII is well established, the role of CII within 
the disease is still not understood. Given that only a small subset of patients present with 
autoantibodies to CII, it is now accepted that they are secondary to inflammation and not of 
pathological significance 113. In recent years, CII that has been post-translationally modified 
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by ROS (ROS-CII) has been highlighted within the context of RA. In 2005, Nissim et al 
simulated the post-translational modifications of CII by ROS in vitro. This modified CII was 
used as the antigenic coating in an enzyme linked immunosorbent assay (ELISA) to test the 
reactivity of sera from patients with arthritis. The ELISA showed that sera from patients with 
RA were positive binders to ROS-CII (45.2%, with 22.6% considered strong binders), whereas 
only one sample bound strongly to CII (3.2%). Sera from non-RA patients showed minimal 
binding to ROS-CII (2.4%) and no binding to CII 108. The study also assessed the binding of 
sera from CIA mice to native and ROS-CII by ELISA. The binding of sera from CIA mice was 
stronger to native CII but showed positive binding to modified CII. It was also observed that 
mice with a lower disease activity exhibited lower binding to modified CII 108. Follow up 
studies by Nissim’s group confirmed the presence of autoantibodies to ROS-CII in RA patients 
92. When stratifying patients, it was found that binding is particularly high in early RA subsets, 
with 92.9% of patients binding strongly to ROS-CII 92. These studies have opened discussion 
regarding the role ROS-CII plays in arthritis, and have provided the basis for a potential 
additional biomarker of RA.  
 
Interestingly, it has also previously been found that oxidative post-translationally modified CII 
is present in OA cartilage 115. These results were unexpected as OA is considered a 
degenerative disease rather than an autoimmune disease, and generally very little is known 
about the importance, if any, of post-translational modification in the progression of disease. 
However, several studies have suggested the presence of autoantibodies to native proteins, 
suggesting a role of the adaptive immune system within the disease 116,117. However, the 
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titration of autoantibodies in OA patients is often significantly lower than RA patients, hence 
why there is currently no biomarker diagnostic for OA 92.  
 
 
1.4.2 Antibodies to Post-Translationally Modified Collagen II Raised from a 
Phage Display Library 
Having found that autoantibodies to ROS-CII are present in a high number of RA patients, it 
was therefore likely that the antigen ROS-CII exists in the inflamed joint. This neoantigen was 
hypothesized to be found exclusively in the inflamed joint, where the high levels of ROS have 
modified CII. If this hypothesis was correct then it offers a novel way to target arthritic joints.  
 
To target the potential neoantigen, Hughes et al produced single chain variable fragments 
(scFv) specific to ROS-CII from a semisynthetic phage display human library 118. CII was 
exposed to .OH, HOCl, ONOO−, or ribose to modify the protein in vitro. Using the phage 
display library, 3 rounds of subtractive selection (using native CII for subtraction) was 
performed to find scFv specific to the various ROS-CII. Soluble scFv were obtained from an 
infected, non-suppressor Escherichia coli HB2151 strain. To test the specificity of the 
produced scFv in vitro, immunostaining of tissue sections from RA and OA patients was 
performed. The immunostaining showed the scFv bound specifically to damaged cartilage, 
but not healthy cartilage. Interestingly, binding was present in both RA and OA samples, 
albeit with different patterns. RA samples showed a diffused staining throughout all layers of 
cartilage, whereas OA samples showed staining specifically at sites exhibiting features of 
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active OA. The scFv also showed strong staining to cartilage tissue from murine models of 
arthritis, both OA and RA 118.  
 
The antibodies were also tested in vivo using optical imaging techniques. By fluorescently 
labelling the scFv, localisation could be observed using biofluorescence in vivo imaging 
system in arthritic mice. Models of monoarthritis were used to assess the specific localisation 
in the one inflamed joint or paw, and successful localisation was observed 39,118. 
The production of scFv specific to ROS-CII gives potential for targeting therapeutics 
specifically to the arthritic joint. Hughes et al proved this concept by fusing vIL-10 to one of 
the anti-ROS CII scFv clones, namely 1-11E, and administering systemically in arthritic mice. A 
matrix metalloprotease (MMP) cleavage site meant the vIL-10 would only be released in the 
arthritic joint. The study found the antibody localised in the arthritic joint and reduced 
inflammation more effectively than vIL-10 fused to a non-specific scFv 39.  
 
The specificity of these anti-ROS CII scFv mean therapeutics can be targeted specifically to 
the inflamed joint. This holds great importance as unwanted side effects can be potentially 
reduced, and novel anti-inflammatories can be delivered exactly to the site of the body they 
need them. The candidate antibody used in these studies, ‘1-11E’, undergoes glycosylation of 
the binding site during production, which hinders its binding potential. This can be prevented 
with the use of an N-linked glycosylation inhibitor, such as tunicamycin, however the result is 
cell death during transfection and a large reduction in the overall antibody production. 
Translationally, the 1-11E antibody has a major disadvantage. To have another candidate 
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from the same library that shows similar binding patterns, without the issues of production, 
would be highly beneficial and is one of the major goals of my thesis. 
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1.5 Microvesicles 
Intercellular communication is a hallmark of survival in a multicellular organism, and in the 
last two decades a new mode of communication has arisen in the form of extracellular 
vesicles (EV). EV have been found to act as vehicles for the transfer of membrane or cytosolic 
protein, lipids and RNA between cells 119. It has only become apparent in recent years how 
physiologically relevant EV are, and the importance to understand both the mechanisms in 
which they are released and the effect they have on other cells.  
 
In recent years, the nomenclature regarding the subtypes of extracellular vesicles has 
become more refined. The release of apoptotic bodies from cells undergoing apoptosis has 
been long known, however it is only recently appreciated that healthy cells shed vesicles 
from their plasma membrane 119. These vesicles, ranging in size from around 100-1000nm 
120,  are referred to as microvesicles (but also known as microparticles, ectosomes and 
shedding vesicles). The term exosome was initially given to vesicles in the size range of 40-
1000nm, but are now referred to as vesicles of 40-100nm released during reticulocyte 
differentiation as a consequence of multivesicular endosome (MVE) fusion with the 
membrane 119,121.  Exosomes and microvesicles (MV) are released through different 
mechanisms, however identification and differentiation after their release still proves 
difficult.  
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1.5.1 Microvesicle Formation and Function 
For many years, the small vesicles shed from the surface of cells were considered nothing 
more than artifacts, however their importance is now becoming appreciated as their 
mechanisms attempt to be alluded. Microvesicles are speculated to be released by most, if 
not all, cell types 122, and increases in their production have been associated with certain 
diseases 123. Before the shedding of MV from the cell membrane, budding of small 
cytoplasmic protrusions occurs, which then detach by fission of their stalk 122. Protein 
accumulation in the membrane, and therefore in the content of the shed vesicle, has been 
shown to occur within the budding process 122. The mechanism in which this occurs remains 
obscure and not well understood.  
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Figure 11. Illustration representing the formation of microvesicles from a cell membrane. The increase in intracellular calcium 
results in cytoskeletal rearrangement and the shedding of vesicles containing cargo molecules. Image created with 
Biorender. 
 
Resting cells can shed MV, however the rate of shedding drastically increases upon 
stimulation. It is now accepted that calcium induces strong shedding rates. A sustained influx 
of calcium results in the cytoskeletal rearrangement, and calcium dependent proteases 
cleave talin and -actinin, freeing the plasma membrane from the cytoskeleton 124,125. 
Shedding of vesicles results in the constant removal of small portions of the plasma 
membrane, which must be replaced to protect the parent cell. Upon stimulation, the high 
rate of shedding must be compensated by a concomitant input from the cytoplasm. This 
mechanism is termed regulated exocytosis of non-secretory vesicles 122,126.  
 
 68 
Upon shedding, many MV will not remain intact and will release their contents. This will 
occur within the extracellular space and the results of this release depend on the material 
contained within the vesicle. For example, a vesicle containing MMP can result in the 
destruction of extracellular matrix, a mechanism by which tumour cells increase their 
mobility 122. The release of cargo can also be important for the release of signalling 
molecules. An example of this is the release of the pro-inflammatory cytokine IL-1β from 
vesicles derived from dendritic cells and macrophages 127.  Those vesicles that do not release 
their cargo following shedding will continue to interact with their target cell. It has been 
found that MV will not interact with any cell but only those that they recognize specifically 
122. An example of this is a study conducted by Losche et al, in which they discovered that the 
vesicles shed from platelets transfer tissue factor to monocytes, but not to neutrophils 128. In 
many cases the interaction is limited to the cell surface, usually the MV binding to receptors 
present on the target cell. It is also recognised that MV can fuse into the plasma membrane 
of the target cell or be taken up into the cell by endocytosis, which will vary dependent on 
the cell type 122.  
The function of MV during inflammation is becoming better characterized as time goes on. 
Inflammation is typically thought of as a cell driven process, either directly or indirectly by 
soluble mediators. The shedding of vesicles is now known to participate in the process of 
inflammation, acting in both a pro- and anti-inflammatory nature. MV from a single cell type 
can vary in its nature dependent on the stage of inflammation. For example, the MV shed by 
neutrophils in the early stages of inflammation stimulate macrophages to produce anti-
inflammatory factors such as transforming growth factor ß (TGF-ß) and Interleukin-10 (IL-10) 
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and reduce pro-inflammatory factors such as TNF-α and Interleukin-8 (IL-8) 122,129. During 
later time points, the MV shed from neutrophils can have a pro-inflammatory nature, 
stimulating the release of factors such as Interleukin-6 (IL-6) and monocyte chemotactic 
protein 1 (MCP1), which drive inflammation 130,131.  
 
The overall function of MV cannot be simply summarized as it appears from the literature 
that both the cell type involved in the shedding and the microenvironment following release 
alter the overall function of the vesicle. In the context of inflammation, MV could be 
categorized into those which exhibit a pro-inflammatory nature and those that exhibit an 
anti-inflammatory nature, with one cell type capable of shedding both kinds of vesicle. The 
complexity of MV release is beginning to be dissected, but there are still many areas of 
vesicle biology that are not understood.  
 
 
1.5.2 Neutrophil Derived Microvesicles and Arthritis 
In 2004, Gasser and Schifferli first proposed that polymorphonuclear neutrophil (PMN) 
derived MV hold anti-inflammatory and immunosuppressive qualities, contradicting the 
proposed hypothesis that they would increase IL-8 and TNF production 129. Before these 
findings, MV from platelets, endothelial cells and monocytes were found to activate 
monocytes and endothelial cells in a pro-inflammatory manner 129. Conversely, neutrophil 
derived MV increased the release of TGF-β in macrophages, and were able to actively inhibit 
inflammatory responses of macrophages to zymosan and lipopolysaccharide 129. The 
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mechanism in which PMN MV elicit an anti-inflammatory response is now well characterized. 
Phosphatidylserine (PS) is present on the outer membrane of PMN derived MV, which was 
found to repress inflammation and promote anti-inflammatory pathways, in particular 
through the production of TGF-β 132.  Hoffmann et al presented that this phenomenon occurs 
through the interaction of PS with the PS receptor. Interestingly, PS liposomes did not inhibit 
bone marrow derived dendritic cell activation in vitro, but had a significant effect on the 
other adaptive immune cells used in the study. The authors state that bone marrow derived 
dendritic cells do not express PS receptor, strengthening the theory that PS exhibits its anti-
inflammatory effects through the binding to PS receptor 132.  
 
Later studies have also found that PMN MV inhibits the nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) complex. PMN MV inhibits the NF-κB p65 translocation 
to the nucleus in macrophages, leading to the down regulation of pro-inflammatory genes, 
including TNF, IL-1, IL-6 and IL-8 133. By using a blocking antibody, the authors showed that 
MerTK is centrally involved in the inhibition of NF-κB.  This blockade was proposed to be 
through MerTK mediated activation of the PI3K/Akt pathway, resulting in negative regulation 
of the NF-κB complex 133. The regulation of NF-κB via PI3K/Akt proves controversial however, 
with both negative and positive gene expression demonstrated.  
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Figure 12. Summary of the descriptions in literature of the interaction of neutrophil derived microvesicles on various myeloid 
cells. The actions of neutrophil derived microvesicles on myeloid cells induces a pro-resolving phenotype. Image created 
with Biorender. 
 
 
Studies over the past 10 years by members of our laboratory have extended the existing 
knowledge regarding PMN derived MV. In 2008, Dalli et al described the expression and 
functional activity of Annexin A1 (AnxA1) on PMN MV 134. AnxA1 is an endogenous 
glucocorticoid-regulated protein that is able to potently counter-regulate inflammation 135. 
The study also found the potent anti-migratory effect of PMN MV, which also relies on the 
presence of AnxA1 as shown by generating vesicles from AnxA1 knock out mice 134. More 
recent studies by Headland et al uncovered the chondroprotective effects of PMN MV in a 
K/BxN mouse model of arthritis 136. The studies also provided evidence of MV penetration 
into cartilage tissue, a property that is exclusive to PMN MV and not observed by PMN 136.  
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There is mounting evidence demonstrating the anti-inflammatory effects of PMN MV, 
contrary to the initial hypothesis based on MV derived from platelets and endothelial cells. 
The anti-inflammatory effects of PMN MV in inflammatory arthritis are significant, and the 
chondroprotective effects are important as no current existing therapy can penetrate and 
protect native cartilage. Hence, the use of PMN MV for therapeutic purposes is becoming an 
area of great interest for future studies. 
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1.5.3 Microvesicles as Therapeutic Vectors 
The ability of PMN MV to enter cartilage is a unique quality which has not previously been 
observed. The additional benefits of the described anti-inflammatory properties of PMN MV 
make them a viable therapeutic.  MV have been exploited for therapy in experimental 
models multiple times in the literature. For example, MV derived from mesenchymal stem 
cells have been used to stimulate cardiac tissue repair in mice 137 and MV derived from 
dendritic cells have been used in cancer immunotherapy 138. The notion that MV can play an 
efficacious role in the treatment of disease is becoming clear, and can potentially apply to 
PMN MV in the context of arthritis. 
 
Microvesicles have previously been utilized as scaffolds for therapeutic purposes. In 2011, 
Norling et al enriched MV from human PMN with aspirin-triggered resolvin D1 or a lipoxin A4 
analogue 139. These enriched MV dramatically reduced polymorphonuclear cell influx in 
murine peritonitis, shortened resolution intervals and exhibited pro-resolving actions, 
therefore accelerating keratinocyte healing 139. In 2013, Dalli et al administered alpha-2-
macroglobulin (A2MG) enriched PMN MV to mice with microbial sepsis. Administration of 
A2MG-enriched-microparticles protected against hypothermia, reduced bacterial titres, 
elevated immunoresolvent lipid mediator levels in inflammatory exudates and reduced 
systemic inflammation 140.  These studies have shown the potential of using PMN MV as a 
pro-resolving scaffold. The enrichment of PMN MV with protein has been successful and 
efficacious in models of peritonitis and sepsis.  In the context of arthritis, Headland et al 
found that the intravenous administration of PMN MV in arthritic mice was not sufficient to 
 74 
reduce arthritic scores, and intra-articular injection was necessary to see a reduction in 
inflammation 141.  This slightly hinders the therapeutic potential of PMN MV in arthritis, as 
translationally a non-invasive administration such as intravenous injection would be 
preferred. Nonetheless, the study did not administer a range of doses, and it is likely a higher 
number of MV are needed to show efficacy when administered systemically.  
 
Targeting the PMN MV to the arthritic joint by enriching the vesicles with antibodies specific 
to damaged cartilage proposes a viable way to deliver PMN MV systemically. Furthermore, 
MV could potentially be enriched with both antibodies that target and localize them to the 
arthritic joint and anti-inflammatory therapeutics. Enrichment of MV with antibodies has not 
been previously attempted and will form part of the basis of this thesis.  
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1.6 Hypothesis and Aims 
A common feature of both OA and RA is cartilage damage. My primary supervisor’s research 
group have developed antibodies specific to collagen type II that has been post-
translationally modified by reactive oxygen species (ROS-CII), which selectively binds to 
damaged arthritic cartilage. Previous work has demonstrated that anti-ROS-CII could be used 
to direct therapeutics to the inflamed arthritic joints 39. Importantly, the anti-ROS-CII-
therapeutic fusion accelerated the reduction of inflammation in diseased joints, with similar 
features as healthy joints after treatment. 
 
The main hypothesis of my thesis is that anti-ROS-CII can be used to deliver biological 
scaffolds specifically to arthritic joints. This will enable the development of potent yet safe 
treatments. The current study focused on utilizing neutrophil derived extracellular 
microvesicles (MV) as biological scaffolds; which exhibit inherent anti-inflammatory and pro-
resolving properties and have been shown to penetrate and protect cartilage.  
 
The main objectives of the thesis were to test and assess the specific targeting and 
therapeutic potential of anti-ROS-CII fortified PMN MV, additionally loaded with either single 
or combined therapeutics. The working hypothesis is that PMN MV enriched with anti-ROS-
CII antibodies will be localized and retained within the arthritic joint. Incorporating combined 
therapies will help to resolve inflammation, whilst simultaneously the PMN MV scaffold will 
protect cartilage. Hence, anti-ROS-CII fortified PMN MV can be developed into a ‘magic 
 76 
bullet’ combined treatment that can address the safety issue of systemic treatment by 
ensuring targeting specifically to the arthritic joint.  
 
Specific aims: 
In Vitro Assays 
• Express new candidate antibody ‘3-11E’ (scFv produced by bacterial expression and 
IgG/fusion antibodies by transient transfection) 
• Analysis of new candidate antibody, including ELISA, SDS PAGE, and 
immunofluorescence 
• Generate PMN MV in vitro and analyse by flow cytometry and nanoparticle tracking 
• Fortify PMN MV with anti-ROS-CII antibodies by aqueous energy dissemination.  
• Analyse the fortified MV by flow cytometry, ELISA, and immunofluorescence.  
 
In Vivo Assays 
A. Localization studies 
• Analysis of the localisation of new candidate anti-ROS-CII antibody ‘3-11E’ in mouse 
models of arthritis 
• Localisation study of 3-11E fused to an anti-inflammatory cytokine 
• Localisation study of PMN MV fortified with anti-ROS-CII 
B. Treatment studies 
• Treatment study of PMN MV fortified with anti-ROS-CII fused to an anti-inflammatory 
cytokine 
• Treatment study of PMN MV fortified with multiple therapeutics 
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Chapter 2: Materials and Methods 
 
2.1 Production of Antibodies to Post-Translationally Modified Collagen II 
2.1.1 Production of scFv from Escherichia Coli HB2151 
E. Coli (previously transformed by a member of the Nissim Lab with the plasmid of the scFv 
antibody) were cultured overnight in 5 mL OF 2xTY broth supplemented with 1% glucose and 
100 µg/mL ampicillin at 37°C and 125 rpm. Following overnight incubation, cultures were 
diluted 1:100 in 2xTY broth supplemented with 0.1% glucose and 100 µg/mL ampicillin. 
Cultures were grown until optical density (OD) at 600 nm reached between 0.6 and 0.9. 
Induction of bacteria using 1 mM isopropyl β-D-thiogalactoside (IPTG, Sigma I5502) was 
conducted between OD 0.6 and 0.9 and cultures were incubated overnight at 30°C and 125 
rpm. The following day, bacteria cultures were centrifuged at 4000g at 4°C for 15 minutes. 
Supernatant was collected and stored at 4°C. Bacterial pellets were resuspended in 1/20 of 
the original volume of 30 mM Tris pH 7.0, 20% sucrose and 1 mM EDTA and incubated on ice 
for 20 minutes. Resuspended pellets were then centrifuged at 10,800g at 4°C for 15 minutes. 
Supernatant was then collected and combined with the previously collected supernatant and 
stored at 4°C. Pellets were then resuspended in 5 mM magnesium sulfate solution and 
incubated on ice for 20 minutes.  Resuspended pellets were then centrifuged at 10,800g at 
4°C for 15 minutes. As previously described, supernatant was collected, combined with 
previous supernatant and stored at 4°C for purification.  
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2.1.2 Harvesting of Plasmid DNA  
E. coli (previously transformed with the plasmid of interest) were cultured overnight in 250 
mL of LB Broth (Sigma L3022) supplemented with 1% glucose and 100 µg/mL Ampicillin at 
37°C and 125 rpm. Bacterial cultures were harvested by centrifugation at 6000g for 20 
minutes. DNA isolation was conducted using a Qiagen QIAFilter Plasmid Maxi Kit according to 
the manufacturer’s instructions. Briefly, bacteria were lysed and DNA was purified by the 
QIAGEN-tip containing a resin to bind plasmid DNA. Subsequent quantification of DNA was 
conducted using NanoDrop spectroscopy at 260 nm.  
 
 
2.1.3 Production of IgG and Fusion Proteins by Transient Transfection 
Transient transfection of IgG and vIL-10 fusion antibodies were conducted in Expi293f cells. 
Transfection was only performed in Expi293f cells below passage 20 and with a cell viability 
of >90%. Plasmid DNA isolation was conducted as described above. Firstly, 7.5 × 107 cells 
were seeded in 25.5 mL of Expi293f Expression Medium (Thermo Fisher A1435101) in a 125 
mL sterile, disposable conical flask. Cells were counted using a hemocytometer and viability 
was assessed using Trypan Blue exclusion. For each 25.5 mL transfection, 30 µg of plasmid 
DNA was added to Opti-MEM® I reduced serum medium (Thermo Fisher 31985070) to a total 
volume of 1.5 mL. Following plasmid DNA dilution, 81 μL of ExpiFectamineTM 293 Reagent 
was diluted in Opti-MEM® I medium to a total volume of 1.5 mL. This was mixed gently and 
incubated for 5 minutes at room temperature. Following a 5-minute incubation, the diluted 
DNA was combined with the diluted ExpiFectamine and mixed gently. The mixture was 
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incubated for 20 minutes at room temperature to allow the DNA- ExpiFectamineTM 293 
Reagent complexes to form. Following the incubation, the 3 mL mixture was added to the 
previously prepared cell suspensions. Cells were incubated for 20 hours at 37°C, 125 rpm and 
8% CO2 in air. Following 20 hours of culture, 150 μL of ExpiFectamineTM 293 Transfection 
Enhancer 1, and 1.5 mL of ExpiFectamineTM 293 Transfection Enhancer 2 were added to each 
flask. Cultures were incubated for 5 days to allow optimal expression. Harvesting of 
antibodies was conducted by centrifugation at 423g for 5 minutes. Supernatant was 
collected and stored at 4°C for purification.  
 
2.1.4 Purification of Antibodies  
IgG and vIL-10 fusion antibodies were purified by nickel column purification due to the 
presence of a histidine tag, whereas scFv antibodies were purified by protein A column 
purification.  
2.1.4.1 Nickel Column Purification 
Supernatants to be purified were treated with a 10x concentrated lysis buffer, composed of 
50 mM monosodium phosphate, 300 mM sodium chloride and 10 mM imidazole. Ni-NTA 
slurry (Qiagen 1018244) was pre-incubated in 1x lysis buffer and centrifuged for 2 minutes at 
423g. Ni-NTA slurry was resuspended in 1 mL of lysis buffer and was added to the 
supernatant containing the antibody. Supernatant + Ni-NTA resin was incubated at 4°C on a 
roller for 3 hours. Supernatant + Ni-NTA were then loaded into a 15 mL column with a 
tapped bottom outlet. Supernatant could flow through the column collecting the resin. Flow 
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through was stored at 4°C for SDS-PAGE analysis. Resin was then washed with 15 mL of wash 
buffer, composed of 50 mM monosodium phosphate, 300 mM sodium chloride, 20 mM 
imidazole plus 0.05% Tween 20. Wash fractions were stored at 4°C for SDS-PAGE analysis. 
Antibodies were then eluted using 50 mM monosodium phosphate, 300 mM sodium chloride 
and 250 mM imidazole into 0.5mL fractions and stored at 4°C for analysis. All collected 
samples were tested by SDS-PAGE and spectrophotometry at 280 nm.  
2.1.4.2 Protein A Column Purification 
Supernatants to be purified were treated with 10x binding buffer solution (200 mM sodium 
phosphate, pH 7.0). Protein A slurry (GE Healthcare 17-0780-01) was added to a 15 mL 
column with a tapped bottom outlet and was washed using phosphate buffer saline (PBS) 
and 1x binding buffer solution. Supernatant was then allowed to flow through the column 
twice at 4°C. Protein A resin was then washed with 25 mL volumes of PBS, PBS + 0.5 M 
sodium chloride, 0.2 M glycine solution pH 6.0 and finally with 0.2 M glycine solution pH 5.0. 
Each wash flow through was collected and stored at 4°C for analysis. Antibodies were then 
eluted using a 0.2 M glycine solution pH 3.0, and collected into fractions containing 200 µL of 
Tris pH 9.0 solution, to a total volume of 1 mL. Eluted fractions were stored at 4°C until 
analysis. All collected samples were tested by SDS-PAGE and spectrophotometry at 280 nm. 
 
2.1.5 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
Resolving gels were produced with varying percentages of acrylamide depending on the 
known molecular weight of the antibody being analysed: for scFv with a molecular weight of 
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around 25-30 kDa a 15% solution was used; for scFv-vIL-10 fusion antibodies with a 
molecular weight of around 50 kDa a 12% solution was used and for IgG antibodies with 
heavy chain molecular weight of around 50 kDa and a light chain molecular weight of around 
25 kDa a 10% solution was used. Following polymerization of the resolving gel, the stacking 
gel was prepared. The stacking gel was assembled with 0.75 mm combs to produce 10 wells. 
Following polymerization, the gel was assembled in an electrophoresis tank and filled with 
SDS running buffer. Samples were denatured using a 4x concentrated -Mercaptoethanol 
solution and incubated for 5 minutes at 95°C. Protein ladder and samples were added to the 
wells in the stacking gel. The electrophoresis tank was assembled, and gels were run at 100 V 
for 1 hour and 30 minutes. Following electrophoresis, protein was visualized by an incubation 
with Coomassie brilliant blue solution (0.2% Brilliant blue Sigma B-7920, 45% methanol and 
10% acetic acid) following by destaining (40% methanol and 10% acetic acid solution).  
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2.1.6 In vitro post-translational modification of Collagen II 
Bovine sourced collagen II (CII) was diluted 1 mg/mL in 0.1M Acetic Acid for three hours at 
4°C on a roller. Following three hours of incubation and dissolving of the CII, the acetic acid 
was replaced with PBS by dialysis using a Slide-A-Lyzer dialysis cassette (10,000 MWCO, 
Thermo Scientific). CII was post translationally modified in vitro to mimic native ROS 
modifications by the following incubations: 
- 2 M of D-Ribose for 72 hours at 37°C to mimic non-enzymatic glycation. 
- 1 mM Sodium hypochlorite for 10 hours at 37°C to mimic HOCl modification. 
 
2.1.7 Enzyme Linked Immunosorbent Assay 
Immunosorbent 96 well plates were coated with 100 µL of 10 µg/mL collagen II or ROS 
modified collagen II. Coatings were incubated overnight at 4°C. Following overnight 
incubation, plates were washed with 200 µL of PBS + 0.05% Tween 20  (PBST) and blocked 
with 2.5% powdered milk (Marvel) in PBST. Plates were blocked for 2 hours at room 
temperature. Primary antibody (anti-ROS-CII) was serially-diluted in blocking solution and 
added to the plate. Primary antibody was incubated for 2 hours at room temperature. 
Following incubation, plates were washed with 200 µL of PBST. Secondary antibody was 
diluted (anti-hIgG (Sigma A8792) 1:1000 dilution; anti-His Tag (Sigma A7058) 1:4000 dilution) 
and added to each well. The secondary antibody was incubated for 2 hours at room 
temperature before three washes with 200 µL of PBST. The ELISA was then developed using 
100 µL of TMB solution (0.1 mg/mL TMB, 0.1M sodium acetate and 2 µL per 10mL of 30% 
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Hydrogen peroxide). The reaction was stopped using 50 µL of 20% Sulfuric acid and 
absorbances were read at 450 nm.  
 
 
2.2 In vivo localisation studies of scFv, IgG and vIL10 Fusion Antibodies to 
Post-Translationally Modified Collagen II in Mouse Models of Arthritis 
2.2.1 Labelling of Antibodies using a Cyanine Based Fluorophores 
CyDye kits were purchased from GE Healthcare and used according to the manufacturer’s 
instructions.  For IgG and vIL10 fusion protein labelling, 1 mg of protein was labelled using 
one dye vial. For scFv protein labelling, 200 µg of protein was labelled using one dye vial. 
Different mass of protein was used depending on the molecular weight to ensure molar 
equivalence. The CyDye was resuspended in 400 µL of PBS. The appropriate volume of 
antibody (depending on concentration) was added to the 400 µL of dye alongside a 1/10 
dilution of 1 M Sodium bicarbonate pH 9.0. Antibody + dye was incubated in the dark for 1 
hour at room temperature with gentle agitation. To separate free dye after incubation, 
samples were run through a PD-10 desalting column (GE Healthcare). Antibody was eluted by 
adding 3 mL of PBS to the column and collecting the eluates. 
 
The formulae used to calculate protein concentration uses absorbance at 280 nm, which is 
typical for protein quantification. The absorbance of the cyanine dye is also measured at the 
appropriate wavelength (678 nm) and multiplied by the amount absorbance of the cyanine 
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dye at 280 nm. This calculation removes the influence of the cyanine dye to give a true 
antibody concentration in mg/mL. To calculate the dye to protein ratios, the molar extinction 
coefficient of the antibody is divided by the molar extinction coefficient of the dye. This 
number is then used alongside the maximum absorbance of the dye and the absorbance of 
antibody concentration at 280 nm to calculate a value that represents the number of dye 
molecules per antibody.  
 
2.2.2 Localisation of Antibodies in a Mouse Model of Rheumatoid Arthritis 
Antigen induced arthritis (AIA) was performed on female, 10-week-old C57BL/6 mice. Mice 
were housed in groups of five in individually vented cages, maintained at 21 ± 2 °C on a 12-
hour light/dark cycle and with food and water provided. All experimental protocols were 
performed in compliance with the UK Animals (Scientific Procedures) Act 1986 regulations 
for the handling and use of laboratory animals (Home Office project licence PPL no: 
70/8264). Mice were anaesthetized using 2.5% isoflurane. Mice were primed on day 0 with 
subcutaneous injection of 100 µg of methylated bovine serum albumin (mBSA) in complete 
Freund’s adjuvant (CFA). On day 21, mice were injected intra-articularly with 50 µg of mBSA 
in saline to stimulate inflammation in the knee joint. Inflammation was stimulated in only 
one knee, with contralateral knees acting as healthy controls. 
 
As demonstrated in Figure 13, on day 22, 24 hours after stimulating inflammation in the knee 
joint, mice were administered Cy5.5 labelled anti-ROS-CII antibodies intravenously (10 µg of 
IgG and vIL-10 fusion antibody and 50 µg of scFv). Following intravenous administration, mice 
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were biofluorescently imaged by in vivo optical imaging at several time points, as described 
in 2.2.4. Fluorescence in the knee joints were analysed by creating Regions of interest (ROI) 
using Living Image 4.4 software and assessing average fluorescence intensity. 
 
 
Figure 13. Timeline of the Antigen Induced Arthritis (AIA) mouse model. Mice were primed on day 0 by a subcutaneous 
injection at the base of the tail of methylated bovine serum albumin (mBSA) in complete Freund’s adjuvant. On day 21, mice 
were challenged with an intra-articular injection of mBSA in one knee joint to induce inflammation. On day 22, mice were 
treated intravenously with antibody, followed by assessment from day 22 onwards. Image created with Biorender. 
 
2.2.3 Localisation of Antibodies in a Mouse Model of Osteoarthritis 
Destabilisation of the medial meniscus (DMM) performed on male, 10-week-old C57BL/6 
mice in collaboration with the Kennedy Institute of Rheumatology, University of Oxford. 
Members of the Lim Lab at the Kennedy Institute of Rheumatology, University of Oxford, 
performed all surgeries. Mice were housed in groups of five in individually vented cages, 
maintained at 21 ± 2 °C on a 12-hour light/dark cycle and with food and water provided. All 
experimental protocols were performed in compliance with the UK Animals (Scientific 
Procedures) Act 1986 regulations for the handling and use of laboratory animals. Mice were 
 86 
anaesthetised with 2.5% isoflurane. Following capsulotomy, the right meniscotibial ligament 
was transected, resulting in the release of the medial meniscus from its tibial attachment. 
Sham surgery consisted of capsulotomy alone. For pain relief, animals were given Vetergesic 
by subcutaneous injection prior to recovery from anaesthesia. Animals were monitored daily 
post-surgery. 
 
At time points following DMM surgery (4 and 8 weeks post-surgery), mice were injected 
intra-articularly with 1µg of scFv antibody into both DMM and sham knees. Retention of the 
antibody within the knee joints was analysed by biofluorescence imaging by In vivo optical 
imaging at several time points. Fluorescence in the knee joints were analysed by creating 
regions of interest (ROI) using Living Image 4.4 software and assessing average fluorescence 
intensity as described in 2.2.4. 
 
2.2.4 In vivo Imaging System  
The knee area of mice was shaved before fluorescence imaging with IVIS Lumina III imager, 
using the excitation wavelength of 675 nm and an emission wavelength of 720 nm for Cy5.5 
fluorescence (Perkin Elmer, Waltham, Massachusetts, USA) together with a black and white 
photograph for orientation. Images were taken at different time points up to 336 hours post-
i.a. injection or 48 hours post-i.v. injection. Images were analysed using Living Image 4.4 
(Perkin Elmer, Waltham, Massachusetts, USA) to obtain the average fluorescence intensities 
of a circular region of interest encompassing the knee joint. No background intensities were 
subtracted from the values; autofluorescence is only present in C57BL/6 mice in shaved 
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areas, and the data from the contralateral knee joints is shown in all figures and time points 
to indicate the nonspecific retention of antibody. Following the last imaging time point, mice 
were euthanized. 
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2.3 In vitro Analysis of Arthritic and Non-Arthritic Knee Joints Treated with 
vIL10 Fusion Antibodies  
2.3.1 Processing of Knee Joints  
Knee joints were removed from euthanized mice and incubated in 4% formalin at room 
temperature for 48 hours.  
2.3.1.1 Decalcification of Bone and Paraffin Embedding 
Following the 48-hour incubation in 4% formalin, knees were transferred into 10% 
ethylenediaminetetraacetic acid (EDTA) in PBS pH 7.0 solution. Knees were maintained in 
EDTA solution at room temperature whilst shaking for 4 weeks, with twice weekly changes of 
the EDTA solution. Following decalcification of bone, joints were embedded in paraffin wax in 
preparation for microtome cutting (paraffin embedding provided by Barts Cancer Institute 
Pathology Service, Charterhouse Square, Queen Mary University of London). 
 
2.3.1.2 Section Cutting of Paraffin Embedded Joints 
Paraffin embedded tissue blocks were chilled on ice and a water bath was preheated to 40°C 
prior to sectioning. The paraffin block was inserted into the holder of the microtome and 
orientated so the blade cut directly across the block. The block was trimmed to remove 
surrounding paraffin and until the tissue was exposed. The block was cut into 5 µM thick 
tissue sections. Each tissue section was transferred upon the preheated water. Charged 
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microscope slides were used to pick up sections and were placed in an oven at 37°C to dry. 
Following incubation at 37°C, the slides were as in 2.3.2 prior to immunostaining. 
 
2.3.2 Histological Staining of Knee Joints 
Prior to all immunostaining, slides were heated for 20 minutes at 60°C. All steps were 
conducted at room temperature unless stated otherwise. Paraffin wax was removed from 
the slides by two incubations in Histoclear (National Diagnostics HS-202) for 5 minutes. Slides 
were then dehydrated by two incubations in 100% Ethanol for 5 minutes. Samples were then 
rinsed briefly in distilled water before continuing staining as described in 2.3.2.1 and 2.3.2.2.  
2.3.2.1 Safranin O Staining 
A 0.2% safranin O solution (Sigma S8884, in dH20) and 0.1% fast green solution (Sigma F7258, 
in dH20) were prepared for staining. Slides were incubated in 0.1% Fast Green solution for 5 
minutes. Slides were then incubated in a 1% acetic acid solution for 10 seconds and 
transferred to the 0.2% safranin O solution. Slides were incubated in safranin O for 5 
minutes. Slides were then rinsed for 2-minutes in distilled water before dehydrated by two 
incubations for 5 minutes in 100% Ethanol and dewaxed by two incubations for 5 minutes in 
Histoclear. Slides were air dried before mounting using DePex (VWR 100503-836) and cover 
slips. Mounted slides were dried overnight in a fume hood. 
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2.3.2.2 Hematoxylin and Eosin Staining 
A 1% Eosin solution (VWR341972Q) was prepared for staining. Meyer’s Hematoxylin was 
purchased as a ready-to-use solution (Sigma MHS16). Slides were incubated in Harris 
Hematoxylin for 2 minutes. Slides were washed in distilled water for two minutes to remove 
all excess Hematoxylin. Slides were then incubated in acidic alcohol (1% hydrochloric acid 
(HCl) in 70% ethanol) for 10 seconds before being washed tap water for 2 minutes. Samples 
were then incubated in 1% Eosin solution for 2 minutes before washing in distilled water 
until the water was clear. Tissue was then dehydrated by two incubations for 5 minutes in 
100% Ethanol and incubated twice for 5 minutes in Histoclear. Slides were air dried before 
mounting using DePex and cover slips. Mounted slides were dried overnight in a fume hood.  
 91 
2.4 In vitro Analysis of Antibody Binding to Diseased and Healthy Tissues by 
Immunofluorescence  
2.4.1 Mouse Models of Disease 
Slides for mouse models of arthritis were obtained following embedding of knees following in 
house in vivo experiments (as previously described), or kindly donated by collaborators from 
the Kennedy Institute of Rheumatology.  
2.4.2 Immunofluorescence Using Anti- Post-Translationally Modified Collagen II 
Antibodies 
Slides were heated for 20 minutes at 60°C. All steps were conducted at room temperature 
unless stated otherwise. Paraffin wax was removed from the slides by two incubations in 
Histoclear for 5 minutes. Slides were then dehydrated by two incubations in 100% Ethanol 
for 5 minutes. Samples were then rinsed briefly in distilled water and air dried. Once fully 
dried, slides were fixed for 5 minutes using 4% Paraformaldehyde (PFA) in PBS. Slides were 
then washed twice on a shaker for 5 minutes with PBS. Solutions of 0.02 % HCl and 0.02 % 
HCl + 15 mg/mL pepsin (Sigma P7125) were pre-heated during the washes to 37°C in a water 
bath. After washing in PBS, slides were incubated in 0.02 % HCl for 15 minutes at 37°C. 
Following incubation in HCl, slides were transferred to 0.02 % HCl + 15mg/mL Pepsin solution 
and incubated for 45 minutes at 37°C. Slides were then washed briefly using PBS and distilled 
water and air dried. Tissue was then fixed again by incubating in 4 % PFA solution for 5 
minutes. Slides were then washed twice on a shaker for 5 minutes with PBS, followed by two 
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incubations in 50 mM ammonium chloride solution for 5 minutes. Circles were drawn 
carefully around the samples using hydrophobic pen (DAKO) and non-specific sites were 
blocked using 20% Foetal Bovine Serum (FBS) in PBS + 1% Tween 20 for 1 hour. During the 
blocking stage, primary antibodies (fluorophore conjugated anti-ROS-CII and controls) were 
diluted to a maximum concentration of 10 µg/mL in blocking solution. Following completion 
of the blocking stage, primary antibodies were added to the samples and incubated 
overnight in the dark at 4°C. The following day, slides were washed three times for 10 
minutes in PBS + 1% Triton X. Following the washes, slides were mounted using Fluoroshield 
with DAPI (Sigma F6057) and coverslips, and allowed to dry before storing at 4°C in the dark, 
prior to imaging on a classic motorised epifluorescence microscope (Olympus, BX61) 
equipped with a high-definition digital camera (Hamamatsu, Orca-R2). Images were acquired 
at room temperature using Cell P/Sense software. The acquisition parameters were 
determined using the positive and negative control slides to achieve the maximum sensitivity 
and specificity. 
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2.5 Microvesicle Generation 
2.5.1 Neutrophil Isolation from Peripheral Blood 
Blood donations were collected from consenting, healthy individuals with approval from the 
Barts and the London Research Ethics Committee (QMREC 2014.61). Healthy donor blood 
(60 mL) was added to 10% v/v sodium citrate (stock concentration of 3.2% w/v) to prevent 
clotting. The whole blood sample was centrifuged at 120g for 20 minutes at room 
temperature to separate the platelet rich plasma (PRP). PRP was discarded and 10 mL of PBS 
without calcium chloride or magnesium chloride (PBS--) , followed by 8 mL of 6 % w/v Dextran 
(MW 450,000-600,000, Sigma 31392) were carefully layered upon the blood. Tubes were 
inverted gently to mix the contents but subsequently avoid neutrophil activation and left for 
15 minutes at room temperature to sediment the red blood cells. Following sedimentation, 
the top layer of leukocytes was collected and gently layered upon 10mL of Histopaque 1077 
in a fresh tube. The leukocytes and histopaque were centrifuged at 420g for 30 minutes at 
room temperature to form density layers. The plasma, mononuclear cell and histopaque 
layers were aspirated and disposed of leaving only the neutrophil and erythrocyte pellet. The 
pellet was resuspended quickly in 9 mL of ice-cold ultrapure water, before returning the 
isotonic balance with 1 mL of 10x Hanks Balanced Salt Solution (Sigma H4641). The 
suspension was made up to 50 mL with PBS-- and centrifuged at 300g for 10 minutes at room 
temperature to pellet the neutrophils. Following centrifugation, the supernatant was 
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aspirated and neutrophils were resuspended in 1 mL of PBS--. Cells were counted using a 
1:100 dilution in Turks stain.  
 
2.5.2 Microvesicle Isolation by Stimulation with Tumour Necrosis Factor Alpha 
The process of neutrophil isolation and stimulation, and the subsequent microvesicle 
formation and isolation is illustrated in Figure 14. To generate microvesicle release by the 
isolated neutrophils, cells were stimulated with tumour necrosis factor alpha (TNF). Cells 
were resuspended to a concentration of 2x107 cells/mL and stimulated with 50 ng/mL of 
human TNF for 20 minutes at 37C. Following stimulation, suspensions were centrifuged at 
4400g for 15 minutes at 4C to remove cells and large platelets. Supernatants were 
transferred to fresh tubes and centrifuged at 13,000g for 2 minutes at 4C to remove small 
platelets and apoptotic bodies. Supernatants were again transferred to fresh tubes and 
fluorescently labeled using 50 μM of BODIPY FL (Thermo Fisher D2184) or BODIPY TR 
(Thermo Fisher D6116). The supernatants were then centrifuged at 20,000g for 30 minutes 
at 4C to pellet the fluorescent microvesicles. The supernatants containing the smaller 
exosomes were discarded and the microvesicles were resuspended in 70 μL of PBS--. 
Resuspended fluorescent microvesicles were then ready for use in experiments.  
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Figure 14. Schematic of microvesicle isolation from healthy donors. Neutrophils are isolated from the whole blood of healthy 
volunteers and activated with TNFα to stimulate microvesicle shedding. Microvesicles are then purified by differential 
centrifugation. Image created with Biorender. 
 
2.5.3 Flow Cytometric Analysis of Microvesicles 
Microvesicles were fluorescently labeled with BODIPY as previously described. Vesicles were 
diluted 1:3 in PBS-- for flow cytometric analysis. The ImagestreamX Mk II flow cytometer was 
used for analysis of microvesicles. All samples were acquired on an ImageStreamX MkII 
imaging cytometer, x60 magnification; with low flow rate/high sensitivity using INSPIRE 
software. The instrument and software were set up as follows: Channels 1 and 9 for 
brightfield imaging and channel 6 for side scatter channel, plus the fluorescence channels 
required. Lasers 488 and 745 were activated for fluorescence and side scatter quantification. 
To obtain a collection gate, a scatter plot of BODIPY fluorescence intensity was plotted 
against side scatter intensity. The gate was drawn around the low to mid BODIPY 
fluorescence intensity but low side scatter population, which is characteristic of fluorescent 
microvesicles. The high side scatter and low BODIPY fluorescence population confirmed the 
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presence of speed beads, used as an internal calibrator for the machines image capture. The 
gated populations were interrogated using the image gallery. Fluorescent microvesicles 
appear as small, spherical points and can be easily discriminated from cells and speed beads. 
IDEAS software was used to determine the concentration of the microvesicle population. 
Raw image files with the entire number of acquired events were opened. A scatter plot was 
recreated plotting BODIPY intensity against side scatter. The microvesicle gate was re-applied 
and adjusted as necessary. The objects/mL analysis was performed, which included 
quantification of all the events recorded and the microvesicle alone population exclusively.  
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2.6 Fortifying Microvesicles with Anti-Post-Translationally Modified 
Collagen II Antibodies 
Fluorescent microvesicles were quantified as objects/mL as previously described. As 
illustrated in Figure 15, a ‘phospholipid cake’ was created by adding 100 µg of 1,2-dioleoyl-
sn-glycero-3-phospho-L-serine (phospholipid, Avanti 181PS) to a pear-shaped glass flask, and 
evaporating the chloroform solvent using a nitrogen stream. The result was a layer of dried 
phospholipid on the bottom of the glass which when resuspended in an aqueous solution 
forms liposomes.  
 
 
Figure 15. Schematic of the production of enriched vesicles using phosphatidylserine liposome formation. Phospholipid is dried 
and the antibody/microvesicle cocktail is added. The solution is then sonicated at 3 amplitude microns for 5 minutes to 
simultaneously create the formation of liposomes which entrap the antibody, but also provide fluidity to the microvesicle 
membrane allowing the liposomes to incorporate. Image created with Biorender. 
 
A solution of fluorescent anti-ROS-CII scFv antibody and fluorescent MV was prepared, using 
an in-house optimized protocol of 10 µg of antibody for every 5x105 microvesicles (using 1.5-
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2.5x106 vesicles in a 0.5mL reaction) 139,140. The MV/antibody solution was added to the 
phospholipid cake. The solution was sonicated for 5 minutes on a low setting of 3 amplitude 
microns using a Soniprep 150 ultrasonic disintegrator with an exponential probe. Samples 
were then appropriately prepared for further experimentation. 
 
2.6.1 Imagestream Analysis  
All samples were acquired on an ImageStreamX MkII imaging cytometer, x60 magnification; 
with low flow rate/high sensitivity using INSPIRE software. The instrument and software were 
set up as follows: Channels 1 and 9 for brightfield imaging and channel 12 for side scatter 
channel, plus the fluorescence channels required. Lasers 488 and 745 were activated for 
fluorescence and side scatter quantification. A compensation matrix was created using 
fluorescent microvesicles alone and fluorescent antibody incorporated into unlabelled 
microvesicles. Fluorescent microvesicles were also used as a negative control for antibody 
incorporation gating. In the IDEAS software, the compensation matrix was applied to all 
analysis. The MV alone population was gated as previously described. A scatter plot was 
created using fluorescence intensity of MV against fluorescence intensity of antibody. A Cy5 
positive gate was drawn on the MV alone population- of which the Cy5 positivity should be 
<1%. The Cy5 positive gate was copied and used to assess positivity of antibody 
incorporation. Experimental samples of MV enriched with antibody were acquired in INSPIRE 
and analysed in IDEAS software in the same manner as the MV alone population. After gating 
the positive microvesicle population, a scatter plot was created of fluorescence intensity of 
vesicles and fluorescence intensity of antibody. The Cy5 positive gate was applied to the 
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graph to give a percentage positivity of MV that were positive for antibody. This population 
of antibody positive MV was quantified by the objects/mL analysis.  
 
2.6.2 Enzyme Linked Immunosorbent Assay 
Immunosorbent 96-well plates were coated with 100 µL of 10µg/mL collagen II or ROS 
modified collagen II. Coatings were incubated overnight at 4°C. Following overnight 
incubation, plates were washed five times with 200 µL of PBS-- and blocked with 2.5% 
powdered milk in PBS--. Plates were blocked for 2 hours at room temperature. During the 
blocking incubation, the primary antibodies were prepared. For the ELISA to analyse the 
fortification of MV with antibody, antibody alone, MV alone and antibody positive MV were 
used as ‘primary antibodies’. A phospholipid cake was prepared as previously described. For 
the ELISA, a concentration of 0.1 mg/mL of antibody was used to give a 10 μg/well input 
concentration. A solution of MV plus anti-ROS-CII antibody was prepared using 10 µg of 
antibody for every 5x105 microvesicles. Total volume was adjusted depending on the number 
of wells. The MV/Antibody solution was added to the phospholipid cake and sonicated as 
previously described. Following sonication, the solution was transferred to an eppendorf and 
centrifuged at 20,000g for 30 minutes to pellet the MV and remove any unincorporated, free 
antibody. MV were resuspended in 2.5% Milk in PBS-- in the same volume as before the 
centrifugation step. Antibody enriched MV were added as primary antibody in the ELISA, as 
well as anti-ROS-CII alone as a positive control and negative control antibody. Following 
incubation, plates were washed five times with 200 µL of PBS--. Secondary antibody was 
diluted in 2.5% powdered milk in PBS-- (anti-hIgG final concentration 10 µg/mL; anti-His tag 
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final concentration 2.5 µg/mL) and added to each well. The secondary antibody was 
incubated for 2 hours at room temperature before five washes with 200 µL of PBS--. The 
ELISA was then developed using 100 µL of TMB solution (0.1 mg/mL TMB, 0.1 M sodium 
acetate and 2 µL per 10 mL of 30% Hydrogen Peroxide). The reaction was stopped using 50 
µL of 20% Sulfuric Acid and absorbance was read at 450 nm.  
 
2.6.3 Immunofluorescence 
Slides were heated for 20 minutes at 60°C. All steps were conducted at room temperature 
unless stated otherwise. Paraffin wax was removed from the slides by two incubations in 
Histoclear for 5 minutes. Slides were then dehydrated by two incubations in 100 % Ethanol 
for 5 minutes. Samples were then rinsed briefly in distilled water and air-dried. Once fully 
dried, slides were fixed for 5 minutes using 4% Paraformaldehyde (PFA) in PBS. Slides were 
then washed twice on a shaker for 5 minutes with PBS. Solutions of 0.02 % HCl and 0.02% 
HCl + 15 mg/mL Pepsin were pre-incubated during the washes to 37°C in a water bath. After 
washing in PBS, slides were incubated in 0.02% HCl for 15 minutes at 37°C. Following 
incubation in HCl, slides were transferred to 0.02% HCl + 15 mg/mL pepsin solution and 
incubated for 45 minutes at 37°C. Slides were then washed briefly using PBS and distilled 
water and air dried. Tissue was then fixed again by incubating in 4% PFA solution for 5 
minutes. Slides were then washed twice on a shaker for 5 minutes with PBS, followed by two 
incubations in 50 mM ammonium chloride solution for 5 minutes. Circles were drawn 
carefully around the samples using DAKO hydrophobic pen and non-specific sites were 
blocked using 2.5% w/v powdered milk in PBS-- for 1 hour. During the block, the MV enriched 
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with antibodies were prepared as described in 2.6. MV and antibody solution was prepared 
using a final concentration of 10 µg/ml of antibody for every 5x105 microvesicles. Volume 
was adjusted depending on the number of samples (100 µL per sample was prepared). 
Following completion of the blocking stage, MV alone, antibody enriched MV or antibody 
alone were added to the samples and incubated overnight in the dark at 4°C. The following 
day, slides were washed five times for 10 minutes in PBS--. Following washes the slides were 
mounted using Fluoroshield with DAPI and coverslips and allowed to dry before storing at 
4°C in the dark, prior to imaging on a classic motorised epifluorescence microscope 
(Olympus, BX61) equipped with a high-definition digital camera (Hamamatsu, Orca-R2). 
Images were acquired at room temperature using Cell P/Sense software. The acquisition 
parameters were determined using the positive and negative control slides to achieve the 
maximum sensitivity and specificity. 
 
2.6.4 In vivo Localisation Studies of Antibody Enriched Microvesicles in a 
Mouse Model of Arthritis 
Antigen induced arthritis (AIA) was performed on female, 10-week-old C57BL/6 mice. Mice 
were housed in groups of five in individually vented cages, maintained at 21 ± 2 °C on a 12-
hour light/dark cycle and with food and water provided. All experimental protocols were 
performed in compliance with the UK Animals (Scientific Procedures) Act 1986 regulations 
for the handling and use of laboratory animals (Home Office project licence PPL no: 
70/8264). Mice were anaesthetized using 2.5% isoflurane. Mice were primed on day 0 with 
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subcutaneous injection of 100µg of methylated bovine serum albumin (mBSA) in complete 
Freund’s adjuvant (CFA). On day 21, mice were injected intra-articularly with 50 µg of mBSA 
in saline to stimulate inflammation in the knee joint. Inflammation was stimulated in only 
one knee, with contralateral knees acting as controls. 
 
On day 22, 24 hours after stimulating inflammation in the right knee joint, mice were 
administered with fluorescently labelled anti-ROS-CII enriched MV or MV alone (600,000 
antibody enriched MV or 600,000 MV alone). Following intravenous administration, mice 
were biofluorescently imaged by in vivo optical imaging at several time points. Fluorescence 
in the knee joints were analysed by creating Regions of interest (ROI) using Living Image 4.4 
software and assessing average fluorescence intensity. At the end-point of the experiment 
mouse organs were imaged ex vivo to assess fluorescence in the stomach, intestines, liver, 
heart, lungs, kidneys and spleen. Knee joints were also imaged ex vivo.   
 
Bioluminescence imaging was performed at several time points 10 minutes following 
intraperitoneal injection of 100 µL luminol sodium salt 50 mg/mL (Sigma Aldrich). Luminol is 
a redox sensitive compound that emits blue luminescence (λmax 425 nm) when exposed to 
reactive oxidants. Mice were imaged 10 minutes after intraperitoneal injection at an 
exposure time of 5 minutes with high binning and open emission filter. Luminescence in the 
knee joints were analysed by creating Regions of interest (ROI) using Living Image 4.4 
software and assessing average luminescence intensity.  
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2.6.5 Ex Vivo Detection of Antibody Enriched Microvesicles in the Arthritic Joint 
At the end-point of the experiments, knees were harvested and snap frozen in Optical 
Cutting Temperature Compound (OCT, Cellpath) by immersing in pre-cooled isopentane. 
Knees were stored at -80°C until use. Knee joints were sectioned using an OFT5000 cryostat 
microtome (Bright Instruments), with specimen and chamber temperature maintained at -
20°C. Knee joints were cut into 17µm sections using MX35 premier blades (Thermofisher 
Scientific), and mounted onto superfrost plus slides (ThermoFisher Scientific). Slides were air 
dried at room temperature for 30 minutes before mounting using Fluoroshield mounting 
medium (Sigma, F6182) and analysis by confocal microscopy. Sections were imaged on a 
Leica SP8 confocal microscope with the use of a 20×water-dipping objective. Images were 
attained with the use of sequential scanning of different channels at a XY resolution of 1024× 
600 with a speed of 700 Hz, zoom factor of 1.28 and line average of 4. Images were analysed 
with the image processing software IMARIS.  
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2.7 Fortifying Microvesicles with Anti-Post-Translationally Modified 
Collagen II Antibodies and Additional Therapeutics 
2.7.1 Fortifying Microvesicles with Therapeutic Antibodies 
Microvesicles were fortified with therapeutic antibodies in the same manner as was earlier 
described (Figure 15, section 2.6). The therapeutic antibodies used were 3-11E/vIL-10- 3-11E 
anti-ROS-CII scFv antibody fused to viral IL-10; and Anti-mTNF- an antibody specific against 
mouse TNF. Both antibodies were expressed in house by transient transfection as 
previously described. 
A solution of 3-11E/vIL-10 antibody and fluorescent MV was prepared, using 10 µg of 
antibody for every 5x105 microvesicles (using 1.5-2.5x106 vesicles in a 0.5mL reaction). For 
situations where multiple antibodies were used, 50 picomolar of each antibody were used, to 
accommodate for the differences in molecular weight due to the differing sizes of antibodies. 
This equated to 5 µg of 3-11E/vIL-10 and 7.5 µg of anti-mTNF. MV/antibody solution was 
added to the phospholipid cake and sonicated as previously described. 
 
2.7.2 ImagesteamX Analysis 
ImagestreamX analysis was conducted to assess the antibody incorporation as described in 
section 2.6.1. The MV alone population was gated as previously described. Single antibody 
loaded MV were used as fluorescence minus one controls for double positive antibody 
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gating.  A Cy5 positive gate was drawn on the MV enriched with Anti-mTNF. An AF488 
positive gate was drawn on the MV enriched with 3-11E/vIL-10. Both gates were copied and 
applied to the MV enriched with both antibodies analysis to determine double positivity. This 
population of antibody positive MV was quantified by the objects/mL analysis.  
 
2.7.3 Enzyme Linked Immunosorbent Assay 
ELISA analysis was conducted to assess the antibody incorporation as described in section 
2.6.2. Immunosorbent 96 well plates were coated with 100 µL of 10 µg/mL of glycated CII or 
100 ng/mL of recombinant mouse TNF. A solution of MV plus 3-11E/vIL-10 antibody and MV 
plus anti-mTNF was prepared using 10 µg of antibody for every 5 x 105 microvesicles. A 
solution of MV combined with both antibodies was prepared using 5 µg of 3-11E/vIL-10 and 
7.5 µg of anti-mTNF antibody for every 5 x 105 microvesicles. Antibody incorporation was 
performed as previously described in 2.7.1 and only the microvesicles pelleted down were 
run on the assay. Antibody enriched MV were added as primary antibody in the ELISA, as well 
as anti-ROS-CII alone and anti-mTNF alone as controls. Secondary antibody was diluted in 
2.5% powdered milk in PBS-- (anti-human IgG 1:1000 dilution; anti-mouse IgG 1:1000 
dilution) and added to each well. The ELISA was developed and absorbance was read as 
previously described.   
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2.7.4 MTT Assay 
3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay was performed to 
assess the function of the anti-mTNF antibody in inhibiting TNF dependent cell death. L929 
cells were used in the assay which are TNF sensitive. Cells were cultured in DMEM + 10% FBS 
+ 1% penicillin/streptomycin (complete media). Cells were seeded at 50,000 cells/mL in 96 
well flat bottom plates for 18 hours. Following the incubation time, media was replaced with 
complete media plus 1 µg/mL Actinomycin D and 0.45 ng/mL of recombinant mouse or 
human TNF. Anti-mTNF antibody at two concentrations, MV alone and enriched MV were 
added to the media and incubated for 24 hours. Following incubation time, MTT was added 
to each well at a concentration of 500 µg/mL. Plates were incubated for 3 hours at 37 °C. 
Media was then removed and a solution of 90% isopropanol/10% DMSO was added and 
incubated for 15 minutes at room temperature. Absorbance was read at 595 nm. MTT assay 
was repeated over three different L929 passages. Data are presented as % of viability 
compared to positive control (L929 cells without TNF in culture medium).  
 
2.7.5 Treatment of a Mouse Model of Rheumatoid Arthritis Using 
Microvesicles Fortified with Therapeutics  
Antigen induced arthritis (AIA) was performed on female, 10-week-old C57BL/6 mice as 
previously described in section 2.2.2. On day 22, 24 hours after stimulating inflammation in 
the knee joint, mice were administered treatments intravenously. Mice treated with MV 
enriched with therapeutics were administered 600,000 antibody-positive MV. For mice being 
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treated with MV enriched with multiple therapeutics, 600,000 MV positive for both 
antibodies were administered. Treatment was administered 24 and 72 hours after 
stimulation of inflammation in the knee joint. Knees were measured with digital calipers at 
daily increments from baseline, before the induction of inflammation in the knee. At the end-
point of experiment, knee joints were harvested and either snap frozen for confocal 
imaging/RT-qPCR or fixed in 4% neutral buffered formalin for histological analysis. 
 
2.7.6 Histological Analysis of Knee Joints 
Safranin O/fast green staining was conducted as previously described in 2.3.2. Joints were 
scored 0–4 for disease activity for each of: subsynovial inflammation, synovial lining 
thickening, cartilage matrix depletion, chondrocyte death, pannus formation, marrow 
involvement, synovial fluid cells, and bone erosion. The scores are presented as total score 
out of 36 for each of the two animals assessed. 
 
2.7.7 RT-qPCR Analysis of Knee Joints 
2.7.7.1 RNA Extraction 
Total RNA was extracted from snap frozen knee joints using Trizol method. Knee joints were 
placed into reinforced homogenizer tubes (Precellys Lysing Kit for Hard Tissue, MK28) and 1 
mL of Trizol was added. Knee joint tissue was homogenized using a Precellys 24 homogenizer 
(Bertin Technologies) for 2 rounds of 30 seconds, and then centrifuged for 5 minutes at 
maximum speed. Supernatant was then homogenized using a syringe and 21 G needle and 
centrifuged for 10 minutes at maximum speed. Supernatants were transferred into new 
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eppendorfs and made up to 1 mL with Trizol before adding 200 µL of precooled chloroform. 
Samples were shaken vigorously for 30 seconds and incubated on ice for 1 minute. Samples 
were then centrifuged for 15 minutes at 10,000g. The clear, aqueous layer was transferred 
to a new eppendorf before adding 500 µL of precooled isopropanol. Samples were shaken 
vigorously for 30 seconds before incubating on ice for 1 hour. Following incubation, samples 
were centrifuged for 40 minutes at 20,000g. Avoiding the pellet, isopropanol was then 
removed and 1 mL of precooled 70% ethanol was added. Samples were centrifuged for 5 
minutes at 20,000g. Ethanol was then removed from the sample and the pellet was air dried 
on ice. Once the pellet was dried, the pellet was resuspended in 20 µL of RNAse free water. 
Nanodrop ND-1000 (Nanodrop Technologies) was used to obtain RNA concentration and 
purity.  
 
2.7.7.2 Removal of Genomic DNA 
Genomic DNA contamination was removed using DNase Max Kit (Qiagen) according to the 
manufacturer’s instructions. Briefly, for each sample 1 µL of DNase Max Enzyme, 5 µL of 10x 
DNase Max Buffer and 29 µL of RNase free water was combined. To this digestion reaction, 
15 µL of RNA was added. The digestion reaction was incubated for 20 minutes at 37 °C. 
Following incubation, 5 µL of DNase Max Removal Resin was added and incubated for 10 
minutes at room temperature with regular inverting. The sample was centrifuged at 13,000 g 
for 1 minute to pellet the resin. The supernatant was then transferred to a new eppendorf, 
analysed by Nanodrop ND-1000 to assess purity following DNA removal and then stored at -
80 °C until further use. 
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2.7.7.3 cDNA Synthesis 
cDNA was produced from RNA using a high capacity cDNA reverse transcription kit (Applied 
Biosystems) according to the manufacturer’s instructions. Briefly, a 2x master mix was firstly 
prepared by combining 2 µL of 10X RT Buffer, 0.8 µL of 25X dNTP Mix, 2 µL 10X RT Random 
Primers, 1 µL Multiscribe Reverse Transcriptase and 4.2 µL of nuclease free H2O for each 
sample. RNA was diluted to a concentration of 1 µg in 10 µL of nuclease free H2O and added 
to the 2X master mix in an individual 0.2 mL PCR tube. Reverse transcription was performed 
in a thermal cycler under the following conditions: Step 1- 10 minutes at 25 °C; Step 2- 120 
minutes at 37 °C; Step 3- 5 minutes at 85 °C and then held at 4 °C. cDNA was stored at -20 °C 
until use.  
 
2.7.7.4 RT-qPCR 
For each reaction, a total volume of 10 μl was used, consisting of 1 μl of cDNA, 5 μl of 2X 
Power SYBR Green Mastermix (Applied Biosystems, Inc.), 3 μl of dH2O, and 1 μl of gene-
specific primer. Primers were commercially available (Qiagen) and the following were used to 
probe specific mRNA targets: Rpl32, QT00131992; Col2a1, QT01055523; Sox9, QT00163765; 
Acan, AT00175364; Il10, QT00106169; Il1β, QT01048355; Il4, QT00160678; Il6, QT00098875; 
Adamts5, QT00131376; Fpr2, QT00171514; Mmp13, QT00111104; Tnf, QT00104006. Real-
time PCR was carried out with the following amplification settings: 95°C for 15 min; 35 cycles 
of 94°C for 15 s, 55°C for 30 s, and 72°C for 30 s, followed by melt curve analysis, using the 
ABI Prism 7900 Real-time PCR system (Applied Biosystems Inc.). Data are expressed as 
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relative units calculated by 2-Δ∆CT by normalization relative to RPL32 and to fold change over 
knee joints from naïve control samples. Negative controls were also run and included cDNA 
without primer and RNA reverse transcribed in the absence of reverse transcriptase.  
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2.8 Statistical Analysis 
Statistical analysis was performed using Graphpad Prism 7 software. Data are expressed as 
mean ± standard error of mean (SEM), unless indicated otherwise. A P value of <0.05 was 
considered significant to reject the null hypothesis. Two-way ANOVA was used in 
circumstances where two or more groups existed with two variables (e.g. time and 
treatment) with Bonferroni post-hoc test. One way ANOVA was used in circumstances where 
three or more groups were being tested with one variable. For RT-qPCR analysis, Kruskal 
Wallis test with Dunn’s multiple comparison post-test was performed to compare three or 
more groups in a non-parametric fashion.  
 
2.9 Biorender Software  
All original schematics and cartoons used herein were created with Biorender 
(https://biorender.io/). 
 
 
  
 112 
Chapter 3: Results 
3.1 Validation of Anti-ROS-CII in Vitro  
The antibodies used herein were previously raised from a scFv phage display human library 
by the Nissim Lab. Antibody phage display is a technique based on the genetic engineering of 
bacteriophages with repeated rounds of antigen guided selection to allow in vitro selection 
of antibodies. It is a powerful technique that is responsible for the production of some of the 
most potent and widely used medicines worldwide.  
 
For the antibodies used within this thesis, native CII and ROS-CII were the antigens used for 
selection. For ROS-CII antibody selection, 3 rounds of subtractive selection performed using 
native CII for subtraction. The result was a panel of antibodies with varying specificities to CII 
and ROS-CII 118.  The antibodies raised by phage display were scFv format, with subsequent 
subcloning performed to produce full IgG versions. The Nissim lab selected antibody 
candidates based on their binding specificity and affinity, with 1-11E antibody being a 
primary candidate for targeting ROS-CII. As aforementioned, the 1-11E antibody was found 
to undergo glycosylation during production, inhibiting its binding potential. Therefore, 
alternative antibody candidates were selected, and hence 3-11E was chosen for future 
studies and is the candidate primarily used herein.  
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Antibody Name Binding Specificity Generation Format Reference 
1-11E ROS-CII scFv Phage 
Library142 
scFv, IgG and 
scFv-vIL-10 fusion 
39,115,118 
3-11E ROS-CII scFv Phage 
Library142 
scFv, IgG and 
scFv-vIL-10 fusion 
n/a 
6-11D CII & ROS-CII scFv Phage 
Library142 
scFv n/a 
C7 HEL scFv Phage 
Library142 
scFv, IgG and 
scFv-vIL-10 fusion 
39,115,118 
Table 1.  Description of binding specificity and format of 1-11E, 3-11E, 6-11D and C7 antibodies.  
 
3.1.1 Electrophoretic Analysis of Antibodies after Purification 
Following the antibody production, either by bacterial expression or transient transfection in 
mammalian cells, protein was purified by either protein A or Ni-NTA column. To evaluate the 
purification process, an SDS-PAGE with coomassie blue staining was performed to visualize 
protein.  
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Figure 16. SDS PAGE analysis of antibody following purification dialysis. (A) 12% polyacrylamide gel of purified scFv (25 kDa). 
Minimal protein of interest is observed in the flow through and washes, with an abundance of protein visible in the eluates. 
(B) Following dialysis, a clean band of protein at 25 kDa is visible. MK, molecular weight marker; Control; scFv antibody; FT, 
flow through; BSA, bovine serum albumin.   
 
Figure 16(A) shows a representative SDS-PAGE following the purification of an anti-ROS-CII 
scFv. A protein ladder depicting a variety of weights in kDa confirms the expected molecular 
weight of the protein. The flow through from the purification shows an abundance of protein 
at a variety of molecular weights, but no large amount at the 25 kDa range. Furthermore, 
there is little protein at the 25 kDa weight in the lanes containing the washes. The 
purification eluates, however, contain a visibly larger amount of protein at the 25 kDa range, 
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indicating the production and purification was successful. The eluted protein is the same 
molecular weight as the scFv control, suggesting that it is a scFv antibody. The standard yield 
from a scFv production was around 300 µg/mL.  
 
Following the purification, antibodies must be dialysed into a phosphate buffer solution, as 
the purification process uses strongly acidic buffers to elute the protein. Following dialysis, 
an SDS-PAGE is performed once more to ensure protein isn’t lost during the process. Figure 
16(B) shows a typical SDS-PAGE following the dialysis of the antibody into a neutral buffer. As 
well as a scFv control, BSA concentration controls are included. The dialysed antibody shows 
as a strong band at 25 kDa, similarly to the SDS-PAGE performed after purification. This is 
indicative that no protein was lost during the dialysis process. 
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3.1.2 Electrophoretic Analysis of in vitro Modifications of Collagen II 
The antibodies used in this thesis were raised from phage display library using in vitro 
modified CII as an antigen. ELISA uses the in vitro modifications to test the binding of 
produced antibodies. The coating step of the ELISA uses the native and ROS-CII as the 
antigen, therefore before antibody binding can be checked the in vitro modifications must be 
performed. Figure 17 shows a representative SDS page of the CII modifications. Glycated CII 
(Gly CII) and chlorinated CII (HOCl CII) are used throughout this thesis as the two post-
translational modifications as they have previously found to be the most reactive to RA 
patient’s sera 107.  
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Figure 17. SDS-PAGE analysis of collagen II following in vitro mimicking of ROS modification. CII is observed in its native state, 
with a molecular weight of 141 kDa. Gly CII can be seen to have a larger molecular weight than CII, representing the addition 
of sugar molecules. HOCl CII almost completely loses the native CII band and appears a smear of protein due to 
fragmentation. MK, molecular weight marker; CII, native collagen II; Gly CII, native collagen II modified by non-enzymatic 
glycation; HOCl CII, native collagen II modified by chlorination.  
 
The molecular weight of native CII is 141 kDa, which is observed in the SDS page as a single 
band. Gly CII appears as a slightly larger molecular weight, with additional smearing of the 
protein. This is due to the addition of sugar molecules, resulting in a shift in the position of 
the CII α-chain band to a region of slightly higher molecular mass, as well as fragmentation to 
bands in the electrophoretic region of 50–150 kDa. The degradation of CII caused by 
chlorination from HOCl is observed in lane 4. HOCl CII almost completely loses the 141 kDa 
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band and appears as a smear of protein. The modifications shown in Figure 17 are as 
previous data would suggest. 
 
3.1.3 Antibody Binding to Target 
Once the antibodies had been produced, purified and dialysed into a neutral pH buffer, their 
binding capacities were checked by ELISA. The unique quality of an antibody is its binding 
specificity, therefore assessing that the antibody has retained its specific binding qualities 
throughout the production and purification is paramount. The graphs below show an ELISA 
of the correct binding specificities from three scFv antibodies produced as part of the 
studies. 
 
 
Figure 18. ELISA to assess binding of produced antibodies. (A) ELISA of negative control antibody ‘C7’, specific to Hen Egg 
Lysozyme (HEL). The antibody showed no binding to native collagen (CII), glycated collagen II (Gly) or HOCl modified collagen 
II (HOCl). Binding of negative control antibody ‘C7’ to HEL is statistically significantly greater than its binding to collagen II 
types. (B) ELISA of positive control antibody ‘6-11D’, specific to both native and ROS-modified CII. 6-11D showed strong 
binding to all collagen types, which was statistically significantly greater than binding to negative control HEL. (C) ELISA of 
anti-ROS-CII antibody ‘3-11E’, specific to ROS modified CII. 3-11E showed specific binding to Gly and HOCl CII, but no binding 
to native CII or HEL. Binding to both Gly CII and HOCl CII is statistically significantly greater than binding to both CII and HEL. 
Two-way ANOVA was performed with Bonferroni multiple comparisons to compare overall column effect between antigen 
types. ** P ≤0.01; **** P ≤0.0001. CII, native collagen II; Gly CII, native collagen II modified by non-enzymatic glycation; 
HOCl CII, native collagen II modified by chlorination. 
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Figure 18(A) shows the binding capacity of our negative control antibody, namely C7, to both 
native and ROS-modified CII. The C7 scFv shows no specific binding to either native CII or 
ROS-modified CII, even at high concentrations. C7 is specific to Hen Egg Lysozyme, and a 
concentration dependent increase in binding was observed. Figure 18(B) shows the binding 
capacity of a positive control antibody, namely 6-11D. 6-11D scFv is specific to both native CII 
and ROS modified CII, and as Figure 18(B) shows, strong binding to all collagen types was 
observed in a concentration-dependent manner. Figure 18(C) demonstrates the binding of 
one of the anti-ROS-CII antibodies, namely 3-11E. 3-11E scFv shows strong, specific binding 
to both modified forms of CII in a concentration dependent manner, but no binding to native 
CII even at high concentrations.  
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3.1.4 Antibody Binding in Tissue from a Rheumatoid Arthritis Mouse Model 
To further assess the specificity of the anti-ROS-CII antibody, 3-11E, immunofluorescence 
was conducted using tissue from arthritic mice. In this instance, sections from mice with AIA 
were used.  
 
Figure 19 shows representative images obtained following immunofluorescence staining. In 
healthy mouse tissue, there is minimal staining with either 3-11E scFv or C7 scFv. The 
structure of the cartilage and bone is identifiable by the DAPI stain, and no staining of 3-11E 
scFv is identifiable in either tissue. Furthermore, the 3-11E scFv stain is comparable to the C7 
negative control, confirming that our anti-ROS-CII antibody does not bind to healthy 
cartilage.  In AIA knee tissue, there is strong, pericellular staining within the cartilage by 3-
11E scFv. The staining of 3-11E is diffused throughout the cartilage and focused around the 
chondrocytes, which is not observed in the staining of healthy tissue. Furthermore, the 3-11E 
scFv staining in arthritic knees is exclusive to the cartilage, with no staining present in the 
bone tissue. The negative control antibody also showed no binding in the AIA tissue, 
confirming that the 3-11E scFv binding is specific to damaged cartilage.  
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Figure 19. Immunofluorescence staining of AIA knee tissue using anti-ROS-CII fluorescently labelled scFv and fluorescently labelled negative control scFv antibody. Healthy mice knee sections are 
used as additional controls. Blue = DAPI stain; Red= Cy5.5 labelled antibody. AC = articular cartilage; SB = subchondral bone; BM = bone marrow. Representative images of 3 samples per group.
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3.1.5 Antibody Binding in Tissue from an Osteoarthritis Mouse Model 
After observing positive, specific binding in AIA tissue, immunofluorescence was repeated 
in tissue from mice subjected to DMM surgery. Figure 20 shows the representative 
images of the staining. As previously observed with the AIA immunofluorescence, there is 
no specific binding of 3-11E scFv or C7 scFv in healthy mouse cartilage.  
 
The DMM tissue used for the immunofluorescence is from mice 8 weeks or 12 weeks 
post-surgery. In the 8 weeks post-surgery tissue, there is strong staining by 3-11E scFv in 
the cartilage. Similarly, to binding in the AIA tissue, the staining appears to be around the 
chondrocytes in the cartilage. There is no evident binding to the tissue of the bone, and 
the point where the tide mark between cartilage and bone exists is clear due to the 
specific binding of 3-11E scFv. The C7 scFv negative control shows no specific binding in 
the 8 weeks post-surgery tissue.  
 
In the tissue taken from 12 weeks post-surgery mice, 3-11E scFv also shows strong 
binding specific to the cartilage. There is no binding observed in the bone tissue. C7 scFv 
showed no specific binding in the 12 weeks post-surgery tissue.   
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Figure 20. Immunofluorescence staining of DMM knee tissue using anti-ROS-CII fluorescently labelled scFv and fluorescently labelled negative control scFv antibody. Healthy mice knee sections are 
used as additional controls. Blue = DAPI stain; Red= Cy5.5 labelled antibody. AC = articular cartilage; SB = subchondral bone; BM = bone marrow. Representative images of 3 samples per group.
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3.2 Validation of Anti-ROS-CII In Vivo  
3.2.1 In vivo Imaging System Analysis Shows Localisation of Antibodies in 
Antigen Induced Arthritis Mouse Model 
To analyse the localisation of anti-ROS-CII antibodies exclusively to the arthritic joint, 
optical imaging was utilised to track the fluorescence of the labelled scFv after 
intravenous administration. An antigen induced arthritis mouse model was used due to 
the ability to induce inflammation in the right knee, with the contralateral knee acting as 
an internal control. Figure 21 shows the results of the optical imaging following 
intravenous administration of scFv antibodies. The 1-11E and 3-11E candidates were used 
for optical imaging to assess the comparative localisation of the already established 1-11E 
with the new 3-11E candidate. As described in Table 1, both 1-11E and 3-11E are specific 
to ROS-CII. C7 is specific to HEL and was used as a negative control in these experiments. 
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Figure 21. Localisation of anti-ROS-CII antibodies (1-11E scFv, 3-11E scFv) and negative control antibody (C7 scFv) in an 
antigen induced arthritis mouse model. Fluorescence is calculated using region of interests (blue circles) and plotted as 
radiant efficiency (A). Representative images from time point 3 of fluorescent localisation of injected antibodies. 
Arthritis is present exclusively in the right knee as indicated with a black arrow (B) n = 6-8 mice per group. Two-way 
ANOVA was performed with Tukey multiple comparisons to compare differences in treatment groups at each time 
point. * denotes statistical significance between 1-11E scFv and C7 scFv; # denotes statistical significance between 3-
11E scFv and C7 scFv. ** P ≤0.01; *** P ≤0.001. 
 
 
Figure 21(A) depicts the fluorescence present in the right knee of AIA mice injected 
intravenously with scFv. Identical regions of interest were drawn on each knee of mice 
(depicted as blue circles in Figure 21(B)) to give a quantitative measure of fluorescence. 
Figure 21(B) shows IVIS images of three mice 2 hours post injection with 1-11E, 3-11E and 
C7 scFv. For 3-11E and 1-11E scFv there is accumulation of scFv in the arthritic knee, but 
not the contralateral. The C7 scFv control shows no specific localisation in the arthritic 
knee. The localisation of the anti-ROS-CII was strong in the arthritic knees, with peak 
localisation at the 3-hour time point, which coincides with the half-life of the scFv. 
 
Following confirmation of the scFv localisation, optical imaging was performed using the 
IgG format of each antibody. The IgG format was produced from the scFv clones and is a 
full-length antibody, with a larger molecular weight and extended half-life. The beneficial 
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use of an scFv or IgG would vary depending on the nature of an experiment. The IgG 
format is beneficial as it contains the Fc portion, which has been found to interact with 
the neonatal Fc receptor, causing the IgG to be recycled and thus having an extended 
half-life 143, whereas the smaller scFv format has found to have greater penetrative 
characteristics than the full size antibody 144. It is important to characterise both formats 
in vivo to assess these abilities and determine which is best used for future studies.  
 
 
 
Figure 22. Localisation of anti-ROS-CII antibodies (1-11E IgG, 3-11E IgG) and negative control antibody (C7 IgG) in an 
antigen induced arthritis mouse model. Fluorescence is calculated using region of interests (blue circles) and plotted as 
radiant efficiency (A). Representative images from time point 24 of fluorescent localisation of injected antibodies. 
Arthritis is present exclusively in the right knee as indicated with a black arrow (B).  n=3 mice per group. Two-way 
ANOVA was performed with Bonferroni multiple comparisons to compare differences in treatment groups at each time 
point (no statistical significance). 
 
 
Figure 22(B) shows IVIS images of 3 mice 48 hours post injection with 1-11E, 3-11E and 
C7 IgG. 1-11E and 3-11E show clear localisation in the arthritic knee, however at the 48-
hour time point there is an observation of the C7 IgG control in the arthritic knee. From 
the plot in Figure 22(A), it is evident that the peak of fluorescence has not been reached. 
The half-life of IgG is around 100 hours, therefore the presence of C7 IgG in the arthritic 
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knee at 48 hours is likely to be non-specific and due to the high level of antibody in 
circulation. The low levels of C7 IgG fluorescence at every previous time point and in the 
contralateral knee is also indicative of this, particularly when comparing to 1-11E and 3-
11E IgG where there is a steady increase over time.  
 
Interestingly, the localisation of 3-11E IgG appears more specific than 1-11E IgG. Mice 
treated with 1-11E IgG showed high fluorescence in the contralateral knee throughout 
the time course, whereas mice treated with 3-11E IgG had high fluorescence in the AIA 
knee but very little in the contralateral. This high specificity in vivo is further indication 
that 3-11E makes a good alternative candidate to 1-11E.  
 
The optical imaging performed in the AIA model confirmed the localisation previously 
observed with the 1-11E antibody 118. Furthermore, the 3-11E-candidate antibody has 
shown similar localisation patterns to 1-11E in vivo. Together with the in vitro data, this 
validates the use of 3-11E for targeting the arthritic joint. 
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3.2.2 Targeting of vIL-10 to the Arthritic Joint using Antibodies to Post-
Translationally Modified Collagen II 
Antibodies against ROS-CII were raised by phage display and fused to vIL-10 via a MMP 
cleavable linker by previous members of the Nissim Lab. To confirm the localisation of the 
fusion antibody before use for therapy in future experiments, a study in mice with AIA 
was performed. The aim of the study was to confirm that the produced anti-ROS-CII scFv 
fused to vIL-10 could localize to the joint in the same manner that was observed with the 
scFv and IgG protein alone, as was observed in Figure 21 and Figure 22.  
 
Figure 23 shows the results of the optical imaging localisation study. The quantification of 
fluorescence in Figure 23(A) shows 3-11E/vIL-10 peak fluorescence at 72 hours post 
injection, which coincides with the half-life of the protein. The C7/vIL-10 shows no 
specific localisation in the arthritic knee. Figure 23(B) shows representative images of the 
optical imaging process 72 hours post injection. The fluorescence of 3-11E/vIL-10 is 
predominantly in the arthritic knee, with little fluorescence in the contralateral. C7/vIL-10 
showed little fluorescence in the arthritic knee, with one mouse showing higher 
fluorescence as seen in Figure 23(B). Overall, however, the fluorescence of C7/vIL-10 was 
non-specific and antibody levels were low in the arthritic and contralateral knees. 
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Figure 23. Localisation of anti-ROS-CII antibody fused with vIL-10 (3-11E/vIL-10) and negative control antibody fused to vIL-
10 (C7/vIL-10) in an antigen induced arthritis mouse model. Fluorescence is calculated using region of interests (blue 
circles) and plotted as radiant efficiency (A). Representative images from time point 72 of fluorescent localisation of 
injected antibodies. Arthritis is present exclusively in the right knee as indicated with a black arrow (B). n=5 mice per 
group. Two-way ANOVA was performed with Bonferroni multiple comparisons to compare differences in treatment 
groups at each time point. Statistical significance was observed at 96 hours between 3-11E/vIL-10 AIA knee 
fluorescence with  3-11E/vIL-10 contralateral knee fluorescence and C7/vIL-10 AIA and contralateral knee 
fluorescence.* P ≤0.05. 
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3.2.3 Arthritic Knees Treated with Antibodies to Post-Translationally 
Modified Collagen II Show Stronger Safranin O Staining and Fewer 
Cellular Infiltrates 
Following the localisation study, knee joints were harvested to assess the effect of the 
vIL-10 fused to the antibodies on the knee histology.  Mice were injected with 3-11E/vIL-
10 on day 1 post arthritis induction, with euthanisation and harvesting of knee joints 
occurring on day 7. Both arthritic and non-arthritic knees were stained with safranin O (to 
stain proteoglycans) and hematoxylin and eosin (H&E, to stain basophilic and acidophilic 
structures). Staining was also conducted on healthy control mouse knees. As shown in 
Figure 24, the c7/vIL-10 treated mice show a loss of safranin O stain in the AIA knee. 
There are also many cellular infiltrates observed in the joint space in the AIA knee. The 
contralateral knee of the C7/vIL-10 treated mice shows a stronger safranin O stain, less 
visible structural damage and few cellular infiltrates. The 3-11E/vIL-10 treated mice show 
strong safranin O stain in both the AIA knee and contralateral knee. There is evidence of 
cellular infiltrates in the H&E staining of the 3-11E/vIL-10 mice, but much fewer than the 
C7/vIL-10 treated mice. The 3-11E contralateral knee shows strong safranin O stain with 
minimal damage and infiltration.  
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Figure 24. Representative images of histological staining of knees from mice treated with anti-ROS-CII antibody fused with vIL-10 (3-11E/vIL-10) and negative control antibody fused to vIL-10 (C7/vIL-
10). Safranin O and Hematoxylin and Eosin (H&E) staining of both AIA knee and contralateral knee of arthritic mice treated with either anti-ROS-CII fused to vIL-10 or negative antibody fused to 
IL-10. Healthy mice knee sections are used as controls.  Images representative of 5 mice per group.
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3.2.4 In vivo Imaging System Analysis Shows Localisation of Antibodies in 
Destabilisation of the Medial Meniscus Osteoarthritis Mouse Model 
The previous experiments have confirmed that anti-ROS-CII localize in the arthritic joint in 
a mouse model of RA. Experiments were also conducted using a mouse model of 
osteoarthritis to determine whether the same localisation occurs. These experiments 
were conducted primarily for the validation of the new anti-ROS-CII candidate in an OA 
model for means of future work outside of this thesis. The OA model used was 
destabilisation of the medial meniscus (DMM), a surgical model in which the medial 
meniscus in one knee joint is severed, causing mechanically induced osteoarthritis.  
 
Figure 25 depicts the results following intra-articular administration of anti-ROS-CII 3-11E 
scFv and positive control 6-11D scFv (which binds to both unmodified and modified CII) at 
4 weeks post-surgery. As aforementioned, regions of interest were generated to quantify 
fluorescence, which is depicted Figure 25(A). 6-11D shows strong retention in both DMM 
and contralateral knees, which is mostly cleared by 128 hours. 3-11E showed strong 
retention in the DMM knee, similarly to the levels observed for 6-11D. However, 3-11E 
was not retained in the contralateral knee, observed from the first time point of 2 hours. 
The ratio of fluorescence in the operated knee and contralateral knee is depicted in 
Figure 25(B). 6-11D has a low ratio of around 1, representing the equal fluorescence in 
both the arthritic and non-arthritic knees. 3-11E has a higher ratio, peaking at 54 hours at 
7, indicating the greater fluorescence observed in the DMM knee. Figure 25(C) and (D) 
are images from the optical imaging process of mice 4 hours post injection with 3-11E 
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scFv and 6-11D scFv, respectively. Mice injected with 3-11E scFv retain antibody in the 
DMM knee, but minimal fluorescence is observed in the contralateral. Mice injected with 
6-11D, however, have strong fluorescence in both the DMM and contralateral knees.  
 
 
Figure 25. Retention of anti-ROS-CII antibody (3-11E scFv) and positive control antibody (6-11D scFv) in a destabilisation of 
the medial meniscus osteoarthritis model 4 weeks post-surgery. (A) Knee fluorescence is calculated using region of 
interests (blue circles) and plotted as radiant efficiency. (B) Ratio of fluorescence in operated versus contralateral knee. 
Arthritis is present exclusively in the left knee as indicated with a black arrow (C and D). Representative images from 
time point 54 of fluorescent localisation of injected antibodies. n = 3 mice per group. Two-way ANOVA was performed 
with Bonferroni multiple comparisons to compare differences in treatment groups at each time point. * P ≤0.05. 
 
 
The same experiment was repeated at 8 weeks post-surgery and is shown Figure 26. 6-
11D shows retention in both the DMM knee and contralateral, however the first time-
point shows a weaker retention of 6-11D in the DMM knee compared to the 
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contralateral. 3-11E scFv continues to show strong retention in the DMM knee, but not in 
the contralateral. Similarly, to the 4-week time point, by 128 hours most of the antibody 
has been cleared from the joint. The ratio between the operated and contralateral knees 
is low for the 6-11D control, staying around 1. The ratio for the 3-11E scFv is greater, 
peaking at the 4-hour time point at a value of 3. The ratio observed for 3-11E scFv in the 
4-week experiment was larger and peaked later than the 8-week experiment. Figure 
26(C) and (D) are images from the optical imaging process of mice 24 hours post injection 
with 3-11E scFv and 6-11D scFv, respectively. Mice injected with 3-11E scFv retain 
antibody in the DMM knee, but minimal fluorescence is observed in the contralateral. 
Mice injected with 6-11D, however, have equal fluorescence in both the DMM and 
contralateral knees. 
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Figure 26. Retention of anti-ROS-CII antibody (3-11E scFv) and positive control antibody (6-11D scFv) in a destabilization of 
the medial meniscus osteoarthritis model 8 weeks post-surgery. (A) Knee fluorescence is calculated using region of 
interests (blue circles) and plotted as radiant efficiency. (B) Ratio of fluorescence in operated versus contralateral knee. 
Arthritis is present exclusively in the left knee as indicated with a black arrow (C and D). Representative images from 
time point 4 of fluorescent localisation of injected antibodies. n=3 mice per group. Two-way ANOVA was performed 
with Bonferroni multiple comparisons to compare differences in treatment groups at each time point. * P ≤0.05; ** P 
≤0.01. 
 
The work in this thesis thus far has demonstrated the ability of the 3-11E antibody 
candidate to target the arthritic joint in both RA and OA murine models. The 3-11E 
antibody is sufficient for use in future studies in place of the 1-11E antibody, which 
cannot be expressed efficiently due to problems associated with glycosylation of the 
binding site. The anti-ROS-CII antibodies have previously shown to target drugs to the 
joint, but in the following chapters the antibodies will be utilized to target a biological 
scaffold to the joint for the first time. The biological scaffold used will be microvesicles 
derived from neutrophils.  
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3.3 Fortifying Neutrophil Derived Microvesicles with Anti-ROS-CII  
Microvesicles (MV) derived from neutrophils (PMN) have been previously shown to exert 
anti-inflammatory, pro-resolving and penetrative mechanisms in arthritic cartilage. 
Efficacy of MV has only been demonstrated by local administration in the arthritic knee, 
with systemic administration having no effect on clinical scoring 136,141. To overcome this, 
MV have been enriched with anti-ROS-CII antibodies to localise and retain them to the 
arthritic joint, where they can exert their beneficial effects. As will be shown in this 
chapter, MV have been isolated from healthy donor neutrophils and characterised in 
vitro. MV have then been enriched with antibodies using aqueous energy dissemination; 
a technique that has previously been utilised to enrich MV with additional pro-resolving 
mediators and proteins.  
 
3.3.1 Microvesicle Generation Analysis by Flow Cytometry and Nanoparticle 
Tracking 
To confirm the purity of isolated microvesicles from PMN, characterization by flow 
cytometry and nanoparticle tracking analysis was performed. The ImagestreamX (ISx) 
analyser was used for MV analysis due to its high sensitivity and part high-resolution 
microscope, allowing you to observe all the events passing through. Furthermore, the ISx 
can calculate concentration of MV without the use of calibration beads.  
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Figure 27 shows flow cytometric plots and microscopic images obtained from ISx analysis 
of isolated PMN MV labelled with BODIPY FL, which is a non-specific membrane stain. 
Figure 27(A) shows the isolated MV population (blue) plotted as side scatter against the 
fluorescence of BODIPY. The MV population show low side scatter and high fluorescence 
intensity. The population circled in red represent the speed beads that run through the 
ISx for calibration of the flow of the sample and the focus of the microscope. The 
population circled in yellow represents background noise of the machine. Figure 27(B) 
represents the gated MV population, plotted as MV fluorescence against Cy5 
fluorescence. The MV stained with BODIPY FL show negligible Cy5 fluorescence, which 
was important to determine before moving onto fortifying with antibody. Figure 27(C) is a 
representative microscopic image from the ISx analysis of the gated MV population. The 
microscope on the ISx allows for visual confirmation of correct MV gating. Figure 27(C) 
shows the expected visualization of the population following a successful isolation of MV. 
The MV are barely visible on the brightfield channels, represented as CH01 and CH09 in 
the figure. The BODIPY fluorescence, shown in CH02 on the figure, shows a bright green, 
round, small MV. The Cy5 fluorescence, observed in CH09 is negative. The side scatter of 
the MV, shown in CH12 is low and almost non-detectable.  
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Figure 27. Imagestreamx analysis of polymorphonuclear neutrophil derived microvesicles stained with BODIPY. (A) Vesicle 
gating (blue) using side scatter and BODIPY fluorescence. Red circle represents speed beads used to calibrate the 
machine and yellow circle represents noise from the machine. (B) Cy5 positivity of MV. Gating of cy5 positivity is 
conducted for future experiments of fortifying MV with antibody. (C) Representative microscopic image of a gated MV 
obtained from the Imagestreamx during analysis.  
 
 
Isolated MV were also run on the Nanosight nanoparticle tracker to confirm size and 
concentration. Figure 28(A) is a plot representing the different sizes within the population 
and the concentrations at which they arise. From this representative plot, we can see 
most of the population is around 116 nm, with additional vesicles at 167nm, 235nm, 
312nm and 596nm. The background of the plot shows an image taken from the 
nanoparticle analysis, with each particle being tracked individually by a red dot. Figure 
28(B) shows a scatter plot of every particle passed through the analyser. As evident from 
the plot, the population diameter is most abundant from the 50-250nm range, with the 
largest event sizing at around 600nm. Figure 28(C) represents a cumulative plot of the 
percentile of the population plotted against the size in nm. From the plot, we can confirm 
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that 100% of our population is 600nm or less. Furthermore, we can confirm that a very 
small proportion of the population is less than 100nm.  
 
 
 
Figure 28. Nanoparticle Tracker analysis of isolated microvesicles. (A) Plot showing the distribution of size in nm against 
concentration of the isolated sample. (B) Scatter plot showing the size and intensity of all events run through the 
analyser. (C) Cumulative plot showing the percentile of the population and size in nm.  
 
3.3.2 Double Positive Events for Microvesicle and Antibody Following 
Aqueous Energy Dissemination 
To attempt to present anti-ROS-CII antibodies upon the surface of PMN MV, aqueous 
energy dissemination was performed in the presence of liposome forming phospholipid. 
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This technique has been used previously to enrich microvesicles with protein and lipid 
mediators, but never attempted with antibodies 139,140. Aqueous energy dissemination 
uses sonication to form small, nano-sized liposomes. These nano-sized liposomes entrap 
the antibody upon formation. Simultaneously, the energy provided from the sonication 
causes fluidity of the microvesicle membrane, allowing liposomes (with antibody 
entrapped) to incorporate and fuse with the membrane.  
 
A comparison study was first performed to assess the optimal conditions for enrichment 
and to assess whether sonication is necessary to have the desired effect. Figure 29 
depicts a representative replicate of MV resuspended (A and C) or vortexed (B and D) 
with phospholipid and anti-ROS-CII scFv. MV manually resuspended in phospholipid with 
anti-ROS-CII shows incorporation of antibody on 48% of the population (Figure 29(A)). As 
seen in Figure 29(C), the double positive population are visible on the brightfield 
microscope (CH01 and CH09), have strong BODIPY fluorescence (CH02), show positive 
antibody fluorescence (CH11) and have a visible side scatter (CH12). MV that were 
vortexed in phospholipid with anti-ROS-CII shows incorporation of antibody on 5.6% of 
the population, lower than that of the manually resuspended (Figure 29(B)). The events 
of the double positive population, seen in Figure 29(D), are like that of the manually 
resuspended. They are visible by brightfield (CH01 and CH09), show fluorescence of MV 
and antibody (CH02 and CH09, respectively) but have a larger side scatter (CH12). 
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Figure 29. Imagestreamx analysis of polymorphonuclear neutrophil derived microvesicles enriched with anti-ROS-CII. (A) 
MV were incubated with anti-ROS-CII and liposome forming phospholipid and resuspended with a pipette for 5 
minutes. (B) MV were incubated with anti-ROS-CII and liposome forming phospholipid and vortexed for 5 minutes. (C) 
Representative microscopic image of resuspended MV plus anti-ROS-CII. (D) Representative microscopic image of 
vortexed MV plus anti-ROS-CII. Ch01 & Ch09: brightfield; Ch02: MV fluorescence; Ch11: antibody fluorescence; Ch12: 
side scatter.  n = 4 replicates. 
 
A representative replicate of MV sonicated in phospholipid with anti-ROS-CII scFv are 
shown in Figure 30. Three sonication conditions were used: (i) 5 minutes’ sonication at 1 
amplitude micron (Figure 30(A)); (ii) 5 minutes’ sonication at 3 amplitude microns (Figure 
30(B)) and (iii) 10 minutes’ sonication at 3 amplitude microns (Figure 30(C)). The first 
condition resulted in an incorporation of 20%, the second an incorporation of 68% and 
the third 38%. From the microscopic images, there are differences observed between the 
conditions. The first condition shows a less rounded fluorescence of the vesicle (CH02, 
Figure 30(D)) and a large side scatter (CH12, Figure 30(D)).  The second condition showed 
a larger size as seen in the vesicle fluorescence (CH02) and antibody fluorescence (CH11) 
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of Figure 30(E). The side scatter of the second condition is reduced compared to the first, 
and the shape of the vesicle is rounder. The third condition results in what looks more 
like a regular vesicle (CH02, Figure 30(F)), with the exception that it is also positive for the 
antibody fluorescence (CH11, Figure 30(F)). The side scatter is significantly reduced also, 
resembling that of the vesicle alone population (CH12, Figure 30(F)).  
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Figure 30. Imagestreamx analysis of polymorphonuclear neutrophil derived microvesicles enriched with anti-ROS-CII. (A) 
MV were incubated with anti-ROS-CII and liposome forming phospholipid and sonicated for 5 minutes at 1 amplitude 
microns. (B) MV were incubated with anti-ROS-CII and liposome forming phospholipid and sonicated for 5 minutes at 3 
amplitude microns. (C) MV were incubated with anti-ROS-CII and liposome forming phospholipid and sonicated for 10 
minutes at 3 amplitude microns. (D) Representative microscopic image of MV plus anti-ROS-CII sonicated for 5 minutes 
at 1 amplitude micron. (E) Representative microscopic image of MV plus anti-ROS-CII sonicated for 5 minutes at 3 
amplitude microns. (F) Representative microscopic image of MV plus anti-ROS-CII sonicated for 10 minutes at 3 
amplitude microns. Ch01 & Ch09: brightfield; Ch02: MV fluorescence; Ch11: antibody fluorescence; Ch12: side scatter.  
n = 4 replicates. 
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3.4 Antibodies Incorporated onto Microvesicles Can Still Bind to Its 
Target 
3.4.1 Enzyme Linked Immunosorbent Assay 
Analysis of incorporation by ISx showed double positive events, indicating that 
incorporation was successful. The percentage of incorporation varied under the differing 
conditions. The successful incorporation of anti-ROS-CII upon PMN MV is redundant if the 
antibody does not retain its binding properties. To assess whether the antibody is still 
functional, an ELISA was conducted using the MV fortified with anti-ROS-CII. The ELISA 
antigen was the same as when testing the production of the antibody. Before testing by 
ELISA, the MV incorporated with anti-ROS-CII (all conditions) were pelleted at 20,000g for 
30 minutes to remove any unbound, free anti-ROS-CII. The pellet was resuspended in the 
same volume of PBS-- and both the resuspended pellet and supernatant was tested on 
ELISA to determine the activity of the antibody. In the glycated ELISA (Figure 31(A)), the 
resuspended condition showed activity in the resuspended pellet (R Pellet), with less 
reactivity in the supernatant (R Sup). The vortexed condition showed very similar 
reactivity (V Pellet and V Sup). Of the sonication conditions, sonication one showed nearly 
equal reactivity between the pellet and supernatant (S1 Pellet and S1 Sup), similarly to 
sonication condition 2 (S2 Pellet and S2 Sup). Sonication condition number three showed 
very low activity in the pellet (S3 Pellet), with more activity in the supernatant (S3 Sup). 
The activity of sonication condition 3 overall, however, was much lower than all other 
conditions.  
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Figure 31. ELISA of microvesicles fortified with anti-ROS-CII. (A) ELISA using glycated CII as antigen. (B) ELISA using HOCl 
modified CII as antigen. Microvesicles were pelleted to remove free antibody. Both the resuspended pellet and 
supernatant of each condition was tested by ELISA. Based on the flow cytometric incorporation data and the antibody 
activity on the MV data, sonication condition 2 was decided to be the best for enriching MV with anti-ROS-CII (indicated 
with red arrows). R, resuspended condition; V, vortexed condition; S1, sonication condition 1; S2, sonication condition 
2; S3, sonication condition 3; Pellet, Resuspended MV pellet; Sup, supernatant. n = 3 replicates. 
 
Figure 31(B) represents the same samples run using the HOCl CII as the antigen in the 
ELISA. Interestingly, the activity differs slightly than the Glycated CII ELISA. Resuspension 
and vortexing conditions have much more activity in the supernatant than in the pellet. 
Sonication condition 1 has equal activity between the pellet and supernatant, like the 
Glycated CII ELISA. Sonication condition 2 showed greater activity in the pellet than in the 
supernatant. Similarly, to the Glycated CII ELISA, sonication condition 3 has very low 
antibody activity in the pellet, with more in the supernatant. Also, similarly, the 
sonication condition 3 has an overall lower activity than the other conditions.  
 
Based on the flow cytometric incorporation data and the antibody activity on the MV 
data, sonication condition 2 was decided to be the best for enriching MV with anti-ROS-
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CII (indicated with red arrows in Figure 31). Sonication condition 2 saw the greatest 
percentage of incorporation, ranging throughout repeated experiments from 60-80%. 
Furthermore, the antibody activity on MV that have been incorporated through 
sonication condition 2 showed stronger activity than the supernatants and all other 
conditions. This confirms the incorporation data and that sonication condition 2 is the 
best option. Sonication condition 2 will be used throughout for antibody incorporation 
onto MV.   
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3.4.2 Immunofluorescence 
To try and visualize the incorporation of anti-ROS-CII on MV, as well as confirm the ability 
of enriched MV to bind to arthritic tissue, immunofluorescence was conducted using the 
MV enriched with anti-ROS-CII as a primary antibody. The immunofluorescence was 
conducted on two types of arthritic tissue as previously described: AIA and DMM mouse 
model tissue.  
 
Figure 32 shows the immunofluorescence on AIA tissue. In the 3-11E scFv control we see 
strong pericellular staining, characteristic of the anti-ROS-CII antibody. Using the MV 
alone as a ‘primary antibody’ does not result in strong staining, although MV are 
detectable in the cartilage, as shown by white arrows. The 3-11E/Microvesicles showed 
much stronger MV staining within the cartilage. Interestingly, however, there is little co-
localisation of antibody and MV visible in the slide. The amount of antibody used in the 
MV preparation is lower than the antibody alone control, so a reduced fluorescence of 
antibody compared to control is expected. The lack of co-localisation may be due to the 
separation of MV from anti-ROS-CII after retention in the mouse tissue, although this 
wasn’t further investigated. Slides stained using C7/Microvesicle as a ‘primary antibody’ 
showed little fluorescence of either antibody or MV, indicating that the retention of MV 
observed in the 3-11E/MV treated sample is due to the specificity of 3-11E to ROS-CII. 
 148 
 
Figure 32. Immunofluorescence staining using microvesicles enriched with antibodies on rheumatoid arthritis mouse model 
tissue. Sections were cut from paraffin embedded AIA knees and were immunofluorescently stained using scFv 
antibody alone, microvesicle alone or scFv enriched microvesicles. Blue= DAPI stain, Red= Cy5.5 labelled antibody, 
Green= BODIPY labelled microvesicles. AC = articular cartilage; SB = subchondral bone. Data representative of 3 
samples per group. 
 
The immunofluorescence using DMM tissue showed similar results to the AIA tissue, as 
seen in Figure 33. The 3-11E scFv control showed a strong staining specifically to the 
cartilage, as expected. The MV alone slide showed the presence of some staining in the 
cartilage, as shown by white arrow heads. The 3-11E/Microvesicles treated slide showed 
greater green MV fluorescence in the cartilage, with the antibody stain also detectable 
still. Once again, there is little co-localisation observed. The negative control 
C7/Microvesicles showed little fluorescence of either antibody or MV.  
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Figure 33. Immunofluorescence staining using microvesicles enriched with antibodies on osteoarthritis mouse model 
tissue.  Sections were cut from paraffin embedded DMM knees and were immunofluorescently stained using scFv 
antibody alone, microvesicle alone or scFv enriched microvesicles. Blue= DAPI stain, Red= Cy5.5 labelled antibody, 
Green= BODIPY labelled microvesicles. AC = articular cartilage; SB = subchondral bone. 
 
The immunofluorescence alongside the flow cytometry and ELISA data (Figure 31, Figure 
32 and Figure 33) indicated that anti-ROS-CII can be used to retain MV to arthritic tissue. 
Following validation of reactivity in vitro, we attempted to systemically deliver MV into 
arthritic mice. 
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3.5 Microvesicles Fortified with Anti-Post-Translationally Modified 
Collagen II Antibodies Localise in Arthritic Joints 
Before imaging commenced using the MV enriched with anti-ROS-CII, tweaks had to be 
adapted for use in the in vivo imaging system (IVIS) used for experiments. BODIPY FL is a 
fluorophore used under a 488nm laser, with a maximum excitation of 503nm and 
maximum emission of 512nm. When imaging mice by optical imaging, it is important to 
use fluorophores as near infrared as possible to avoid problems with autofluorescence. 
Fluorophores under the 488nm laser would result in a great amount of autofluorescence, 
so a switch from BODIPY FL to BODIPY Texas Red was necessary. The excitation and 
emission of BODIPY Texas Red is 580nm and 620nm, respectively.  
 
Because the spectrum of Texas Red is close to Cy5.5 (excitation and emission 660nm and 
710nm, respectively), a simple experiment was set up to ensure there was no spill over 
between the fluorophores. Figure 34 shows the results of the experiment, in which serial 
dilutions of MV and antibody were imaged in eppendorfs until saturation to assess 
whether a spill-over would occur. Figure 34(A) shows the imaging under the Texas Red 
scan. The image on the left shows the fluorescence of MV in serial dilution (MV1 being 
fully concentrated down to MV4 at a lower concentration). The high 10 second scan 
saturated the MV1 eppendorf. No fluorescence was observed for any of the antibody 
eppendorfs. The graph shows the quantified fluorescence, obtained by drawing regions 
of interest. Figure 34(B) depicts the imaging under the Cy5.5 scan. The image shows the 
strong fluorescence of the 3-11E scFv antibody in serial dilution (scFv1 fully concentrated 
down to scFv4 at lower concentration). A 10 second scan was performed which saturated 
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the scFv1 eppendorf, and again no fluorescence spill over was detected as seen in the MV 
eppendorfs. The graph depicts the quantified fluorescence, and is a mirror image of the 
graph in Figure 34(A).  
  
 
Figure 34. In vivo imaging system scans of serial dilutions of microvesicles stained with Texas Red BODIPY and antibody 
stained with Cy5.5. Both microvesicles and antibody were imaged under the Texas Red scan at serial dilutions of 1:2, 
1:4, 1:8 and 1:16. (excitation 580nm, emission 620nm, panel A) and Cy5.5 scan (excitation 660nm, emission 710nm, 
panel B) to determine spill-over of fluorophores.  
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3.5.1 In Vivo Imaging System Analysis of Localisation of Microvesicles 
Enriched with Anti-ROS-CII in Antigen Induced Arthritis 
 
After confirming the absence of spill over between Texas Red and Cy5.5 fluorophores, the 
microvesicles enriched with anti-ROS-CII were administered intravenously and tracked in 
AIA mice. All in vivo work conducted from this point were conducted in the inflammatory 
arthritis model antigen induced arthritis.  Mice were imaged by IVIS, scanned under both 
the Texas Red and Cy5.5 settings.  
 
Figure 35 shows the results of the in vivo localisation study of MV fortified with 3-11E 
scFv or C7 scFv (negative control antibody). Mice were injected intravenously 24 hours 
(day 1) after inducing arthritis. (A) and (B) are graphs representing the Texas Red scans, 
whereas (C) and (D) represent the Cy5.5 scans. Figure 35(A) shows the vesicle 
fluorescence of 3-11E/MV and C7/MV in the AIA and contralateral knees of mice. Mice 
injected with 3-11E/MV show more fluorescence in the AIA knee, peaking at 18 hours 
post injection. The contralateral knee of both 3-11E/MV and C7/MV show low MV 
fluorescence. The C7/MV injected mice have a slightly higher fluorescence in the AIA 
knee than the contralateral, but with no specific peak. Mice injected with MV alone show 
high fluorescence in the arthritic knee in the first time point, which is quickly diminished 
over the time course of the experiment. Figure 35(B) is a representation of the ratio 
between the vesicle fluorescence in the AIA knee and fluorescence in the contralateral 
knee. At 3 hours post injection, there is little difference between the mice injected with 
3-11E/MV and C7/MV, but at the 18-hour time point there is an increase in the ratio in 
mice injected with 3-11E/MV, of around 3.5. This indicates there is a localisation of 3-
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11E/MV in the arthritic knees of mice. The C7/MV group ratio decreases at the 18-hour 
time point to 1, where it remains for the continuation of the time points. Figure 35(C) 
represents the antibody fluorescence of 3-11E/MV and C7/MV in the AIA and 
contralateral knees of mice. Like the vesicle fluorescence, the contralateral knees show 
little fluorescence at every time point. The C7/MV fluorescence in the AIA knee is lower 
than the vesicle fluorescence and closer to that of the contralateral knees. The 3-11E/MV 
fluorescence in the AIA knee peaks at 18 hours. Figure 35(D) represents the ratio of the 
antibody fluorescence in the AIA knee and contralateral knee in mice injected with 3-
11E/MV or C7/MV. The C7/MV antibody fluorescence stays low, at a value of 1 at each 
time point, indicating there is no accumulation of C7/MV in either joint. The 3-11E/MV 
ratio peaks at 18 hours at a value of just over 3, indicating there is a localisation of 3-
11E/MV in the arthritic knee.  
 
The in vivo localization data indicates that MV go to the inflamed joint after intravenous 
administration, however the MV do not stay at the inflamed site for long, as seen by the 
clearance after the 3 hour time point.  The 3-11E enriched MV also go to the inflamed 
site after administration, but are able to be retained in the joint for longer, as observed 
with the peak of MV fluorescence at the 18-hour time-point and high fluorescence at the 
end-point of experiment. As this effect isn’t observed in the healthy contralateral knee, 
nor in the arthritic knees of mice treated with non-specific antibody enriched MV 
(C7/MV), we can attribute that the retention of MV in the arthritic joint is due to the 
enrichment with 3-11E.  
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Figure 35. Localisation of microvesicles enriched with anti-ROS-CII antibodies (3-11E/MV) and microvesicles enriched with 
negative control antibody (C7/MV) in an antigen induced arthritis mouse model. Mice were injected intravenously with 
600,000 fluorescently labelled fortified MV. Arthritis is present exclusively in the right knee and left knee acts as 
contralateral control. Fluorescence is calculated using region of interests and plotted as radiant efficiency (A and C). (B 
and D) Ratio of fluorescence in AIA versus contralateral knee. n = 3 or 4 mice per group. Two-way ANOVA was 
performed with Tukey multiple comparisons to determine significant differences in knee fluorescence between 3-
11E/MV and C7/MV treated mice at each time point (no statistically significant difference). 
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3.5.2 Ex Vivo Analysis of Organs and Joints 
Following the completion of the in vivo localisation study 48 hours post injection, mice 
were sacrificed, and their organs and joints were imaged ex vivo by optical imaging, using 
the same Texas Red and Cy5.5 scans. Ex vivo imaging of knee joints was performed. 
Images obtained from the ex vivo optical imaging are shown in Figure 36 and Figure 37.  
Figure 36 shows images obtained of mice injected with either MV alone or 3-11E scFv 
alone, scanned for both Texas red and Cy5.5. The mice injected with microvesicles alone 
show no specific fluorescence for Texas red and are completely negative for Cy5.5. Mice 
injected with 3-11E scFv alone show a strong, specific fluorescence for Cy5.5 in the right 
arthritic knee, but no fluorescence in the contralateral knee. There is a slight fluorescence 
of Texas red in the 3-11E scFv alone mice, which should be completely negative.  
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Figure 36. Localisation of anti-ROS-CII, but not microvesicles alone, to arthritic joints. Images of ex vivo optical imaging 
scans of joints of mice injected intravenously with either 600,000 microvesicles or 50 µg of anti-ROS-CII. AIA mice were 
sacrificed 48 hours post treatment injection and hind legs were imaged ex vivo. Right knee joint (left hand in image) is 
arthritic and left knee joint (right hand in image) is the contralateral control. Top panels: Texas red indicates 
fluorescence from MV labelled with BODIPY Texas Red. Bottom panels: Cy5.5 indicates fluorescence from conjugated 
scFv antibody. 
 
Figure 37 depicts images of mice injected with 3-11E/MV or C7/MV, scanned for both 
Texas red and Cy5.5. Mice injected with 3-11E/MV show a specific AIA knee Texas red 
fluorescence, with no fluorescence in the contralateral knees. The mice injected with 3-
11E/MV also show a specific AIA knee Cy5.5 fluorescence. This fluorescence is lower than 
the 3-11E scFv alone treated mice due to the differing levels of antibody being 
administered. The mice administered with 3-11E/MV are receiving significantly lower 
doses of antibody (around 9.6 µg per 600,000 MV, compared to 50 µg in the antibody 
alone mice). Mice injected with C7/MV show minimal Texas red fluorescence in either 
knee, with one mouse showing higher fluorescence in the contralateral knee. However, 
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the mice injected with C7/MV have no Cy5.5 fluorescence in either the AIA or 
contralateral knee.          .
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Figure 37. Localisation of microvesicles enriched with anti-ROS-CII, but not microvesicles enriched with anti-HEL, to arthritic joints. Images of ex vivo optical imaging scans of joints of mice injected 
with either 600,000 microvesicles fortified with anti-ROS-CII or 600,000 microvesicles fortified with negative control antibody. AIA mice were sacrificed 48 hours post treatment injection and 
hind legs were imaged ex vivo. Top panels: Texas red indicates fluorescence from MV labelled with BODIPY Texas Red. Bottom panels: Cy5.5 indicates fluorescence from 
conjugated...scFv…antibody. 
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The quantification of Texas Red fluorescence of the joints is shown in Figure 38(A), with 
the Cy5.5 fluorescence of the joints depicted in Figure 38(B). Similarly to the fluorescence 
of the organs, the 3-11E scFv injected mice act as a negative for the Texas red 
fluorescence. The mice injected with MV alone show the same Texas red fluorescence as 
the 3-11E scFv injected mice, therefore there are no vesicles present in either knee joint 
of mice injected with MV alone. The mice injected with the 3-11E/MV show the highest 
fluorescence in the AIA knee. The contralateral knee is lower and close to that of the 3-
11E scFv alone injected mice. The higher fluorescence in the AIA knee of mice injected 
with 3-11E/MV is indicative of the targeting of the MV to the joint. The mice administered 
with C7/MV show basal fluorescence in the AIA knee, suggesting that the fluorescence 
seen in the AIA knee of 3-11E/MV mice is specific. 
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Figure 38. Ex vivo fluorescence measurements of the knee joints of mice injected with microvesicles enriched with anti-
ROS-CII antibodies (3-11E/MV) and microvesicles enriched with negative control antibody (C7/MV). Fluorescence is 
calculated using region of interests and plotted as radiant efficiency. Two-way ANOVA with Bonferroni multiple 
comparison test was performed to compare differences in localisation between AIA and contralateral knee for each 
treatment group. **** P ≤0.0001. n = 3-4 mice per group. 
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Figure 39(A) shows the biodistribution of MV (Texas red) fluorescence in various organs 
taken 48 hours after injection of either MV alone, 3-11E scFv alone, 3-11E/MV or C7/MV. 
Mice injected with 3-11E scFv alone act as a negative control for the Texas red 
fluorescence (as they are labelled with only Cy5.5). Compared to the 3-11E scFv alone, 3-
11E/MV and C7/MV mice do not show retention of vesicles in any organ. Figure 39(B) 
shows the biodistribution of Cy5.5 (scFv) fluorescence of mice administered either MV 
alone, 3-11E scFv alone, 3-11E/MV or C7/MV. Mice injected with MV alone act as a 
negative control for the Cy5.5 fluorescence (as they are labelled with only Texas Red). 
The 3-11E scFv alone mice show strong fluorescence in the liver and some fluorescence in 
the kidney, but minimal fluorescence in the heart, lungs and spleen. The 3-11E/MV and 
C7/MV group show minimal fluorescence in all organs, indicating there is no 
accumulation present in the organs 48 hours post injection.  
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Figure 39. Ex vivo fluorescence of organs of mice injected with microvesicles enriched with anti-ROS-CII antibodies (3-
11E/MV) and microvesicles enriched with negative control antibody (C7/MV). Fluorescence is calculated using region of 
interests and plotted as radiant efficiency. n = 3 or 4 mice per group. Two-way ANOVA with Bonferroni multiple 
comparison test was performed to compare differences in localisation between each treatment group for each organ. 
** P ≤0.01; **** P ≤0.0001. 
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3.6 Fortifying Microvesicles with Antibodies Fused to Therapeutics 
Reduces Inflammation in Arthritic Mice  
 
Although localisation in the arthritic knee was observed in mice treated with 3-11E/MV, 
there was no difference in the clinical knee swelling between mice treated with MV alone 
and mice treated with 3-11E/MV. Figure 40 shows the normalized knee swelling of mice 
treated with MV alone or 3-11E/MV and non-treated control mice. Each mouse had its 
knee swelling normalized from 0-100%, with baseline levels representing 0% and 100% 
being knee swelling 24 hours after induction, before treatment administration. The 
differences in knee swelling between mice treated with MV alone and 3-11E/MV are 
minimal and not statistically significant (p > 0.9 at each time point). 
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Figure 40. Clinical knee swelling of mice intravenously administered targeted microvesicles. Arthritis was induced on day 0 
by intra-articular injection of mBSA, MV, 3-11E/MV or PBS were administered 24 hours post induction. Knee swelling of 
mice was recorded using digital calipers to assess efficacy of targeting MV to the joint. Although localisation was 
observed, there was no significant difference in knee swelling between mice administered MV alone or mice 
administered 3-11E/MV. Data are shown as normalized knee swelling for each individual mouse, with baseline levels 
representing 0% and 24 hours post induction representing 100%. Two-way ANOVA was performed with Bonferroni 
multiple comparisons to compare differences in treatment groups at each time point (no statistical significance). n = 3 
to 4 mice per group. 
 
After confirming that MV enriched with 3-11E scFv localised to the arthritic joints in mice, 
a treatment experiment was performed to deliver a therapeutic alongside the MV to 
improve clinical efficacy. For these experiments, 3-11E scFv fused with vIL-10 (3-11E/vIL-
10) was used for MV enrichment. This was previously validated by my group and showed 
an acceleration in knee reduction when administered intravenously in the antigen 
induced arthritis mouse model 39.  
 
The AIA model was used for assessment of clinical efficacy as it was the model in which 
localisation of treatment was confirmed. After arthritis was induced, treatment was 
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administered on day 1 and 3 post induction. Figure 41 represents the clinical knee 
oedema following arthritis induction. Figure 41(A) depicts knee swelling of mice injected 
with anti-ROS-CII antibodies fused with vIL-10 (3-11E/vIL-10) and control non-treated 
mice. Figure 41(B) depicts knee swelling of mice injected with vesicles fortified antibodies 
fused with vIL-10 and control non-treated mice (PBS). Mice injected with the 3-11E/vIL-10 
antibody showed a reduction in knee swelling after the first treatment on day one. The 
reduction continues after the second dose of treatment. The mice injected with the 
negative control antibody fused to vIL-10, namely C7/vIL-10, which is specific against hen 
egg lysozyme, did not accelerate reduction in knee swelling, and followed a similar 
pattern to the mice injected with PBS injected mice. Mice treated with microvesicles 
enriched with 3-11E/vIL-10 show an acceleration in reduction of knee swelling. After the 
first treatment with 3-11E/vIL-10 MV, swelling was reduced. Mice treated with C7/vIL-10 
MV also showed a slight, but non-significant reduction in knee swelling (p = 0.13 at day 3 
compared to PBS).  Figure 41(C) is a direct comparison of mice injected with the 3-
11E/vIL-10 fortified microvesicles and 3-11E/vIL-10 alone to assess whether MV add 
additional benefit. The reduction of swelling in mice treated with 3-11E/vIL-10 MV was 
marginally greater than the 3-11E/vIL-10 alone group after first treatment at day 1, with 
3-11E/vIL-10 MV treated mice being statistically significant from PBS treated mice (3-
11E/vIL-10 MV: day 2, p = 0.0112; day 3, p = 0.012),  but 3-11E/vIL-10 treated mice 
showed no statistical significance. However, both treatment groups are statistically 
significant from the control non-treated mice after the second administration of 
treatment (3-11E/vIL-10 MV: day 5, p = 0.033 & 3-11E/vIL-10: day 5, p = 0.0334). Overall, 
there aren’t great differences in the knee swelling of mice treated with 3-11E/vIL-10 MV 
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or 3-11E/vIL-10 alone, which indicates that loading the antibody upon the MV doesn’t 
hinder its therapeutic effects. 
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Figure 41. Clinical knee swelling of mice treated with microvesicles fortified with anti-ROS-CII antibody fused with vIL-10. 
Arthritis was induced on day 0 by intra-articular injection of mBSA, treatment was provided at days 1 and 3. (A) Graph 
depicting clinical knee scoring of mice treated with 3-11E/vIL-10 antibody, negative control antibody or PBS. (B) Knee 
scoring of mice treated with MV fortified with 3-11E/vIL-10, MV fortified with negative control antibody or PBS. (C) 
Graph comparing the efficacy of mice treated with 3-11E/vIL-10 soluble antibody and mice treated with MV enriched 
with 3-11E/vIL-10. Two-way ANOVA was performed with Bonferroni multiple comparisons to compare differences in 
treatment groups at each time point. # denotes statistical significance of 3-11E/vIL-10 against PBS injected mice; * 
denotes statistical significance of 3-11E/vIL-10 MV against PBS injected mice. * P ≤0.05. n = 8 mice per group. 
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To further confirm the efficacy of fortified MV, luminol bioluminescence imaging was 
conducted. Luminol is a chemical that emits chemiluminescence when interacting with an 
oxidizing agent. The chemiluminescence can be detected by an IVIS imaging system to 
assess the levels of oxidants present in the joint. The imaging works on the basis that the 
more inflamed the joint, the more oxidants are present. The contralateral knee acts as a 
control as there is no inflammation present. Figure 42 shows the results from the luminol 
imaging. Similarly to biofluorescence imaging, regions of interest are drawn (depicted as 
blue circles) and quantified data are presented as photon flux. The data are presented as 
fold change over the control knee, which should be negative, for luminol luminescence. 
Figure 42(A) details the results of mice treated with 3-11E/vIL-10, C7/vIL-10 or PBS. At 
day 1 post induction, the groups show similar fold change in luminescence, with C7/vIL-
10 showing a slightly higher level. By day 3 the PBS and C7/vIL-10 show great increases in 
the luminescence of the arthritic knee, but the 3-11E/vIL-10 group shows a similar 
luminescence to the day one level. At day 3, the 3-11E/vIL-10 group is statistically 
significant from the C7/vIL-10 treated group (p = 0.0112). The 3-11E/vIL-10 group 
remains suppressed at the same level throughout the experiment, and by day 5 the 
C7/vIL-10 and PBS group starts to reduce. Figure 42(B) demonstrates the fold 
luminescence of mice treated with 3-11E/vIL-10 MV, C7/vIL-10 MV or PBS. At day 1 post 
induction, the luminescence present in the inflamed joints is similar between the groups, 
with 3-11E/vIL-10 MV showing slightly greater luminescence. By day 3 there is a drastic 
reduction in the mice treated with 3-11E/vIL-10 MV, which continues over day 5 and 7. 
The mice treated with C7/vIL-10 MV have a similar level between days 1 and 3 which 
decreases over days 5 and 7, but not to the extent of the 3-11E/vIL-10 treated mice. 
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Figure 42(C) shows images obtained from the 3 days’ post induction optical imaging 
process.  
 
 
Figure 42. Optical imaging of luminol bioluminescence in knees of mice injected with either antibody alone, antibody 
enriched microvesicles or PBS control following arthritis induction. Arthritis was induced on day 0 by intra-articular 
injection of mBSA in the right knee, treatment was provided at days 1 and 3. Two-way ANOVA was performed to 
determine differences in luminescence between treatment groups at each time point. * P ≤0.05. n = 5 mice per group. 
 
At the end-point of the vIL-10 MV treatment experiment, mouse knees were harvested 
and snap frozen to probe for the localisation of treatment in the arthritic cartilage. Knees 
were sectioned and mounted onto microscope slides and imaged by confocal microscopy. 
The aim of this analysis was to detect the presence of the fluorescent antibody enriched 
MV treatment (for both the Cy5.5 labelled antibody and BODIPY TR labelled MV).  As 
shown in Figure 43 retention of 3-11E/vIL-10 MV was observed in the arthritic cartilage 
(Figure 43(A) and (B)). This retention was still detectable at the end-point of experiment 
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(day 9), 6 days following the second dose of treatment. As shown in Figure 43(C) and 
Figure 43(D), mice treated with 3-11E/vIL-10 MV showed less localisation in the healthy, 
contralateral cartilage, with no specific retention observed at the end-point of the 
experiment. Similarly, mice treated with C7/vIL-10 MV showed no localisation of 
treatment in either the arthritic cartilage (Figure 43(E) and Figure 43(F)) or the healthy, 
contralateral cartilage (Figure 43(G) and Figure 43(H)).  
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Figure 43. Localisation of microvesicles enriched with anti-ROS-CII antibody fused with vIL-10 in the arthritic joint after 
intravenous administration. Arthritis was induced on day 0 by intra-articular injection of mBSA in the right knee, 
treatment was provided at days 1 and 3. At the end-point of experiment (day 7), knees were harvested and snap frozen 
in OCT medium. Knees were sectioned by cryotomy and probed by confocal microscopy to detect the presence of 
fluorescent treatment in the arthritic cartilage. Mice treated with 3-11E/vIL-10 MV showed specific localisation of 
treatment in the superficial layers of the arthritic cartilage (A and B), but not in the healthy contralateral cartilage (C 
and D). Mice treated with C7/vIL-10 MV showed no localisation in the arthritic knee (E and F), nor in the healthy 
contralateral cartilage (G and H). n = 3 mice per group. Red = BODIPY TR; Cyan = 3-11E/vIL-10; White = overlay. AC = 
articular cartilage. n = 3 mice per group. 
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3.7 Combined Therapeutic Antibodies Can Be Co-Loaded upon 
Microvesicles  
In the previous section, I observed an acceleration in the resolution of inflammation 
following the administration of MV enriched with 3-11E/vIL-10 antibody compared to 
control non-treated mice. However, the reduction in swelling between the 3-11E/vIL-10 
MV and 3-11E/vIL-10 groups did not differ greatly. The aim of this part of the work was to 
find out if we can improve efficacy if we targeted MV loaded with multiple therapeutics.  
 
The aim of these experiments was to co-deliver multiple therapeutics which act through 
different pathways to drive for full resolution of inflammation. Such treatment is difficult 
to achieve clinically due to the detrimental, immunosuppressive side effects of 
administering anti-inflammatory drugs. As a proof of concept, the 3-11E enriched MV 
were used to target vIL-10 and anti-mTNF to the joint. Targeting of the double enriched 
vesicles to the arthritic joint (through the actions of the 3-11E antibody) was 
hypothesized to provide the specific localisation of treatment, as had been observed 
consistently throughout this thesis.  
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3.7.1 Imagestream Analysis of Microvesicles Enriched with Multiple 
Antibodies 
To first confirm the presence of both antibodies upon the MV, Imagestream flow 
cytometry (ISX) analysis was performed as previously described. The MV population were 
gated upon by their low side scatter and BODIPY TR fluorescence and then assessed for 
the simultaneous presence of Alexafluor 488 fluorescence (311e/vIL-10 antibody) and 
Cy5.5 fluorescence (anti-mTNF antibody). 
 
Single antibody loaded MV were used as fluorescence minus one controls for gating, to 
ensure a true positive selection of the double loaded MV. Figure 44 demonstrates the 
results of the ISX analysis for the single antibody loaded MV. Figure 44(A) and Figure 44(B) 
show the ISX analysis for MV loaded with anti-mTNF and 3-11E/vIL-10, respectively. Both 
enriched MV show no double positive population, and only positive fluorescence for the 
specific loaded antibody. Figure 44(C) shows a representative example of an anti-mTNF 
positive MV, with Ch01 and Ch09 showing brightfield images, Ch04 showing MV 
positivity, Ch11 showing anti-mTNF fluorescence and Ch12 showing side scatter. Figure 
44(D) shows a representative example of an 3-11E/vIL-10 positive MV, with Ch01 and 
Ch09 shows brightfield images, Ch02 showing 3-11E/vIL-10 fluorescence, Ch04 showing 
MV positivity and Ch12 showing side scatter. 
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Figure 44. Imagestreamx analysis of polymorphonuclear neutrophil derived microvesicles enrichment with anti-ROS-CII  or 
anti-mTNF.  MV were incubated with 3-11E/vIL-10 or anti-mTNF and dried liposome forming phospholipid and 
sonicated for 5 minutes at 3 amplitude microns. (A) Imagestream analysis of MV enriched with anti-mTNF (B) 
Imagestream analysis of MV enriched with anti-ROS-CII (C) Representative microscopic image of MV plus anti-mTNF. 
(D) Representative microscopic image of MV plus anti-ROS-CII. Ch01 & Ch09; brightfield images, Ch02; AF488 
fluorescence, Ch04; BODIPY TR fluorescence, Ch11; Cy5 fluorescence, Ch12; side scatter. n = 4 replicates.  
 
Figure 45 shows ISX analysis of MV fortified with both 3-11E/vIL-10 and anti-mTNF 
antibodies. The dotplot in Figure 45 shows the MV population positive for both Cy5.5 and 
Alexafluor 488 fluorescence, with 78% of MV positive for both antibodies (range of 69-
84% between replicates). A representative image of the double antibody positive MV is 
shown in Figure 45(B), with Ch01 and Ch09 indicating brightfield images, Ch04 indicating 
MV positivity, Ch02 showing 3-11E/vIL-10 fluorescence, Ch11 showing anti-mTNF 
fluorescence and Ch12 showing side scatter.  
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Figure 45. Imagestreamx analysis of polymorphonuclear neutrophil derived microvesicles enriched with anti-ROS-CII and 
anti-mTNF. (A) Imagestream analysis of MV enriched with anti-mTNF and anti-ROS-CII antibodies, showing 78% of MV 
positive for both antibodies (B) Representative microscopic image of MV fortified with anti-ROS-CII and anti-mTNF. 
Ch01 & Ch09; brightfield images, Ch02; AF488 fluorescence, Ch04; BODIPY TR fluorescence, Ch11; Cy5 fluorescence, 
Ch12; side scatter. n = 4 replicates. 
 
To give an insight into how the vesicle population is changing after enrichment with 
antibodies, nanoparticle tracking analysis was conducted to compare the diameter of 
vesicles, vesicles enriched with a single antibody and vesicles enriched with multiple 
antibodies.  Figure 46 shows a representative NTA analysis, comparing MV alone (Figure 
46(A)), MV enriched with single antibody (Figure 46(B)) and MV enriched with multiple 
antibodies (Figure 46(C)). All three groups show a mean diameter within the MV range, 
with the MV alone also group showing some smaller vesicles below 100 nm. There is an 
overall increase in the size of vesicles after enrichment with antibody, however the large 
standard deviations make these increases not significant. Due to their size being between 
100-600 nm, after enrichment with single and multiple antibodies, the vesicles retain an 
NTA profile that resemble MV and no evidence of aggregates or MV debris was observed.  
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Figure 46. Representative nanoparticle tracking analysis comparing microvesicles alone and microvesicles enriched with 
antibodies. (A) NTA analysis of PMN derived MV from healthy donors without any enrichment. (B) NTA anaysis of PMN 
MV enriched with a single antibody. (C) NTA analysis of PMN MV enriched with multiple antibodies. n = 4 replicates. 
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3.7.2 Microvesicles Enriched with Two Antibodies Can Bind Specifically 
to Two Targets 
3.7.3 Enzyme Linked Immunosorbent Assay 
Following confirmation that both antibodies were present upon the MV, analysis was 
performed to confirm the antibodies can still bind to their targets after incorporation on 
MV. ELISA were performed to determine the binding of double antibody enriched MV to 
recombinant mTNF and glycated CII (as an example of ROS-CII). Figure 47 shows the 
results of the ELISA to check binding specificity. For all test conditions, after incorporation 
upon MV the samples were centrifuged at 20,000 g to pellet the MV population for 
testing on the ELISA. Single antibody and MV enriched with single antibody were used as 
positive controls for binding. Enriched antibodies were checked by ImagestreamX before 
use in ELISA to ensure equal numbers of antibody positive MV were used per group.  Both 
single antibodies and MV enriched with single antibody could bind specifically to either 
glycated CII or mTNF target, but not to the alternative target. There was a significant 
difference in the binding of 3-11E/vIL-10 to glycated CII compared to anti-mTNF (p < 
0.0001) and of anti-mTNF to recombinant mTNF compared to 3-11E/vIL-10 (p < 0.0001). 
However, MV enriched with anti-mTNF and 3-11E/vIL-10 could bind to both the glycated 
CII and mTNF targets in ELISA. There was no significant difference in the binding of 3-
11E/vIL-10 + Anti-mTNF MV to both recombinant mouse TNF and glycated CII when 
compared to MV enriched with anti-mTNF and MV enriched with 3-11E/vIL-10, 
respectively (p > 0.99 and p = 0.22). There was however, a significant difference between 
 178 
binding of 3-11E/vIL-10 + Anti-mTNF MV to both recombinant mouse TNF and glycated 
CII when compared to MV enriched with the non-specific antibody (p = 0.0014 compared 
to 3-11E/vIL-10 MV binding to mTNF; and p = 0.0005 compared to anti-mTNF MV binding 
to glycated CII).  
 
 
Figure 47. Binding capacity of microvesicles enriched with multiple therapeutic antibodies. ELISA was coated with 
recombinant mTNF or glycated CII to test the specificity of the antibodies after incorporation. MV enriched with either 
3-11E/vIL-10, anti-mTNF or a combination of both antibodies as previously described. Enriched MV were used as the 
primary incubation to test the binding specificities after incorporation. Two-way ANOVA with Bonferroni post-test was 
performed to determine statistical significance. ** P ≤0.01; *** P ≤0.001; **** P ≤0.0001; ns = not significant. n = 3 
replicates. 
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3.7.4 MTT Cell Cytotoxicity Assay 
Although ELISA analysis confirmed the ability of both 3-11E/vIL-10 and anti-mTNF to bind 
specifically to target after incorporation upon MV, an MTT assay was performed to test 
the physiological functionality of the anti-mTNF to inhibit TNF dependent cell death using 
L929 cells, which are TNF cytotoxic. Figure 48 shows the results of the MTT assay, 
displayed as the average percentage of viability (compared to positive viability control- 
cells without TNF in culture medium), which was performed over three cell passages. The 
L929 cell death can be inhibited by the addition of anti-mTNF antibody to the cell culture 
in a concentration dependent manner, as shown in Figure 48. MV enriched with anti-
mTNF are also able to inhibit cell death to similar abilities as the anti-mTNF antibody 
treated cells. Furthermore, MV enriched with both anti-mTNF and 3-11E/vIL-10 
antibodies are also able to inhibit cell death to the same extent as cells treated with 10 
mM of anti-mTNF alone. The inhibition of death in cells treated with Anti-mTNF MV and 
3-11E/vIL-10 + Anti-mTNF MV was not statistically significant from cells treated with the 
highest dose of anti-mTNF antibody alone (p = 0.3192 and p = 0.06, respectively). L929 
cells treated with MV alone are unable to inhibit cell death, with around 90% of cell 
cytotoxicity after treatment with MV. Similarly, when treating L929 cells with human TNF, 
cell death cannot be inhibited after treatment with anti-mTNF or MV enriched with anti-
mTNF. These differences were statistically significant from cells in the presence of mTNF 
treated with anti-mTNF MV and 3-11E/vIL-10 + Anti-mTNF MV. This indicates the 
specificity of anti-mTNF to mTNF and not TNF derived from other species.  
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Figure 48. Anti-mTNF can still inhibit TNF dependent cell death after enrichment on microvesicles. MTT assay was 
performed to assess the ability of anti-mTNF to inhibit cell death. L929 cells were cultured in the presence of 
recombinant mouse TNF or human TNF and treated with either anti-mTNF alone, anti-mTNF MV, anti-mTNF + 3-
11e/vIL-10 MV or MV alone. MV enriched with anti-mTNF or anti-mTNF + 3-11E/vIL-10 could inhibit TNF dependent cell 
death, unlike MV alone. One way ANOVA with Bonferroni post-test was performed to determine statistical significance. 
** P ≤0.01; *** P ≤0.001. n = 3 replicates at different passage numbers. 
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3.8 Microvesicles Enriched with Multiple Therapeutic Antibodies 
Promotes the Resolution of Inflammation in Arthritic Mice 
3.8.1 Clinical Scoring 
After the in vitro confirmations regarding the incorporation of anti-mTNF upon MV and 
the ability of the anti-mTNF to bind to to mTNF after incorporation upon MV, in vivo 
proof of concept studies were performed to test whether the MV enriched with multiple 
therapies (vIL-10 and anti-mTNF), had an enhanced efficacy compared to the 3-11E/vIL-
10 MV mono therapy.  As with the previous localisation and treatment experiments, the 
in vivo studies were performed in the AIA mouse model. Arthritis was induced by intra-
articular injection in the right knee on day 0, with treatment administered intravenously 
on days 1 and 3. Knee widths were measured at daily time points using digital calipers.  
 
Figure 49 shows the clinical knee scoring of mice treated with MV alone, 3-11E/vIL-10 
MV, 3-11E/vIL-10 + Anti-mTNF MV and control vehicle (PBS) treated mice. Knee scoring 
for each individual animal was normalized, with 0% representing baseline knee 
measurements before disease induction and 100% representing knee measurements of 
each mouse 24 hours after stimulation of inflammation. Mice injected with PBS show an 
exacerbated inflammation, peaking at day 2, which does not return to baseline levels and 
ended at 27% normalized value. Mice treated with MV alone showed better clinical 
scoring than PBS throughout the experiment, which was statistically significant at day 5 (p 
= 0.038). MV alone treated mice had a normalized knee score of 28% at the end-point of 
experiment. Mice treated with 3-11E/vIL-10 MV showed a greater reduction in knee 
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swelling, as expected based on the previous experiments. Normalised knee width values 
for mice treated with 3-11E/vIL-10 MV were reduced to 17% on average at the end-point 
of experiment. Strikingly, mice treated with 3-11E/vIL-10 + Anti-mTNF MV saw a near 
complete attenuation of inflammation in the knee joint. The accelerated reduction in 
knee swelling in 3-11E/vIL-10 + Anti-mTNF MV combination therapy is statistically 
significant compared to mice treated with MV alone (day 2 p= 0.001, day 3 p= 0.023), MV 
loaded with 3-11E/vIL-10 alone (day 2 p= 0.049) and non-treated mice (PBS, day 2 p < 
0.0001, day 3 p < 0.0001, day 4 p < 0.0001, day 5 p < 0.0001, day 7 p = 0.084). The 
normalized knee width of mice treated with 3-11E/vIL-10 + Anti-mTNF MV was 3% at the 
end-point of experiment. 
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Figure 49. Clinical knee swelling of mice treated with microvesicles enriched with multiple therapeutic antibodies. Arthritis 
was induced on day 0 by intra-articular injection of mBSA, treatment was provided at days 1 and 3. Knee width was 
monitored using digital calipers and knee width was normalized to 100% at 24 hours post arthritis induction. Two-way 
ANOVA with Bonferroni post-test was performed to determine differences in knee swelling across each time point: * 
denotes statistical significance between 3-11E/vIL-10 + Anti-mTNF MV and PBS; † denotes statistical significance 
between 3-11E/vIL-10 + Anti-mTNF MV and MV alone; # denotes statistical significance between 3-11E/vIL-10 + Anti-
mTNF MV and 3-11E/vIL-10 MV. 3-11E/vIL-10 MV is also statistically significant from PBS treated mice at days 2 (p = 
0.0031), 3 (p = 0.001), 4 (p = 0.001) and 5 (p = 0.0011). * = P ≤0.05; ** P ≤0.01; *** P ≤0.001; **** P ≤0.0001. n = 6 to 
10 mice per group. 
 
 
A large panel of mice were treated with control antibody or control MV therapies, as 
shown in Figure 50. C7-vIL-10, 3-11E/vIL-10 and anti-mTNF treated mice were all included 
to assess the reduction of swelling at similar equivalent doses. As expected from previous 
experiments, 3-11E/vIL-10 reduces knee swelling most and is statistically significant from 
PBS treated mice. C7/vIL-10, the untargeted equivalent, is unable to reduce knee swelling 
to the same extent. Mice treated with anti-mTNF saw a modest reduction of knee 
swelling, but not to the extent observed with 3-11E/vIL-10. This is explained by the low 
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dose of anti-mTNF used in this study compared to other published work showing efficacy 
in vivo. 
 
Figure 50 panel B shows the knee swelling data for mice treated with the MV control 
therapies. As a control for the combined therapy approach, a non-targeted alternative 
was used. C7/vIL-10 + Anti-mTNF was loaded upon MV to show that the amelioration in 
inflammation observed in the 3-11E/vIL-10 + Anti-mTNF MV is due to the specific 
localisation of the therapy. The C7/vIL-10 + Anti-mTNF MV therapy was unable to reduce 
knee swelling at the rate of the 3-11E/vIL-10 + Anti-mTNF treatment, and statistical 
significance between these two groups was observed at day 2 (p = 0.0058).  C7/vIL-10 + 
Anti-mTNF MV did show statistical significance from PBS treated mice at day 3 (p = 
0.0181), which indicates that administering the combined treatment of vIL-10 and anti-
mTNF upon MV has significant efficacy even without targeting. Single therapy of Anti-
mTNF MV showed no greater efficacy than MV alone.  
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Figure 50. Clinical knee swelling of mice treated with antibody and microvesicle controls. Arthritis was induced on day 0 
by intra-articular injection of mBSA, treatment was provided at days 1 and 3. Knee width was monitored using digital 
calipers and knee width was normalized to 100% at 24 hours post arthritis induction. (A) Knee swelling data of mice 
treated with PBS, C7/vIL-10, 3-11E/vIL-10 or Anti-mTNF controls. * denotes statistical significance between 3-11E/vIL-
10 treated mice and PBS treated mice at days 4 (p = 0.0362) and 5 (p = 0.0104. No statistical significance observed 
between any other treatment groups). (B) Knee swelling data of mice treated with PBS, MV alone, Anti-TNF MV or C7-
vIL-10 + Anti-mTNF MV. * denotes statistical significance between C7-vIL-10 + Anti-mTNF MV treated mice and PBS 
treated mice at day 3 (p = 0.0181. no statistical significance observed between any other treatment groups). Two-way 
ANOVA with Bonferroni post-test was performed to determine differences in knee swelling across each time point. * = 
P ≤0.05. n = 5 to 6 mice per group. 
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3.8.2 Histological Analysis 
At the end-point of the combined antibody MV treatment experiment, three mouse 
knees per group were harvested and snap frozen. Knees were sectioned and mounted 
onto microscope slides and imaged by confocal microscopy. The aim of this analysis was 
to confirm the localisation that was shown in the previous treatment experiment. As 
shown in Figure 51, control PBS treated mice show no fluorescence in the arthritic knee 
joint. Mice treated with MV alone show some vesicle fluorescence in the arthritic joint, 
mainly located within the bone marrow and small amounts detected in the superficial 
layers of the cartilage. Confirming what was observed in the previous treatment 
experiment, mice treated with 3-11E/vIL-10 MV show a high retention of MV 
fluorescence in the arthritic cartilage at the end-point of the experiment. Unexpectedly, 
the mice treated with 3-11E/vIL-10 + Anti-mTNF MV showed extremely little MV 
fluorescence in the arthritic knee joints at the end-point of the experiment. This was the 
case for all three mice in the 3-11E/vIL-10 + Anti-mTNF MV confocal analysis. This 
unexpected clearance of MV was likely linked to the clearance of oedema observed in the 
clinical knee swelling of 3-11E/vIL-10 + Anti-mTNF MV treated mice. 
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Figure 51. Localisation of microvesicles alone, anti-ROS-CII fused to vIL10 enriched microvesicles (3-11E/vIL-10 MV) and anti-ROS-CII fused to vIL10 + Anti-mTNF enriched microvesicles (3-11E/vIL-10 
+ Anti-mTNF MV) in the arthritic joint after intravenous administration. At the end-point of experiment (day 7), knees were harvested and snap frozen in OCT medium. Knees were sectioned by 
cryotomy and probed by confocal microscopy to detect the presence of fluorescent treatment in the arthritic cartilage. As observed previously, mice treated with 3-11E/vIL-10 MV showed 
specific localisation of treatment in the arthritic cartilage. Unexpectedly, mice treated with 3-11E/vIL-10 + Anti-mTNF MV showed no fluorescence retention in the arthritic knee. AC = articular 
cartilage.  n = 3 mice per group.
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Histological staining was also performed to assess cartilage damage and inflammation 
within the joint. Knees were harvested, formalin fixed and decalcified before paraffin 
embedding and sectioning. Knee sections were stained with safranin O to assess cartilage 
damage. Naïve mice showed strong safranin O staining in all layers of the cartilage. PBS 
injected mice shows visual loss of safranin O staining, throughout all layers of some areas 
of the cartilage. MV alone treated mice showed some loss of proteoglycans in the 
cartilage, but overall showed a healthier phenotype, similar to naïve mice . 3-11E/vIL-10 
MV and 3-11E/vIL-10 + Anti-mTNF MV treated mice showed strong staining of cartilage 
but surprisingly had more inflammation present compared to MV alone treated mice, 
although less than the PBS treated controls. 
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Figure 52. Safranin O  staining of treated arthritic mouse knees. Mouse knees were fixed and decalcified before 
sectioning and staining with safranin O to assess cartilage integrity. Representative images of each group are shown. AC 
= articular cartilage.  n = 5 mice per group.
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Stained knee joints were given a value of 0–5 for inflammatory score: 0- normal; 1- acute 
synovitis; 2- marrow reaction; 3- bone erosion; 4- expanded synovial granulation (severe 
thickening); 5- loss of cartilage (as a result of structural collapse) and ankyloses.. As 
expected, PBS mice showed the highest inflammatory grade. Surprisingly, MV alone mice 
scored the best on average, followed by the 3-11E/vIL-10 MV and 3-11E/vIL-10 + Anti-
mTNF mice. This trend is the opposite to the clinical knee swelling, but is likely the 
difference between acute oedema observed in the swelling and cellular changes 
observed in the histology. From these observations, the loaded MV are most efficacious 
to eliminate the initial inflammation in the joint, whereas these additional treatments 
have less of an effect on the infiltrate compared to MV alone. All treatment groups see an 
improvement compared to PBS control mice, however, in line with the clinical knee 
measurements..  
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Figure 53. Histological arthritis scores of antigen induced arthritic stifle joints. Joints were scored 0-5 based on the degree 
of inflammation within the joint. Mice were treated intravenously with either PBS, MV Alone, 3-11E/vIL-10 MV or 3-
11E/vIL-10 + Anti-mTNF MV. One-way ANOVA with Dunn’s multiple comparisons test was performed to determine 
differences in inflammatory score. No statistical significance was observed.  
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3.8.3 RT-qPCR of Knee Joints 
As aforementioned, arthritic knee joints were harvested and snap frozen immediately. 
Knee joints were thawed and excess muscle and bone was removed before RNA was 
extracted by trizol method. RNA was reverse transcribed into cDNA and analysed by RT-
qPCR to look at the expression of a panel of chondroprotective and chondrodestructive 
genes within the knee joint. Figure 54 shows the expression of chondroprotective genes 
within the knee joints of treated mice. Gene expression was calculated as 2-∆∆Ct relative to 
housekeeping gene RPL32. Relative gene expression is shown over naïve mice expression. 
Overall, the chondrodestructive panel showed larger variation in gene expression 
between treatment groups than the chondroprotective panel. Figure 54 shows the 
expression of chondroprotective genes in mice treated with PBS, MV alone, 3-11E/vIL-10 
MV or 3-11E/vIL-10 + anti-mTNF MV. PBS treated mice do not see large reductions in the 
expression of chondroprotective genes, with only aggrecan and SOX9 largely 
downregulated. In these two genes, the treatment groups all saw an increase of 
expression, albeit not statistically significant.  
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Figure 54. RT-qPCR analysis of local chondroprotective gene expression in treated mice. RNA was extracted from whole 
knee joints and reverse transcribed into cDNA. RT-qPCR was performed to assess local gene expression of a panel of 
chondroprotective genes. Data shown are 2-∆∆CT with knee joints from naive mice as calibrator and RPL32 as 
housekeeping gene. Data are expressed as min to max floating bars with line at mean. Kruskal Wallis test with Dunn’s 
multiple comparison post-test conducted to test significance (no significant difference). n = 3 mice per group. 
 
Figure 55 shows the expression of chondrodestructive genes within the knee joints of 
treated mice. The chondrodestructive panel saw greater variation of gene expression 
over naïve mice. PBS mice had the most upregulation of all the genes assessed in the 
panel, with a general downward trend for mice treated with MV alone, 3-11E/vIL-10 MV 
or 3-11E/vIL-10 + anti-mTNF MV. ADAMTS5 is the only exception to this, remaining highly 
upregulated in all treatment groups. Mice treated with 3-11E/vIL-10 MV or the combined 
treatment of 3-11E/vIL-10 + anti-mTNF MV overall saw the most reduction in expression 
compared to PBS treated mice, coming closely down to naïve levels. These differences 
were not statistically significant from PBS treated mice, however.  
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Figure 55. RT-qPCR analysis of local chondrodestructive gene expression in treated mice. RNA was extracted from whole 
knee joints and reverse transcribed into cDNA. RT-qPCR was performed to assess local gene expression of a panel of 
chondrodestructive genes. Data shown are 2-∆∆CT with knee joints from naïve mice as calibrator and RPL32 as 
housekeeping gene. Data expressed as min to max floating bars with line at mean. Kruskal Wallis test with Dunn’s 
multiple comparison post-test conducted to test significance (no significant difference). n = 3 mice per group. 
 
 
Figure 56 shows a heat map summary of average gene expression profiles for visual 
clarification and comparison. The left panel represents the genes in the 
chondrodestructive gene panel, with the right panel the chondroprotective cluster of 
genes. Notably, the MV alone, 3-11E/vIL-10 MV and 3-11E/vIL-10 + Anti-mTNF MV 
treated mice have gene expression more similar to naïve mice than the PBS treated mice. 
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Figure 56. Heat map summary of average local gene expression in treated mice. Data shown are 2-∆∆CT with knee joints 
from naive mice as calibrator and RPL32 as housekeeping gene. Chondrodesctructive genes are shown in the left panel, 
with chondroprotective genes in the right panel. The range of gene regulation for chondrodestructive genes was vast, 
from 0-35, whereas chondroprotective gene regulation ranged only from 0-6. n = 3 mice per group. 
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Chapter 4: Discussion of Results 
EV have been extensively explored in recent years as therapeutic vectors. EV can be 
utilised as a scaffold for novel nanomedicines due to the ease of incorporation of drugs, 
and have been utilised in a variety of disorders, with many used for delivering RNA based 
therapies 145,146. PMN MV have been previously enriched with pro-resolving proteins and 
mediators, to facilitate trafficking of mediators with minimal dilution and/or inactivation 
139,140. Loading with additional therapies has enhanced the innate anti-inflammatory 
effect observed by PMN MV. The potential of PMN MV for inflammatory arthritis 
treatment was further propelled following the observations of cartilage penetration and 
protection 136. The pro-resolving and anti-inflammatory properties of neutrophil MV in 
the context of arthritis are now well described, making them an attractive candidate as a 
biological scaffold. Nevertheless, studies have been limited by the need for local 
administration to observe the desired effects 136,147. Existing therapies for RA, such as 
anti-TNF therapy combined with methotrexate, can counteract chronic inflammation and 
reduce symptoms 148, but no current therapy is able to actively protect cartilage from 
further degradation.  
 
The utilization of anti-ROS-CII antibodies provide a means to delivering tailored therapies 
directly to the site of the body that needs it. Previous studies have shown anti-ROS-CII 
fused with anti-inflammatory cytokines localise and reduce inflammation in an arthritis 
mouse model 39. This innovative antibody technology helps to address the unmet need of 
RA treatment to improve therapies by reducing side effects and non-response. For the 
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first time, we have enriched MV with an antibody as means of specific delivery of MV to 
the diseased tissue.  
 
This thesis aimed to challenge this current state of treatment and make a progressive 
step towards: i) producing an effective treatment of systemically injected MV; (ii) 
targeting MV biological scaffolds loaded with therapies to the arthritic cartilage; (iii) 
developing a new combined therapy using traditionally used anti-inflammatory therapies 
alongside PMN MV.  
 
This thesis aimed to test the possibility of targeting PMN MV using antibodies to ROS 
modified CII and assess the ability to resolve ongoing inflammation. The potency has 
been evaluated both with and without additional anti-inflammatory therapeutics. 
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4.1 Anti-ROS-CII Antibodies Localise Specifically in the Arthritic Joint  
The first part of my project was to validate a new anti-ROS-CII candidate and its reliability 
for targeting to the arthritic joint. Initial experiments were centered on the production 
and validation of anti-ROS-CII in vitro. The main candidate used in this thesis, 3-11E scFv, 
has not been characterised and validated previously, whereas, the candidate 1-11E had 
been utilized in previous experiments and thus published material is available 39,115,118. As 
previously explained, the 3-11E scFv candidate has been utilised in this thesis due to the 
problems arising during the 1-11E scFv candidate production. The 1-11E candidate 
undergoes glycosylation of the binding site during production, which can be inhibited by 
treating the cells with tunicamycin, but subsequently results in a low yield. Thus, the 3-
11E scFv candidate was explored in this thesis as an appropriate alternative to target the 
arthritic joint.  
 
The expected and observed in vitro findings were similar to that of the established 1-11E 
antibody. The molecular weight of the produced antibody was standard for a scFv (Figure 
16) and the binding of the antibody was strong to the ROS modified CII, but minimal to 
the native CII (Figure 18). The characteristics of the 3-11E antibody appears very similar 
to that of the 1-11E candidate in vitro 39,118 . Immunofluorescence using the 3-11E 
antibody also shows similar patterns to that of the 1-11E antibody, binding strongly in RA 
mouse tissue around the chondrocytes in a pericellular fashion (Figure 19) 39. Following 
validation of the 3-11E antibody in vitro, localisation studies were performed in vivo. For 
the initial in vivo experiments, 1-11E was included as a comparative control, as well as the 
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C7 negative antibody. The 3-11E showed strong localisation in the arthritic joint following 
systemic administration. Mice injected with scFv antibodies showed similar localisation of 
1-11E and 3-11E, although 1-11E was slightly higher (Figure 21). The C7 scFv injected 
mice showed no specific localisation in the arthritic joint.  
 
Similarly, for the mice injected with IgG antibodies, 3-11E and 1-11E showed strong 
localisation in the arthritic knee, with no localisation in the contralateral control knees 
(Figure 22). The difference between 3-11E and 1-11E in the IgG injected mice was lower 
than the scFv injected mice. The standard error is high in the IgG injected mice, but an n 
of 3 mice per group is likely responsible for that error. The behavior of the 1-11E antibody 
was similar to that observed in previous published data, which both confirmed the 
previous publications and that the optical imaging system is running efficiently 39,118. The 
observation of the 3-11E localisation being like the 1-11E antibody certifies that the new 
candidate behaves similarly to the 1-11E candidate, and that using the 3-11E candidate 
for targeting the joint is viable.  
 
After the validation of the 3-11E antibody in an inflammatory arthritic model, the in vivo 
localisation of the antibody in an OA model was evaluated. As OA is considered less 
inflammatory than RA 50, the antibodies were administered by intra-articular injection as 
opposed to intravenous administration. The lack of vascularization in the knee in OA, 
which is often not the case in models of RA due to de novo blood vessel formation 149, 
meant the scFv (with a short half-life) may not reach the joint well in an OA model 150.  To 
overcome this, intra-articular injection and the retention of the antibody in the joint was 
assessed to determine if the 3-11E candidate binds to osteoarthritic cartilage.  
 200 
 
The experiment used the 6-11D antibody as a positive control, which binds to both 
healthy and ROS modified cartilage. As expected, the retention of the 6-11D antibody is 
high in both the arthritic and contralateral knees of mice at 4 weeks and 8 weeks post-
surgery (Figure 25 and Figure 26). The 3-11E antibody was retained exclusively in the 
arthritic knee of mice at both 4 weeks and 8 weeks post-surgery. The antibody injected 
into the contralateral knees was cleared quickly, indicating that 3-11E binds to 
osteoarthritic cartilage as well as rheumatic cartilage. The 1-11E candidate was previously 
shown to bind to arthritic cartilage in the mouse model of DMM, so the retention of 3-
11E scFv in the DMM model is not surprising 115. As the previous experiments comparing 
the 1-11E and 3-11E localisation in the AIA model showed similar behavior of the two 
candidates, the same is likely for localisation in OA tissue.  
 
The ratio of 3-11E fluorescence observed in the arthritic and contralateral knees was 
lower at 8 weeks post-surgery than 4 weeks post-surgery. Additionally, the binding of 3-
11E antibody to OA tissue by immunofluorescence appears slightly dampened in later 
time points (Figure 20). This may be due to the cumulative degradation of cartilage 
throughout the model. DMM is a progressive model resulting in degenerative cartilage 
loss over time 151. It is possible that as cartilage damage becomes extensive, the ROS 
modified CII epitopes become destroyed, hence antibody binding would decrease. The 
molecular changes to the cartilage in the earlier stages of disease likely results in stronger 
binding than in the later stages of disease, where overt cartilage damage is evident. In 
terms of translation into patient strategies, I envisage that the 3-11E antibody can be 
utilized for early OA detection, when molecular changes are occurring in the cartilage, but 
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overt damage is not necessarily observed. The 3-11E antibody could potentially be used 
translationally as an imaging tool in humans as an immunoconjugate for SPECT or PET 
imaging, such as is currently used in oncologic imaging 152.  
 
To assess the ability of the 3-11E antibody to target a therapeutic agent to the arthritic 
joint, a localisation study using 3-11E fused to vIL-10 was conducted. A similar study was 
conducted previously using the 1-11E antibody, and found that localisation in the joint 
resulted in the cleavage of the matrix metalloprotease (MMP) linker fusing the antibody 
to the vIL-10 39. Whilst in a fused form, the vIL-10 is latent, and thus cannot exert its anti-
inflammatory effects. The antibody must localise in the inflammatory microenvironment 
(rich in MMP) for the cleavage to occur and for the vIL-10 to manifest. The localisation 
study conducted in an AIA mouse model found that the 3-11E/vIL-10 antibody still 
localizes successfully in the arthritic joint. Furthermore, the immunohistochemistry 
analysis showed the effects of the therapeutic vIL-10, with fewer cellular infiltrates and a 
greater safranin O staining in the arthritic joint of mice treated with 3-11E/vIL-10. This 
effect was not observed in mice injected with C7/vIL-10- vIL-10 fused to a negative 
antibody which did not localise and hence cleave the MMP linker.  This is further 
validation of the antibody targeting strategy and hence reinforcing the observation that 
the 3-11E antibody behaves similarly to the 1-11E counterpart. 
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4.2 Aqueous Energy Dissemination Results in Positive Incorporation of 
Anti-ROS-CII upon Microvesicles 
Having validated the 3-11E antibody in vitro and in vivo, the focus of the project shifted 
into the aim of targeting of MV to the arthritic joint. As aforementioned, the 3-11E 
antibody was used throughout the continuation of the studies of this thesis. 
 
The generation of MV from PMN was first performed according to established techniques 
of our laboratory. Analysis of the MV generated from activated PMN was conducted by 
two methods; flow cytometry and nanoparticle tracking.  The analysis conducted by ISx is 
beneficial as it allows visual observation of the sample to ensure you have a relatively 
pure MV population 136. The method of generating MV is robust, as ISx analysis is 
reproducible throughout different MV productions. Furthermore, the nanoparticle 
tracking analysis allows for identification of the purity of the MV population based on 
size. The MV produced are rarely less than 100nm or greater than 1000nm, suggesting 
that, by the official nomenclature of extracellular vesicles, the population are primarily 
‘microvesicles’, as opposed to exosomes. Studies previously conducted by Norling et al 
and Dalli et al utilized a technique termed as aqueous energy dissemination 139,140. This 
technique involves using liposome forming phospholipid to enrich MV with proteins or 
lipids. Liposomes are formed when the phospholipid is exposed to an aqueous solution, 
and the size of the liposomes can be altered by techniques such as sonication. In the 
previous studies, MV have been  successfully enriched with pro-resolving proteins in the 
context of peritonitis and sepsis. This enrichment technique showed efficacy in vivo in 
 203 
both studies, and provides an opportunity to simply, cheaply and effectively incorporate 
antibodies upon MV to target them to the arthritic joint.  
 
The initial studies followed protocols adapted from the aforementioned papers 139,140. A 
range of conditions were used to determine the optimum for incorporation of the 
antibody. Sonication is known to be needed to produce liposomes of nanometer size 
range, which would be best to incorporate the antibody without completely masking the 
MV 139. Nonetheless, the conditions of manual resuspension and vortexing were also 
included for comparison. The flow cytometric analysis of incorporation determined 
double positive events, i.e. BODIPY stained vesicles that were positive for Cy5 antibody. 
The manual resuspension showed double positive events which have a larger side scatter 
than vesicles alone. They were also visually observed on the brightfield channels of the 
ISx, unlike MV, indicating they are of larger size. The vortexing condition showed a low 
incorporation, although throughout repeats of the experiment this was variable and did 
increase. The size of these vesicles also appears larger due to the scatter and brightfield 
observations. The sonication conditions appear to show reduced size of MV as the 
intensity and time of sonication increases. The best incorporation was observed 
consistently in the sonication condition of 3 amplitude microns for 5 minutes. The range 
of double positive events throughout repeats was from 50-75%. The microscopic images 
from the ISx analysis show the third sonication condition to produce what looks most like 
an MV before treatment but are also positive for the antibody.  
 
To properly analyse size, nanoparticle-tracking analysis was conducted to determine the 
changes to the MV throughout each condition. After enrichment with antibodies, the MV 
 204 
retained their characteristic size with just a small increase in average diameter. This 
increase was not statistically significant due to the attributions of the standard deviation. 
Previous studies utilizing aqueous energy dissemination observed a decrease in diameter 
following enrichment of protein, which was not observed in these studies 139.  The 
previous analysis was conducted using electron microscopy, whereas herein NTA was 
used. This is likely why differences are observed between studies, particularly as there is 
evidence to suggest the sensitivity of NTA for sizing is lower. Electron microscopy has a 
detection limit as low as 1 nm, whereas NTA has a higher detection limit of around 50-70 
nm 153. Nonetheless, the NTA analysis did confirm that the population of MV was not 
dramatically altered in diameter following incorporation with the antibodies.  
 
After confirming by flow cytometry that the MV are positive for the antibody 
fluorescence after aqueous energy dissemination, it was important to determine whether 
the functions of the antibody were withheld throughout the process. The incorporation 
of anti-ROS-CII is futile if the binding capabilities are masked or destroyed. To check the 
binding of the antibody was still active, the established ELISA used to check the 
production of antibodies was slightly modified for checking the enriched MV. Native CII 
and ROS modified CII were used as the antigenic coating, with the enriched MV used as 
primary antibody (with MV alone and 3-11E alone as negative and positive controls, 
respectively). Importantly, enriched MV were pelleted at 20,000 g to remove the 
supernatant and any unbound antibody. Both the resuspended pellet and supernatant 
were run to determine how much antibody was incorporated as well as if the antibody 
binding site was still active. Sonication condition 2, which produced the most double 
positive events, showed positive binding of the enriched MV to ROS modified CII. There 
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was slightly more antibody activity in the resuspended pellet than in the supernatant, 
which represents the flow cytometry data nicely. Sonication condition 3 had a reduced 
antibody binding in both the resuspended pellet and the supernatant. It is likely that the 
prolonged and intense sonication has damaged the antibody-binding site somehow, due 
to the lack of binding in both the pellet and supernatant. Based on the microscopic 
images taken from the ISx, the microvesicles still seem to be intact in all sonication 
conditions. It is known that the sonication of a range of proteins can induce the formation 
of aggregates that resemble amyloid 154. It is likely that the antibodies are undergoing 
such a process, either masking or denaturing the binding site. The second sonication 
condition proved optimum, with the greatest incorporation and highest antibody activity 
of the enriched MV. This condition was used throughout the continuation of enrichment 
experiments.  
 
The enriched MV were tested by immunofluorescence on AIA and DMM mouse tissue to 
certify the antibody binding but also to try and show the presence of both antibody and 
MV. For the first time, MV alone was used in immunofluorescence to assess their binding 
to arthritic cartilage tissue in vitro. The presence of MV were detected by fluorescence 
microscopy and are indicated with white arrow heads (Figure 32 and Figure 33). Very few 
MV were detected but were detected exclusively in cartilage tissue. The enriched MV 
showed positivity for antibody binding, as well as a huge increase in BODIPY fluorescence, 
albeit there was not a great amount of co-localisation. The C7 enriched vesicles did not 
show any antibody or MV fluorescence in the cartilage tissue. Interestingly, greater 
amounts of MV alone were observed in DMM tissue than AIA tissue, and greater BODIPY 
fluorescence of enriched MV was also observed in DMM tissue than AIA tissue. The 
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increase of MV alone in DMM tissue may be due to factors present more in osteoarthritic 
cartilage, such as a greater expression of FRP2/ALX receptor, which binds AnxA1 155, or 
greater expression of phosphatidylserine receptor, which would bind the microvesicle 
membrane. Literature suggests that the former may be unlikely, as synovial tissue from 
RA patients has been found to have elevated FPR2 mRNA levels compared to the synovia 
from patients with OA 156, albeit FPR2 levels specifically within OA cartilage is not well 
characterised. The high BODIPY fluorescence in the anti-ROS-CII enriched MV is likely due 
to the binding by the antibody, as opposed to binding of the MV to the cartilage. The 
large increase of MV fluorescence in the enriched MV compared to the MV alone 
suggests that the presence of the antibody is responsible. This is promising as it further 
indicates that MV are being delivered to the cartilage in vitro by the enrichment with 3-
11E scFv.  
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4.3 Microvesicles Enriched with Anti-ROS-CII Localise in the Arthritic 
Joint 
In vivo investigations aimed to assess whether the MV enriched with 3-11E scFv localise in 
the arthritic joint. Not only was it important to show the localisation of the MV enriched 
with 3-11E scFv in the same manner as was conducted with the antibody validation, it 
was also important to demonstrate that microvesicles are going to the knee and more 
specifically into the cartilage.  
 
The starting point of these experiments was to assess the spill over between 
fluorophores. Optical imaging has rarely been conducted using multiple fluorophores in 
literature, however it is a perfectly viable option as the technology is built for such 
experiments. To assess the spill over, a simple experiment was conducted using serial 
dilution of both fluorescent MV and 3-11E scFv and imaging at full saturation using the 
IVIS. As observed in Figure 34, there is no spill over between fluorophores observed. 
Although, in theory, the Texas red and Cy5.5 fluorophores were far enough apart on a 
spectrum to avoid such an issue, it was important to clarify this experimentally. The Texas 
Red fluorophore is used at an excitation of 580 nm and an emission of 620 nm. To avoid 
issues with mouse autofluorescence in optical imaging, it is optimal to use a fluorophore 
above the 600 nm range 157. The Texas Red fluorophore sits around the 600 nm range, 
therefore although it is acceptable to use for imaging purposes a fluorophore nearer 
infrared would eliminate any trace of possible issues with autofluorescence. By scanning 
mice pre-treatment to assess autofluorescence levels, this possibility was minimized, 
however a fluorophore with a higher excitation would still be optimal. The Cy5.5 
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fluorophore does not have such issues, with an excitation of 660 nm and an emission of 
710 nm.  
 
Multiple small-scale experiments were necessary to optimize the imaging process using 
multiple fluorophores. There are very few studies published utilizing multiple 
fluorophores in an IVIS system, therefore small-scale localization studies with a low n 
number were performed to assess localisation specificity and experimental parameters. 
The experiment shown in Figure 35 was the first larger scale experiment assessing the 
localisation of enriched MV, both with anti-ROS-CII and negative control antibody. Mice 
injected with fluorescent MV alone and 3-11E scFv alone were included in the experiment 
as imaging controls but were not compared to the enrichment groups for in vivo 
localization due to the potential differences in doses. The localisation study looks at the 
fluorescence of both the MV and the 3-11E scFv to show the presence of both in the 
arthritic joint. As shown in Figure 35, the MV enriched with 3-11E scFv localized in the 
arthritic joint exclusively, like what we typically observe with the 3-11E antibody. The 
Texas Red fluorescence scan shows the localisation of the MV with the antibody. The 
peak for all fluorescence was observed at 18 hours. The half-life of our scFv antibody is 
known, and is around 2 hours. The half-life of a MV has not been well characterised. The 
enrichment process is likely to extend the half-life of both the scFv and the MV, which is 
why we see a peak at 18 hours. The ratio of the fluorescence between the AIA and 
contralateral knee for both the Texas Red and Cy5.5 fluorescence also peaks at 18 hours, 
confirming the peak of localisation for 3-11E enriched MV. The C7 ratio remains low at 1 
for the Cy5.5 fluorescence throughout the experiment, but increases slightly at the 3-
hour time point for the Texas Red fluorescence. The standard error for this time point is 
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quite large for the C7 group, and the increase may be down to the limited number of 
mice. Another possibility may be that the MV injected haven’t been fortified with 3-11E 
scFv, as from the in vitro analysis shown in Figure 30, we know that around 70% are 
fortified with the antibody. As the fluorescence of the C7 isn’t high in either the AIA or 
contralateral knee, the increase in ratio is not of great concern, and does not seem to 
represent a specific accumulation in the joint. 
 
Organs were imaged ex vivo at the end of the experiment to assess whether an 
accumulation of MV or antibody was present. Small molecule drugs are typically 
eliminated through the kidney and liver 158, which is what we see from the Cy5.5 
fluorescence of mice injected with 3-11E antibody. Interestingly, mice injected with MV 
alone also showed clearance of the MV through the kidney and liver, depicted by the 
Texas Red fluorescence. One previous study conducted a similar ex vivo analysis and 
found that extracellular vesicles accumulated in the liver, kidney, brain and intestine 3 
hours post injection 159. Previous studies in literature have also been conducted assessing 
the macrophage dependent clearance of extracellular vesicles through the liver and 
spleen. It was shown that when macrophages are depleted using clodronate, clearance of 
administered extracellular vesicles was much slower 160. Although our analysis was 
conducted at the end-point of the experiment- some 72 hours post injection, we can see 
similarities between the published study and our findings. The organs imaged ex vivo did 
not include the brain in this experiment, which may have seen significant fluorescence 72 
hours post injection. Furthermore, the stomach and intestines were imaged but had to be 
excluded from the analysis due to the chow diet of the mice. Alfalfa in the chow diet is 
highly fluorescent, and to fluorescently image intestinal organs of the mice an alfalfa free 
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diet is necessary 161. Therefore, possible false positive fluorescence of the chow diet in 
this experiment meant the fluorescence of the intestines and stomach were discarded 
from analysis.  
 
Overall, the most significant result of the ex vivo organ analysis was the presence of the 
3-11E scFv antibody in the liver and kidneys. All other groups showed minimal 
fluorescence for both Texas Red and Cy5.5 fluorescence, suggesting that by 72 hours 
most of the products had been cleared systemically.  
 
Knee joints were also imaged ex vivo to assess the localisation of enriched MV in the 
arthritic joint. To show that the PMN MV retain their characteristics previously shown in 
literature 136,141, knees were snap frozen following imaging to be cut and probed for the 
presence of vesicles within the cartilage. The observations of the localisation of MV as 
shown in at the end-point of the experiment specifically within the arthritic, and not 
healthy contralateral cartilage, confirmed the ability of MV to localise in the joint after 
enrichment with 3-11E. Previous studies have shown that MV penetrate ex vivo cartilage 
in the presence, but not absence, of pro-inflammatory cytokines 136,141, however the 
localisation observed in the 3-11E enriched MV mice is dependent on the antibody, as no 
vesicle localisation is observed in the MV alone and negative antibody enriched MV 
groups. Once localized to the arthritic knee, MV were observed within the arthritic 
cartilage, indicating that they are retaining their penetrative characteristics previously 
observed in literature 136,141.  
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4.4 Enriched Microvesicles Can Be Fortified with Anti-Inflammatory 
Therapeutics and Targeted to the Arthritic Joint  
To produce a new generation of therapies, we have utilised the anti-ROS antibody for 
enrichment upon MV. The rationale behind utilising the MV as a biological scaffold to 
carry the targeted therapeutic antibodies is to co-deliver the chondroprotective MV 
alongside anti-inflammatory drugs, which thus far has never been attempted in this 
context. The localisation of 3-11E scFv enriched MV shows, thus far, the successful 
delivery of MV to the arthritic joint. There was no clinical efficacy observed in 
administering the targeted MV on their own systemically. This was likely due to the 
number of vesicles reaching the inflamed joint being lower than what is needed to see 
clinical efficacy. To enhance the therapeutic efficacy, an experiment attempting to 
incorporate an anti-inflammatory therapeutic alongside the anti-ROS-CII was performed. 
In this experiment, 3-11E/vIL-10 fusion protein was used. Previous experiments have 
shown the ability of vIL-10 fused to anti-ROS-CII candidate (1-11E, via MMP cleavable 
peptide linker) to reduce inflammation in a mouse model of arthritis 39. The study showed 
that vIL-10 was latent in the circulation when it was still fused to 1-11E in the anti-ROS-
CII/vIL-10 fusion protein. Once localized in the arthritic joint, where high levels of MMP 
are present, vIL-10 was cleaved by MMP from the fusion and became active. I utilized the 
3-11E/vIL-10 fusion protein for MV enrichment but did not test directly whether the vIL-
10 portion would remain latent in surface of the MV, and instead directly measured 
treatment efficacy of MV loaded with 3-11E/vIL-10 in reducing knee swelling in arthritic 
mice.  
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Figure 41 shows a reduction of the knee swelling in AIA mice injected with the above 
treatments. As previously documented, the anti-ROS-CII fusion with vIL-10 accelerates 
the reduction in knee swelling greater than in mice treated with vIL-10 fused to a 
negative control antibody (C7/vIL-10). Similar, and even enhanced, effects were observed 
in mice treated with MV loaded with 3-11E/vIL-10.  Whether the reduction of knee 
swelling is due to the cleavage of vIL-10 is not known. If the antibody loaded on the MV is 
working in a similar manner to the soluble antibody, then it could be that MMP are still 
able to cleave the latent vIL-10 after incorporation, making the vIL-10 active. However, it 
may also be that the vIL-10 is not latent in our construct, due to conformational 
differences of the 3-11E/vIL-10 on MV compared to the 3-11E/vIL-10 antibody in solution.  
The efficacy of 3-11E/vIL-10 MV in reducing knee swelling suggests that one of the two 
scenarios is true, as MV enriched with vIL-10 fused to the negative control antibody 
(C7/vIL-10) did not show efficacy. Previous work characterizing the proteomic profile of 
neutrophil derived MV discovered that they contain MMP9, but no other MMP. MMP1 
and MMP13 were shown to cleave the vIL-10 portion of the antibody, but as MMP9 has 
more of an important role in cell migration rather than ECM destruction, it it unlikely that 
the neutrophil MV would cleave the MMP linker on the 3-11E/vIL-10 antibody.  
 
Clinical trials systemically administering recombinant IL-10 as an anti-inflammatory 
therapeutic have proved unsuccessful for both high dose and low dose, and due to this IL-
10 has generally been rejected as a systemic treatment option 162–164. This implies that a) 
efficacy is probably due to the targeted treatment and b) vIL-10 is active within the 
inflamed knee whether following cleavage by MMP if needed, or in the context of loading 
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upon MV it is not latent.  To elucidate which mechanism is occurring with regards to the 
activity of vIL-10, future in vitro bioactivity assays should be performed in the presence 
and absence of MMP to determine if cleavage is needed to see vIL-10 activity.  
 
Luminescent optical imaging was performed using luminol sodium salt, which produces 
chemiluminescence once cleaved by reactive oxidants. An inflamed, arthritic knee should 
emit a high level of luminescence, with a healthy knee producing very little. The 
luminescence is shown in Figure 42 as the fold change in photon flux in the arthritic knee 
compared to the healthy contralateral knee. In this way, each mouse has an internal 
control to normalize the luminescence. The treatment groups using either 3-11E or C7 
antibody fused to vIL-10 showed differences akin to that observed in previous studies 39. 
The C7/vIL-10 group shows an increase in the luminescence in the arthritic knee from day 
1 to day 3, following the treatment administration at day 1 post induction. The increase in 
luminescence indicates that the inflammation is worsening, and the C7/vIL-10 treated 
group is like that of the PBS treated group. After 3 days, the inflammation starts to 
decrease in both the C7/vIL-10 and PBS groups, which is typical of the model. 
Interestingly, the mice treated with 3-11E/vIL-10 do not have the increase in 
luminescence between day 1 and 3 post-induction. This is likely due to the suppression by 
vIL-10 present in the arthritic joint. The level of inflammation in the 3-11E/vIL-10 treated 
and C7/vIL-10 treated mice does not return to a level of 1, indicating there is still a low 
level of inflammation at the end of the experiment. This is unexpected, as the PBS treated 
mice do return to a level of 1 by the end of the experiment, indicating that the levels of 
reactive oxidants in the arthritic knee is the same as the healthy, contralateral knee. The 
number of mice used per group was 5, giving statistical power to the experiment, yet the 
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error bars on the antibody treated groups are still large at the last time point. The 3-
11E/vIL-10 MV treated group see a consistent decrease in fold luminescence after the 
first treatment at 1 day post induction. Interestingly, the C7/vIL-10 group does not show 
the increase in luminescence as seen in the antibody alone treated mice. Their levels do 
not decrease to the same degree as the mice treated with 3-11E/vIL-10 MV, but instead 
stay stagnant at a level of around 6-fold. This may indicate that the presence of vesicles 
circulating influences the levels of reactive oxidants in the joint. To properly clarify this, a 
group of mice injected with vesicles alone should also be imaged. In future experiments 
using luminol imaging, such a group will be included to assess whether the circulation of 
MV influences the levels of reactive oxidants in the arthritic joint. The luminol method of 
quantifying inflammation is not perfectly robust, with intraperitoneal injections given at 
each time point and an identical time needed between injecting and imaging. It is likely 
there is a degree of human error caused by having to inject each mouse one after the 
other, which can skew results. Therefore, this data should be taken only as a support of 
the clinical data. 
 
Overall, the data enriching the MV with 3-11E/vIL-10 showed that we do not lose the 
function of our therapy once loaded upon the MV. The similar efficacy observed clinically 
is indicative that our antibody can reduce knee swelling to the same extent when loaded 
upon MV or administered alone. Furthermore, the reduced amount of antibody loaded 
on MV compared to the antibody alone control indicates that potentially less drug is 
needed when loaded upon the MV to achieve the same efficacy. This may be due to the 
slower release of drug when loaded on the MV, as has previously been observed in vitro 
within other studies utilizing EV for drug delivery 165,166. This is an important characteristic 
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given the high expense associated with treating patients with biologics, with over £400 
million spent a year by the NHS on Adalimumab alone 167.  
  
 216 
 
4.5 Microvesicles can be enriched with Multiple Therapeutics to 
Maximize Efficacy  
After efficacy was observed using 3-11E/vIL-10 MV to treat antigen induced arthritis, 
experiments were conducted with the incorporation of an additional anti-inflammatory 
therapy onto the MV. The efficacy of this combined therapy was compared to the single 
antibody 3-11E/vIL-10 MV. For the combined therapy, an anti-mTNF antibody was also 
incorporated onto the MV alongside the 3-11E/vIL-10 antibody. The anti-mTNF antibody 
used is a monoclonal antibody that can bind to both membrane bound and soluble 
mouse TNF. The binding of anti-mTNF to TNF inhibits the binding of TNF to TNFR1 and 
TNFR2, also known as ‘death receptors’, as observed in Figure 57.  A characteristic 
feature of these receptors is the presence of a death domain- which has been shown to 
be responsible for the apoptotic function of the receptor. After binding of TNF to a TNF 
receptor, TRADD (TNFR1-associated death domain protein) interacts with TRAF2 (TNFR-
associated factor 2), FADD (Fas-associated protein with death domain) and NIK (NF-κB-
inducing kinase) 168,169. Downstream signalling of these molecules includes caspase 8 and 
caspase 3 activation- which triggers apoptosis; RIP (receptor interacting protein), p38 and 
ERK (extracellular signal-regulated kinase) activation- which induces inflammation; and 
NF-κB activation- which also induces inflammation as well as proteasome degradation 
168,169.  As shown in Figure 57, the simultaneous delivery of vIL-10 would result in binding 
to IL-10R, causing activation of the JAK/STAT pathways. IL-10 binding triggers an 
intracellular signalling cascade which involves JAK1, Tyk2 and STAT3; STAT3 dimerization 
and nuclear translocation to induce the expression of target genes 170.  TNF receptor 1 is 
 217 
expressed in most tissues and is activated by both membrane bound and soluble TNF. 
TNF receptor 2 is primarily expressed in immune cells and responds to the membrane 
bound homotrimer form of TNF 171. IL-10 receptor is expressed on most hematopoietic 
cells at basal levels but is upregulated upon activation, leading to its inhibitory 
mechanisms 172. By utilizing two drugs, one that is an inflammatory blockade and the 
other a stimulator of anti-inflammatory mechanisms, an enhanced efficacy was observed 
in Figure 49. This efficacy was greater than the non-targeted control (C7/vIL-10 + Anti-
mTNF MV), which suggests the targeting of the therapy is having a great effect. 
Additional studies using Anti-mTNF and 3-11E/vIL-10 combined, or Anti-mTNF and 3-
11E/vIL-10 loaded on a non-specific MV scaffold, such as red blood cell derived MV, are 
needed to assess the efficacy of the PMN MV in the combination therapy.  
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Figure 57. Schematic describing the co-delivery of anti-TNF and anti-ROS-CII fused to vIL-10. Anti-TNF antibody will inhibit 
soluble and membrane bound TNF, inhibiting activation of the TNF pathway and hence activation, inflammation and 
apoptosis. Simultaneously, the vIL-10 portion of the 3-11E/vIL-10 is cleaved in the presence of MMP. Once cleaved, the 
vIL-10 binds to the IL-10 receptor, causing activation of the JAK/STAT pathway and hence the upregulation of anti-
inflammatory, IL-10 responsive genes and the inhibition of pro-inflammatory cytokines. Image created with Biorender.  
 
 
Mice with AIA that were treated with MV loaded with 3-11E/vIL-10 and Anti-mTNF 
showed a complete amelioration of inflammation in the knee. The clinical scoring of mice 
treated with 3-11E/vIL-10 + Anti-mTNF MV outperformed the 3-11E/vIL-10 MV treated 
mice, as well as Anti-mTNF MV, indicating the enhanced efficacy when co-loading two 
anti-inflammatory therapeutics. This efficacy was only observed when the treatment was 
targeted using the 3-11E antibody, as mice treated with C7/vIL-10 + Anti-mTNF MV did 
not result in an amelioration of knee inflammation. The histological analysis did not show 
as clear a picture as the clinical knee swelling, with inflammatory cells still observed 
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within the knee joint. The treatment therefore is likely efficacious in reducing oedema but 
not completely ameliorating the influx of immune cells. The qPCR analysis supported the 
observations in the histology, with the combined treatment group having improved local 
gene expression compared to the PBS control mice, but not yet returned to the state of 
naïve mice.  Further studies are needed to elucidate which beneficial effects are due to 
the targeting using the 3-11E antibody, the presence of MV or the combination of both.  
 
An interesting and unexpected observation was the lack of MV fluorescence detected in 
3-11E/vIL-10 + Anti-TNF treated mice at the end-point of experiment, as shown in Figure 
51. One could speculate that it is likely related to the amelioration of oedema in these 
treated mice, and the return of near homeostatic conditions of the knee joint. As 
previously mentioned, there is limited knowledge regarding the half-life and retention of 
vesicles after administration in mice. Few studies exist that have explored the 
pharmacokinetics and pharmacodynamics, however those that have, involve extracellular 
vesicles administered in healthy mice. To my knowledge, no published pharmacokinetics 
and pharmacodynamics studies have been performed in arthritic mice. The few studies 
available in healthy mice have used vesicles derived from dendritic cells, mesenchymal 
stem cells, HEK293, 4T1, PC3, and MCF-7 cells 159,173,174. Overall, what has been observed 
is a quick clearance through the liver after intravenous administration, but with 
fluorescence still detectable in organs at 48 hours post injection 159,173,174. Although these 
studies have used vesicles of different cell origin in different physiological settings, there 
is a trend towards intravenous administration resulting in a rapid systemic clearance, with 
retention observed in organs specific for such clearance. These studies cannot be directly 
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translated to this work due to the vastly different read-outs, however may be indicative 
that in a non-inflamed, homeostatic state, vesicles are not retained in the body.  
 
Similarly, the mechanism of MV presence within the arthritic joint is not fully understood, 
but significantly elevated levels of MV have been observed in the blood and synovial fluid 
of RA patients 136,175,176. Furthermore, studies confirming the penetration of MV into 
cartilage ex vivo demonstrated that the phenomenon occurs with a higher distribution 
frequency in the presence of pro-inflammatory cytokines 136. These previous observations 
indicate a significant role of neutrophil MV when inflammation is present in the joint.  
The data observed herein, particularly the data showing that MV go to the inflamed joint 
after intravenous administration, further supports these previous findings, and indicates 
that neutrophil MV hold an important mechanistic and therapeutic role in arthritis that is 
yet to be fully elucidated. It is likely that due to this important mechanism, when 
inflammation is reduced in the knee joint subsequently PMN MV also are reduced. This 
could be due to the removal of immune cells within the joint, of which MV have been 
shown to interact with. For example, it has been shown that macrophages phagocytose 
PMN MV, causing alternative activation of macrophages and eliciting a pro-resolving 
effect 147. The phagocytosis of MV would result in the removal of MV from the joint once 
the immune cells were cleared. In a similar manner, MV presence within the cartilage is 
linked to the presence of inflammatory mediators 136. After the first treatment dose of 3-
11E/vIL-10 + Anti-mTNF MV, there was a rapid reduction of swelling from 100% to around 
40%. Although inflammation is still present until the end of the experiment, it could be 
that MV penetration within the cartilage acts through a gradient of inflammatory 
mediators. By the end-point of the experiment, swelling was reduced to 0.3%- near 
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baseline levels, which is likely why in all mice treated with 3-11E/vIL-10 + Anti-TNF MV no 
MV fluorescence could be detected. To confirm these hypotheses, a treatment 
experiment with mice taken off at additional time points could indicate if the reduction of 
inflammation coincides with the reduction of MV within the cartilage. Such studies were 
not feasible due to the time and monetary constraints of this thesis, but in the future, 
could provide greater insight into the underlying mechanisms of PMN MV during 
inflammation.  
 
 
Figure 58. The delivery of vIL-10 and anti-mTNF to the arthritic joint through anti-ROS-CII targeted MV. MV enriched with 
3-11E/vIL-10 and anti-mTNF antibody are administered intravenously in arthritic mice. The therapy is localised and 
retained in the arthritic knee joint by the 3-11E specificity to ROS-CII. The vIL-10 and anti-mTNF are delivered to the 
arthritic joint where they can elicit their anti-inflammatory actions. Simultaneously, the MV are delivered to the 
arthritic cartilage where they can exert their chondroprotective effects. Image created with Biorender.  
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The prime benefit of utilising MV as a biological scaffold is to co-deliver 
chondroprotective vesicles simultaneously with anti-inflammatory therapies, a remedy 
which is imperative to halt and potentially reverse disease damage, but is not currently 
available. Using MV therapeutically could be utilized in an autologous nature. The benefit 
of using autologous MV are that they are readily available from a small volume of blood, 
hold beneficial functions and will not result in a negative immune response, which is a 
potential downfall of using a synthetic scaffold. In this thesis, we have observed 
simultaneous chondroprotective and anti-inflammatory effects from treatment, but these 
effects are unlikely to be completely independent of each other, with MV holding anti-
inflammatory properties and anti-inflammatory drugs sometimes potentiating 
chondroprotective effects. For example, although PMN MV have the unique ability to 
penetrate and protect cartilage, they have also been found to inhibit the release of TNF 
and IL-6 in macrophages, as well as increase the release of TGF-ß 133,147. Similarly, studies 
have indicated that both anti-TNF and IL-10 treatment contributes to inhibiting cartilage 
destruction, albeit likely indirectly through the removal of cytokines which cause 
chondrocyte and synovial activation 177,178. Nonetheless, these studies have shown that 
the combination of targeted MV with anti-inflammatory therapeutics is able to 
significantly reduce knee inflammation.  
 
The studies utilising the anti-inflammatory and chondroprotective effects of MV, both 
herein and previously published in literature, have all used human samples. Although 
efficacy is seen in mice, using mice MV may allow for clearer stratification of the 
mechanism and therapeutic potential of MV. Logistically, using mice MV would be 
difficult due to the low blood volume and hence cell numbers you can obtain. It would 
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also mean using large numbers of mice to obtain the MV for experiments, which does not 
comply with the ethical use of animals in research. Furthermore, the characterisation of 
the protective components of human MV have been translated into mice, as shown by 
the inefficacy of MV treatment in mice lacking the receptor for annexin a1 136.  The use of 
human MV in murine studies can be justified from these viewpoints. 
 
Further studies to decipher the exact efficacious roles of the MV and the loaded 
therapies would be useful to distinguish the exact benefit of using MV as a scaffold, which 
hasn’t been extensively elucidated herein. Nonetheless, previous studies have utilised the 
combination of the innate, protective properties of EV alongside the additional benefits 
of enriching with a drug, however the specific targeting of the therapy through use of an 
antibody has never previously been attempted but has been successful herein.  
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Chapter 5: Concluding Remarks and Future Directions 
The studies conducted for this thesis have demonstrated the ability of enriched MV to be 
localized to the joint.  The potential of PMN MV as a scaffold for the delivery of anti-
inflammatory agents is being tested. The experiment conducted delivering MV with vIL-
10 to the joint is efficacious in localisation, and subsequently reducing inflammation, only 
when targeted using the 3-11E scFv antibody. By enriching the targeted MV with multiple 
therapeutics, the efficacy can be pushed to fully resolve inflammation in our model. 
Furthermore, the targeted therapies have shown specific localisation and retention in the 
arthritic cartilage, as well anti-inflammatory and chondroprotective effects.  
 
This report presents the opportunity of using aqueous energy dissemination for the 
purposes of enrichment of MV using antibodies. Here, the process has been shown to 
successfully incorporate whilst also protecting the binding specificity of the antibody. 
Furthermore, the process has been shown to not hinder the delivery of an anti-
inflammatory therapeutic to the inflamed joint. The technique involves no harsh 
chemistry, is cost effective, efficacious and incredibly flexible. Furthermore, the 
enrichment using liposomes is likely to extend the half-life of both the antibodies and MV, 
as partially demonstrated throughout experiments. Nonetheless, the technique would 
need extensive characterisation to allow the production of consistent batches to meet 
the regulatory approval of a translational therapeutic.  
 
The mouse model used throughout these studies is a T-cell driven monoarthritis model. 
Additional treatment studies could also be performed in other murine models of arthritis, 
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to confirm efficacy in a polyarthritis model with a different aetiology than antigen 
induced arthritis. Previous studies validating MV chondroprotection have been 
performed in the K/BxN serum transfer model and G6PI induced arthritis, and this is the 
first time that protection has been shown in an antigen induced arthritis model. 
Confirmation in other murine models, including the K/BxN serum transfer model, would 
be beneficial for confirmation of this proof of concept. Furthermore, additional studies 
are needed to elucidate the mechanisms of MV presence within the cartilage to fully 
understand when treatments could be administered and how efficacious cartilage 
penetration and protection is.  
 
Herein, the technique has been used in a model of inflammatory arthritis for the proof of 
concept, however it is likely that it can be readily applied to other diseases. An 
appropriate biological scaffold, as well as a specific antibody for targeting is needed, but 
can provide an effective way to co-deliver multiple therapeutics specifically to the area of 
disease..  
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